[{"Element":"<div class=\"WordSection1\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><strong><\/strong><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center;\r text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">ANNEX I<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center;\r text-autospace:none\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.       NAME OF THE MEDICINAL\r PRODUCT<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r vial contains 300 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r vial contains 400 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r pre\u2011filled syringe contains 300 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r pre\u2011filled syringe contains 400 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r reconstitution each ml of suspension contains 200 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">For\r the full list of excipients, see section 6.1.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3.       PHARMACEUTICAL FORM<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Powder\r and solvent for prolonged-release suspension for injection<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Powder:\r white to off-white<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Solvent:\r clear solution<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.       CLINICAL PARTICULARS<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.1     Therapeutic\r indications<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena is indicated for maintenance treatment of schizophrenia in adult\r patients stabilised with oral aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.2     Posology and method of\r administration<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Posology<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">For\r patients who have never taken aripiprazole, tolerability with oral aripiprazole\r must occur prior to initiating treatment with Abilify Maintena.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Titration\r of the dose <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:\r normal\">for Abilify Maintena is not required. <\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">starting\r dose can be administered by following one of two regimens: <\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        One injection start: On\r the day of initiation, administer one injection of 400 mg Abilify Maintena\r and continue treatment with 10 mg to 20 mg oral aripiprazole per day for\r 14 consecutive days to maintain therapeutic aripiprazole concentrations\r during initiation of therapy. <\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        Two injection start:\r On the day of initiation, administer two separate injections of 400 mg\r Abilify Maintena at separate injection sites (see method of administration), along\r with one 20 mg dose of oral aripiprazole. <\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r the <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">injection\r start, the <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">recommended\r maintenance dose of Abilify Maintena is 400 mg.<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> Abilify Maintena<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> should be administered once\r monthly as a single injection (no sooner than 26 days after the previous\r injection).<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If there\r are adverse reactions with the 400 mg dosage, reduction of the dose to\r 300 mg once monthly should be considered.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Missed\r doses<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"614\"> <tr> <td colspan=\"2\" style=\"width:460.7pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"614\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Missed doses<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Timing of Missed Dose<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Action<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">If 2<sup>nd<\/sup> or 3<sup>rd<\/sup> dose is missed and time\r   since last injection is:<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">&gt; 4 weeks\r   and &lt; 5 weeks <\/span><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r   injection should be administered as soon as possible and then the monthly\r   injection schedule should be resumed.<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">&gt; 5 weeks\r   <\/span><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Concomitant\r   oral aripiprazole should be restarted for 14 days with next administered\r   injection<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\r   or two separate injections given at one time, along with a single dose of 20 mg\r   oral aripiprazole. Monthly injection schedule should then resume<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">.<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">If 4<sup>th<\/sup> or subsequent doses are missed (i.e., after\r   attainment of steady state) and time since last injection is:<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">&gt; 4 weeks\r   and &lt; 6 weeks<\/span><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r   injection should be administered as soon as possible and then the monthly\r   injection schedule should be resumed.<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">&gt; 6 weeks<\/span><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Concomitant\r   oral aripiprazole should be restarted for 14 days with next administered\r   injection <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">or two separate injections given at one time, along with a single\r   dose of 20 mg oral aripiprazole. Monthly<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> injection schedule<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> should then resume<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">.<\/span><\/em><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Special\r populations<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Elderly<\/span><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of <em><span style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em> in the\r treatment of schizophrenia in patients 65 years of age or older has not\r been established (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Renal impairment<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">No\r dosage adjustment is required for patients with renal impairment (see section 5.2).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Hepatic impairment<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">No\r dosage adjustment is required for patients with mild or moderate hepatic\r impairment. In patients with severe hepatic impairment, the data available are\r insufficient to establish recommendations. In these patients dosing should be\r managed cautiously. Oral formulation should be preferred (see\r section 5.2).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><a name=\"_Hlk23773509\"><em><span lang=\"EN-GB\" style=\"color:black\">Known CYP2D6 poor metabolisers<\/span><\/em><\/a><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r patients who are known to be CYP2D6 poor metabolisers<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">: <\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        One injection start: The\r starting dose should be 300 mg Abilify Maintena and continue treatment with\r prescribed dose of oral aripiprazole per day for 14 consecutive days. <\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        Two injection start:\r The starting dose should be 2 separate injections of 300 mg Abilify\r Maintena (see method of administration) along with one single dose of the previous\r prescribed dose of oral aripiprazole. <\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r patients who are known to be CYP2D6 poor metabolisers and concomitantly use a\r strong CYP3A4 inhibitor:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        The one injection\r start: The starting dose should be reduced to 200 mg (see section 4.5)\r and continue treatment with the prescribed dose of oral aripiprazole per day\r for 14 consecutive days.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        Two injection start\r is not to be used in patients who are known to be CYP2D6 poor metabolisers and\r concomitantly use a strong CYP3A4 inhibitor.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r the injection start, see table below for the recommended maintenance dose of\r Abilify Maintena. Abilify Maintena should be administered once monthly as a\r single injection (no sooner than 26 days after the previous injection).<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:.25in\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Maintenance dose<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black\"> adjustments due to interactions <\/span><\/em><i><span lang=\"EN-GB\" style=\"color:black\">with CYP2D6 and\/or CYP3A4 inhibitors and\/or\r CYP3A4 inducers<\/span><\/i><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Maintenance\r dosage<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\r adjustments should be made in patients taking concomitant strong CYP3A4\r inhibitors or strong CYP2D6 inhibitors for more than 14 days. If the\r CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the dosage may need to be\r increased to the previous dose (see section 4.5). In case of adverse\r reactions despite dose adjustments of Abilify Maintena, the necessity of\r concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Concomitant\r use of CYP3A4 inducers with Abilify Maintena should be avoided for more than\r 14 days because the blood levels of aripiprazole are decreased and may be\r below the effective levels (see section 4.5).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Maintenance dose<\/span><\/b><\/em><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> adjustments of Abilify Maintena\r in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4\r inhibitors, and\/or CYP3A4 inducers for more than 14 days<\/span><\/b><\/em><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"614\"> <tr style=\"height:22.45pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:22.45pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:177.2pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.45pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Adjusted dose<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr style=\"height:11.2pt\"> <td colspan=\"2\" style=\"width:460.7pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.2pt\" valign=\"top\" width=\"614\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Patients taking 400 mg of Abilify Maintena<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr style=\"height:11.2pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.2pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Strong\r   CYP2D6 or strong CYP3A4 inhibitors<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.2pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">300 mg<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.0pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Strong\r   CYP2D6 and strong CYP3A4 inhibitors<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.0pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">200 mg*<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:11.65pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">CYP3A4\r   inducers<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.65pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Avoid use<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:8.95pt\"> <td colspan=\"2\" style=\"width:460.7pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.95pt\" valign=\"top\" width=\"614\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Patients taking 300 mg of Abilify Maintena<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr style=\"height:8.5pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Strong\r   CYP2D6 or strong CYP3A4 inhibitors<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">200 mg*<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:8.95pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.95pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Strong\r   CYP2D6 and strong CYP3A4 inhibitors<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.95pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">160 mg*<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">CYP3A4\r   inducers<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Avoid use<\/span><\/em><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><em><span lang=\"EN-GB\" style=\"font-size:8.0pt;font-style:normal\">*    <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:8.0pt\">200 mg and 160 mg can be achieved via\r adjustment of the injection volume only by using Abilify Maintena powder and\r solvent for <\/span><span lang=\"EN-GB\" style=\"font-size:8.0pt\">prolonged-release suspension for injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Paediatric\r population<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r safety and efficacy of Abilify Maintena in children and adolescents aged 0\u201117 years\r have not been established. No data are available.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Method\r of administration<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena is only intended for intramuscular use and should not be administered\r intravenously or subcutaneously. It should only be administered by a healthcare\r professional.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r suspension should be injected slowly as a single injection (doses must not be\r divided) into the gluteal or deltoid muscle. Care should be taken to avoid\r inadvertent injection into a blood vessel.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If initiating with the\r two injection start, inject into two different sites in two different muscles.\r DO NOT inject both injections concomitantly into the same deltoid or gluteal\r muscle.<\/span><span lang=\"EN-GB\">For\r known CYP2D6 poor metabolisers administer in either two separate deltoid\r muscles or one deltoid and one gluteal muscle. DO NOT inject into two gluteal\r muscles.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Full instructions for\r use and handling of Abilify Maintena are provided in the package leaflet\r (information intended for healthcare professionals).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">For instructions on\r reconstitution of the medicinal product before administration, see section 6.6.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.3     Contraindications<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.4     Special\r warnings and precautions for use<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"font-style:normal\">During antipsychotic treatment, improvement in the\r patient's clinical condition may take several days to some weeks. Patients\r should be closely monitored throughout this period.<\/span><\/em><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Use in patients who are in an acutely\r agitated or severely psychotic state<\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena should not be used to\r manage acutely agitated or severely psychotic states when immediate symptom\r control is warranted.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Suicidality<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r occurrence of suicidal behaviour is inherent in psychotic illnesses, and in\r some cases has been reported early after initiation or switch of antipsychotic\r treatment, including treatment with aripiprazole (see section 4.8). Close\r supervision of high risk patients should accompany antipsychotic treatment.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Cardiovascular disorders<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r should be used with caution in patients with known cardiovascular disease\r (history of myocardial infarction or ischaemic heart disease, heart failure, or\r conduction abnormalities), cerebrovascular disease, conditions which would\r predispose patients to hypotension (dehydration, hypovolemia, and treatment with\r antihypertensive medicinal products) or hypertension, including accelerated or\r malignant. Cases of venous thromboembolism (VTE) have been reported with\r antipsychotic medicinal products. Since patients treated with antipsychotics\r often present with acquired risk factors for VTE, all possible risk factors for\r VTE should be identified before and during treatment with aripiprazole and\r preventive measures undertaken (see section 4.8).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">QT\r prolongation<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r clinical trials of treatment with oral aripiprazole, the incidence of QT\r prolongation was comparable to placebo. Aripiprazole should be used with\r caution in patients with a family history of QT prolongation (see\r section 4.8).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tardive\r dyskinesia<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r clinical trials of one year or less duration, there were uncommon reports of\r treatment emergent dyskinesia during treatment with aripiprazole. If signs and\r symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose\r reduction or discontinuation should be considered (see section 4.8). These\r symptoms can temporally deteriorate or can even arise after discontinuation of\r treatment.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Neuroleptic\r Malignant Syndrome (NMS)<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">NMS\r is a potentially fatal symptom complex associated with antipsychotics. In\r clinical trials, rare cases of NMS were reported during treatment with\r aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity,\r altered mental status and evidence of autonomic instability (irregular pulse or\r blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs\r may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis),\r and acute renal failure. However, elevated creatine phosphokinase and\r rhabdomyolysis, not necessarily in association with NMS, have also been\r reported. If a patient develops signs and symptoms indicative of NMS, or\r presents with unexplained high fever without additional clinical manifestations\r of NMS, all antipsychotics, including aripiprazole, must be discontinued (see\r section 4.8).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Seizure<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r clinical trials, uncommon cases of seizure were reported during treatment with\r aripiprazole. Therefore, aripiprazole should be used with caution in patients\r who have a history of seizure disorder or have conditions associated with\r seizures (see section 4.8).<\/span><\/em><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Elderly patients with dementia-related\r psychosis<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Increased mortality<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In three\r placebo-controlled trials of oral aripiprazole in elderly patients with\r psychosis associated with Alzheimer's disease (n = 938; mean age:\r 82.4 years; range: 56\u201199 years), patients treated with\r aripiprazole were at an increased risk of death compared to placebo. The rate\r of death in oral aripiprazole-treated patients was 3.5 % compared to\r 1.7 % in placebo. Although the causes of deaths were varied, most of the\r deaths appeared to be either cardiovascular (e.g. heart failure, sudden death)\r or infectious (e.g. pneumonia) in nature (see section 4.8).<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Cerebrovascular adverse reactions<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In the same\r trials with oral aripiprazole, cerebrovascular adverse reactions (e.g. stroke,\r transient ischaemic attack), including fatalities, were reported in patients\r (mean age: 84 years; range: 78\u201188 years). Overall, 1.3 %\r of oral aripiprazole-treated patients reported cerebrovascular adverse\r reactions compared with 0.6 % of placebo-treated patients in these trials.\r This difference was not statistically significant. However, in one of these\r trials, a fixed-dose trial, there was a significant dose- response relationship\r for cerebrovascular adverse reactions in patients treated with aripiprazole\r (see section 4.8).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole<\/span><\/em><span lang=\"EN-GB\" style=\"color:black\"> is not indicated for the treatment of patients\r with dementia-related psychosis.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hyperglycaemia\r and diabetes mellitus<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hyperglycaemia,\r in some cases extreme and associated with ketoacidosis or hyperosmolar coma or\r death, has been reported in patients treated with aripiprazole. Risk factors\r that may predispose patients to severe complications include obesity and family\r history of diabetes. Patients treated with aripiprazole should be observed for\r signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia\r and weakness) and patients with diabetes mellitus or with risk factors for\r diabetes mellitus should be monitored regularly for worsening of glucose\r control (see section 4.8).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hypersensitivity<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hypersensitivity\r reactions, characterised by allergic symptoms, may occur with aripiprazole (see\r section 4.8).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Weight gain<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;background:yellow;\r font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Weight gain is commonly\r seen in schizophrenic patients due to use of antipsychotics known to cause\r weight gain, co-morbidities, poorly managed life-style and might lead to severe\r complications. <em><span style=\"font-style:normal\">Weight gain has been\r reported post-marketing among patients prescribed oral aripiprazole. When seen,\r it is usually in those with significant risk factors such as history of\r diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole\r has not been shown to induce clinically relevant weight gain (see section 4.8).<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Dysphagia<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Oesophageal\r dysmotility and aspiration have been associated with the use of aripiprazole.\r Aripiprazole should be used cautiously in patients at risk for aspiration\r pneumonia.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\">Pathological\r gambling and other impulse control disorders<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Patients can experience increased urges,\r particularly for gambling, and the inability to control these urges while\r taking aripiprazole. Other urges, reported, include: increased sexual urges,\r compulsive shopping, binge or compulsive eating, and other impulsive and\r compulsive behaviours. It is important for prescribers to ask patients or their\r caregivers specifically about the development of new or increased gambling\r urges, sexual urges, compulsive shopping, binge or compulsive eating, or other\r urges while being treated with aripiprazole. It should be noted that\r impulse-control symptoms can be associated with the underlying disorder;\r however, in some cases, urges were reported to have stopped when the dose was\r reduced or the medicinal productation was discontinued. Impulse control\r disorders may result in harm to the patient and others if not recognised. <\/span><\/em><span lang=\"EN-GB\">A dose reduction or stopping of the medicinal product should be\r considered if a patient develops such urges <em><span style=\"color:black;\r font-style:normal\">(see section 4.8<\/span><\/em>).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\">Falls<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Aripiprazole\r may cause somnolence, postural hypotension, motor and sensory instability,\r which may lead to falls. Caution should be taken when treating patients at\r higher risk, and a lower starting dose should be considered (e.g., elderly or\r debilitated patients; see section 4.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Sodium<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena contains less than 1 mmol\r of sodium (23 mg) per dose.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.5     Interaction\r with other medicinal products and other forms of interaction<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">No\r interaction studies have been performed with Abilify Maintena. The information\r below is obtained from studies with oral aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Due\r to its \u03b11-adrenergic receptor antagonism, aripiprazole has the potential\r to enhance the effect of certain antihypertensive medicinal products.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Given\r the primary CNS effects of aripiprazole, caution should be used when\r aripiprazole is administered in combination with alcohol or other CNS medicinal\r products with overlapping adverse reactions such as sedation (see\r section 4.8).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r aripiprazole is administered concomitantly with medicinal products known to\r cause QT prolongation or electrolyte imbalance, caution should be used.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Potential\r for other medicinal products to affect aripiprazole<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Quinidine and other\r strong CYP2D6 inhibitors<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor\r of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while C<sub>max<\/sub>\r was unchanged. The AUC and C<sub>max<\/sub> of dehydro-aripiprazole, the active\r metabolite, decreased by 32 % and 47 %, respectively. Other strong\r inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to\r have similar effects and similar dose reduction should, therefore, be applied\r (see section 4.2).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Ketoconazole and\r other strong CYP3A4 inhibitors<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor\r of CYP3A4 (ketoconazole) increased aripiprazole AUC and C<sub>max<\/sub> by\r 63 % and 37 %, respectively. The AUC and C<sub>max<\/sub> of\r dehydro-aripiprazole increased by 77 % and 43 %, respectively. In\r CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may\r result in higher plasma concentrations of aripiprazole compared to that in\r CYP2D6 extensive metabolisers (see section 4.2). When considering\r concomitant administration of ketoconazole or other potent CYP3A4 inhibitors\r with aripiprazole, potential benefits should outweigh the potential risks to\r the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV\r protease inhibitors may be expected to have similar effects and similar dose\r reductions should, therefore, be applied (see section 4.2). Upon\r discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should\r be increased to the dose prior to the initiation of the concomitant therapy.\r When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram)\r are used concomitantly with aripiprazole, modest increases in plasma\r aripiprazole concentrations may be expected.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Carbamazepine and\r other CYP3A4 inducers<\/span><\/em><\/p> <p class=\"MsoNormal\"><span class=\"BMSHeading3Char\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;font-weight:normal'>Following\r concomitant administration of carbamazepine, a strong inducer of CYP3A4, and\r oral aripiprazole<\/span><\/span><span class=\"BMSHeading3Char\"><\/span><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">to patients with schizophrenia\r or schizoaffective disorder, the geometric means of C<sub>max<\/sub> and AUC for\r aripiprazole were 68 % and 73 % lower, respectively, compared to when\r oral aripiprazole (30 mg) was administered alone. Similarly, for\r dehydro-aripiprazole the geometric means of C<sub>max<\/sub> and AUC after\r carbamazepine co-administration were 69 % and 71 % lower,\r respectively, than those following treatment with oral aripiprazole alone. Concomitant\r administration of Abilify Maintena and other inducers of CYP3A4 (such as\r rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz,\r nevirapine and St. John's Wort) may be expected to have similar effects. The\r concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided\r because the blood levels of aripiprazole are decreased and may be below the\r effective levels.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Serotonin syndrome<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Cases of serotonin syndrome have been\r reported in patients taking aripiprazole, and possible signs and symptoms for\r this condition can occur especially in cases of concomitant use with other\r serotonergic medicinal products, such as SSRI\/SNRI, or with medicinal products\r that are known to increase aripiprazole concentrations (see section 4.8).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.6     Fertility,\r pregnancy and lactation<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pregnancy<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">There are no adequate and well-controlled trials of\r aripiprazole in pregnant women. Congenital anomalies have been reported;\r however, causal relationship with aripiprazole could not be established. Animal\r studies could not exclude potential developmental toxicity (see\r section 5.3). Patients must be advised to notify their physician if they\r become pregnant or intend to become pregnant during treatment with <em><span style=\"font-style:normal\">aripiprazole<\/span><\/em>. Due to insufficient safety\r information in humans and concerns raised by animal reproductive studies, this\r medicinal product should not be used in pregnancy unless the expected benefit\r clearly justifies the potential risk to the foetus.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Prescribers\r need to be aware of the long-acting properties of <em><span style=\"color:black;\r font-style:normal\">Abilify Maintena<\/span><\/em>.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">New-born\r infants exposed to antipsychotics (including aripiprazole) during the third\r trimester of pregnancy are at risk of adverse reactions including\r extrapyramidal and\/or withdrawal symptoms that may vary in severity and\r duration following delivery. There have been reports of agitation, hypertonia,\r hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.\r Consequently, new-born infants should be monitored carefully (see\r section 4.8).<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Breast-feeding<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r is excreted in human milk. A decision must be made whether to discontinue\r breast-feeding or to discontinue\/abstain from aripiprazole therapy taking into\r account the benefit of breast feeding for the child and the benefit of therapy\r for the woman.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Fertility<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p><span lang=\"EN-GB\">Aripiprazole did not impair fertility based on data from\r reproductive toxicity studies.<\/span><\/p> <p><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.7     Effects on ability to\r drive and use machines<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r <\/span><\/em><span lang=\"EN-GB\">has minor to moderate influence on the ability to\r drive and use machines due to potential nervous system and visual effects, such\r as sedation, somnolence, syncope, vision blurred, diplopia (see\r section 4.8).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.8     Undesirable effects<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Summary\r of the safety profile<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r most frequently observed adverse drug reactions (ADRs) reported in \u2265 5 %\r of patients in two double\u2011blind, long-term trials of Abilify Maintena\r were weight increased (9.0 %), akathisia (7.9 %), insomnia\r (5.8 %), and injection site pain (5.1 %).<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tabulated\r list of adverse reactions<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">The incidences of the ADRs associated with aripiprazole\r therapy are tabulated below. The table is based on adverse reactions reported\r during clinical trials and\/or post-marketing use.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">All ADRs are listed by system organ class and frequency;\r very common (\u2265 1\/10), common (\u2265 1\/100 to &lt; 1\/10),\r uncommon (\u2265 1\/1,000 to &lt; 1\/100), rare\r (\u2265 1\/10,000 to &lt; 1\/1,000), very rare\r (&lt; 1\/10,000) and not known (cannot be estimated from the available\r data). Within each frequency grouping, adverse reactions are presented in order\r of decreasing seriousness.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">The frequency of adverse reactions reported during post-marketing\r use cannot be determined as they are derived from spontaneous reports.\r Consequently, the frequency of these adverse events is qualified as \"not\r known\".<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"614\"> <thead> <tr style=\"height:27.4pt\"> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:27.4pt\" valign=\"top\" width=\"104\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:85.05pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Common<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Uncommon<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Not known<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Blood and lymphatic system\r   disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Neutropenia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Anaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Thrombocytopenia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Neutrophil count decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">White blood cell count decreased<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Leukopenia<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Immune system disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypersensitivity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Allergic reaction (e.g. anaphylactic\r   reaction, angioedema including swollen tongue, tongue oedema, face oedema,\r   pruritus, or urticaria)<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood prolactin decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hyperprolactinaemia<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Diabetic hyperosmolar coma<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Diabetic ketoacidosis<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Weight increased<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Diabetes mellitus<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Weight decreased<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hyperglycaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypercholesterolaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hyperinsulinaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hyperlipidaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypertriglyceridaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Appetite disorder<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Anorexia<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hyponatraemia<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Psychiatric disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Agitation<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Anxiety<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Restlessness<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Insomnia<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Suicidal ideation<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Psychotic disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hallucination<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Delusion<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypersexuality<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Panic reaction<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Depression<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Affect lability<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Apathy<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dysphoria<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Sleep disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Bruxism<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Libido decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Mood altered<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Completed suicide<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Suicide attempt<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pathological gambling<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Impulse-control disorders<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Binge eating<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Compulsive shopping<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Poriomania<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Nervousness<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aggression<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Extrapyramidal disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Akathisia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Tremor<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dyskinesia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Sedation<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Somnolence<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dizziness<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Headache<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dystonia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Tardive dyskinesia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Parkinsonism<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Movement disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Psychomotor hyperactivity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Restless legs syndrome<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cogwheel rigidity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypertonia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Bradykinesia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Drooling<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dysgeusia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Parosmia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Neuroleptic malignant syndrome<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Grand mal convulsion<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Serotonin syndrome<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Speech disorder<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Eye disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Oculogyric crisis<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Vision blurred<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Eye pain<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Diplopia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span style=\"color:black\">Photophobia<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ventricular extrasystoles<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Bradycardia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Tachycardia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Electrocardiogram T wave amplitude decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Electrocardiogram abnormal<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Electrocardiogram T wave inversion<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Sudden unexplained death<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Cardiac arrest<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Torsades de pointes<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Ventricular arrhythmias<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">QT prolongation<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypertension<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Orthostatic hypotension<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood pressure increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Syncope<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Venous thromboembolism (including\r   pulmonary embolism and deep vein thrombosis)<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and\r   mediastinal disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cough<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hiccups<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Oropharyngeal spasm<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Laryngospasm<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aspiration pneumonia<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dry mouth<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Gastrooesophageal reflux disease<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dyspepsia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Diarrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Nausea<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Abdominal pain upper<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Abdominal discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Constipation<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Frequent bowel movement<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Salivary hypersecretion<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pancreatitis<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Dysphagia<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Hepatobiliary disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Liver function test abnormal Hepatic enzyme increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Alanine aminotransferase increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Gamma-glutamyl transferase increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood bilirubin increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Aspartate aminotransferase increased<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hepatic failure<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Jaundice<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hepatitis<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Alkaline phosphatase increased<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Alopecia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Acne<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Rosacea<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Eczema<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Skin induration<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span style=\"color:black;\r   font-style:normal\">Rash<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span style=\"color:black;\r   font-style:normal\">Photosensitivity reaction<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span style=\"color:black;\r   font-style:normal\">Hyperhidrosis<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\">Drug Reaction with\r   Eosinophilia and Systemic Symptoms (DRESS)<\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective\r   tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal stiffness<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Muscle rigidity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Muscle spasms<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Muscle twitching<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Muscle tightness<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Myalgia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Pain in extremity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Arthralgia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Back pain<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Joint range of motion decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Nuchal rigidity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Trismus<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Rhabdomyolysis<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Nephrolithiasis<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Glycosuria<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Urinary retention<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Urinary incontinence<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Pregnancy, puerperium and perinatal conditions<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Drug withdrawal syndrome neonatal (see\r   section 4.6)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Reproductive system and breast\r   disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Erectile dysfunction<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Galactorrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Gynaecomastia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Breast tenderness<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Vulvovaginal dryness<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Priapism<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">General disorders and\r   administration site conditions<\/span><\/b><\/p> <p><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site pain<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site induration Fatigue<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Pyrexia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Asthenia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Gait disturbance<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Chest discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site reaction<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site erythema<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site swelling<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site pruritus<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Thirst<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Sluggishness <\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Temperature regulation disorder (e.g.\r   hypothermia, pyrexia)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Chest pain<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Peripheral oedema<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Investigations<\/span><\/b><\/p> <p><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood creatine phosphokinase increased<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood glucose increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood glucose decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Glycosylated haemoglobin increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Waist circumference increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood cholesterol decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood triglycerides decreased<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Blood glucose fluctuation<\/span><\/em><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Description\r of selected adverse reactions<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Injection site\r reactions<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">During\r the double\u2011blind, controlled phases of the two long-term trials,\r injection site reactions were observed; those seen were generally mild to\r moderate in severity, and resolved over time. <\/span><\/em><span lang=\"EN-GB\">Injection\r site pain (incidence 5.1 %), had a median onset on day 2 after the\r injection and a median duration of 4 days.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In an open label study comparing\r bioavailability of Abilify Maintena administered in the deltoid or gluteal\r muscle, injection site related reactions were slightly more frequent in the\r deltoid muscle. The majority were mild and improved on subsequent injections.\r When compared to studies where Abilify Maintena was injected in the gluteal\r muscle, repeated occurrence of injection site pain was more frequent in the\r deltoid muscle.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Leukopenia<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia has been reported in the\r clinical program with <em><span style=\"color:black;font-style:normal\">Abilify\r Maintena<\/span><\/em> and typically started around day 16 after first\r injection, and lasted a median of 18 days.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Extrapyramidal\r Symptoms (EPS)<\/span><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In trials in stable patients with\r schizophrenia, <em><span style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em>\r was associated with a higher frequency of EPS symptoms (18.4 %) than oral\r aripiprazole treatment (11.7 %). Akathisia was the most frequently\r observed symptom (8.2 %) and typically started around day 10 after\r first injection, and lasted a median of 56 days. Subjects with akathisia\r typically received anti-cholinergic medicines as treatment, primarily\r benzatropine mesilate and trihexyphenidyl. Less often substances such as\r propranolol and benzodiazepines (clonazepam and diazepam) were administered to\r control akathisia. Parkinsonism events followed in frequency of 6.9 % for <em><span style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em>, 4.15 %\r for oral aripiprazole 10\u201130 mg tablets and 3.0 % for placebo,\r respectively.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Dystonia<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Class\r effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups,\r may occur in susceptible individuals during the first few days of treatment.\r Dystonic symptoms include spasm of the neck muscles, sometimes progressing to\r tightness of the throat, swallowing difficulty, difficulty breathing, and\/or\r protrusion of the tongue. While these symptoms can occur at low doses, they\r occur more frequently and with greater severity with high potency and at higher\r doses of first generation antipsychotic medicinal products. An elevated risk of\r acute dystonia is observed in males and younger age groups.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Weight<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">During\r the Double-blind, Active-controlled Phase of the 38\u2011week long-term trial,\r the incidence of weight gain of <\/span><\/em><em><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black;font-style:normal\">\u00b3<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> 7 % from baseline\r to last visit was 9.5 % for Abilify Maintena and 11.7 % for the oral\r aripiprazole tablets 10\u201130 mg. The incidence of weight loss of \u2265 7 %\r from baseline to last visit was 10.2 % for Abilify Maintena and 4.5 %\r for oral aripiprazole tablets 10\u201130 mg. During the Double-blind, Placebo-controlled\r Phase of the 52\u2011week long-term trial, the incidence of weight gain of <\/span><\/em><em><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black;font-style:normal\">\u00b3<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> 7 % from baseline\r to last visit was 6.4 % for Abilify Maintena and 5.2 % for placebo. The\r incidence of weight loss of \u2265 7 % from baseline to last\r visit was 6.4 % for Abilify Maintena and 6.7 % for placebo. During\r double\u2011blind treatment, mean change in body weight from baseline to last\r visit was \u20110.2 kg for Abilify Maintena and \u20110.4 kg for\r placebo (p = 0.812).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><i><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Prolactin<\/span><\/i><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>In\r clinical trials for the approved indications and post-marketing, both increase\r and decrease in serum prolactin as compared to baseline was observed with\r aripiprazole (section 5.1).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><i><span lang=\"EN-GB\">Pathological\r gambling and other impulse control disorders<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pathological gambling, hypersexuality,\r compulsive shopping and binge or compulsive eating can occur in patients\r treated with aripiprazole (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Reporting\r of suspected adverse reactions<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Reporting\r suspected adverse reactions after authorisation of the medicinal product is\r important. It allows continued monitoring of the benefit\/risk balance of the\r medicinal product. Healthcare professionals are asked to report any suspected\r adverse reactions via <\/span><\/em><span lang=\"EN-GB\" style=\"background:silver\">the\r national reporting system listed in <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><u><span style=\"background:silver\">Appendix V<\/span><\/u><\/a>.<\/span><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.9     Overdose<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">No cases of overdose associated with\r adverse reactions were reported in clinical studies with <em><span style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em>. Care must\r be taken to avoid inadvertent injection of this medicinal product into a blood\r vessel. Following any confirmed or suspected accidental overdose\/inadvertent\r intravenous administration, close observation of the patient is needed and if\r any potentially medically serious sign or symptom develops, monitoring, which\r should include continuous electrocardiographic monitoring, is required. The\r medical supervision and monitoring should continue until the patient recovers.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">A simulation of dose dumping showed that\r the predicted median aripiprazole concentration reaches a peak of 4,500 ng\/ml\r or approximately 9 times the upper therapeutic range. In case of dose\r dumping, aripiprazole concentrations are predicted to descend rapidly to the\r upper limit of the therapeutic window after approximately 3 days. By\r the 7th day, the median aripiprazole concentrations further decline to\r concentrations following an IM depot dose with no dose dumping. <span style=\"color:black\">While overdose is less likely with parenteral than oral\r medicinal products, reference information for oral aripiprazole overdose is\r presented below.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Signs\r and symptoms<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r clinical trials and post-marketing experience, accidental or intentional acute\r overdose of aripiprazole alone was identified in adult patients with reported\r estimated doses up to 1,260 mg (41 times highest recommended daily\r aripiprazole dose) with no fatalities. The potentially medically important\r signs and symptoms observed included lethargy, increased blood pressure,\r somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports\r of accidental overdose with aripiprazole alone (up to 195 mg) in children\r have been received with no fatalities. The potentially medically serious signs\r and symptoms reported included somnolence, transient loss of consciousness and\r extrapyramidal symptoms.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Management\r of overdose<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Management\r of overdose should concentrate on supportive therapy, maintaining an adequate\r airway, oxygenation and ventilation, and management of symptoms. The\r possibility of multiple medicinal product involvement should be considered.\r Therefore, cardiovascular monitoring should be started immediately and should\r include continuous electrocardiographic monitoring to detect possible arrhythmias.\r Following any confirmed or suspected overdose with aripiprazole, close medical\r supervision and monitoring should continue until the patient recovers.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Haemodialysis<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Although\r there is no information on the effect of haemodialysis in treating an overdose\r with aripiprazole, haemodialysis is unlikely to be useful in overdose\r management since aripiprazole is highly bound to plasma proteins.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.       PHARMACOLOGICAL\r PROPERTIES<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.1     Pharmacodynamic\r properties<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pharmacotherapeutic\r group: Psycholeptics, other antipsychotics, ATC code: N05AX12<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Mechanism\r of action<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">It\r has been proposed that aripiprazole\u2019s efficacy in schizophrenia is mediated\r through a combination of partial agonism at dopamine D<sub>2<\/sub> and\r serotonin 5\u2011HT<sub>1A<\/sub> receptors and antagonism at serotonin 5\u2011HT<sub>2A<\/sub>\r receptors. Aripiprazole exhibited antagonist properties in animal models of\r dopaminergic hyperactivity and agonist properties of dopaminergic hypoactivity.\r Aripiprazole exhibits high binding affinity <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black\">in vitro<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> for dopamine D<sub>2<\/sub> and D<sub>3<\/sub>,\r serotonin 5\u2011HT<sub>1A<\/sub> and 5\u2011HT<sub>2A<\/sub> receptors and has\r moderate affinity for dopamine D<sub>4<\/sub>, serotonin 5\u2011HT<sub>2C<\/sub>\r and 5\u2011HT<sub>7<\/sub>, alpha-1 adrenergic, and histamine H<sub>1<\/sub>\r receptors. Aripiprazole also exhibited moderate binding affinity for the\r serotonin reuptake site and no appreciable affinity for cholinergic muscarinic\r receptors. Interaction with receptors other than dopamine and serotonin\r subtypes may explain some of the other clinical effects of aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r oral doses ranging from 0.5 to 30 mg administered once a day to healthy\r subjects for 2 weeks produced a dose-dependent reduction in the binding of\r <sup>11<\/sup>C\u2011raclopride, a D<sub>2<\/sub>\/D<sub>3<\/sub> receptor ligand,\r to the caudate and putamen detected by positron emission tomography.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Clinical\r efficacy and safety<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Maintenance\r treatment of schizophrenia in adults<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r efficacy of Abilify Maintena in the maintenance treatment of patients with\r schizophrenia was established in two randomised, double\u2011blind, long-term trials.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r pivotal trial was a 38 week, randomised, double\u2011blind, active\u2011controlled\r trial designed to establish the efficacy, safety, and tolerability of this\r medicinal product administered as monthly injections compared to once daily\r oral aripiprazole tablets 10\u201130 mg as maintenance treatment in adult\r patients with schizophrenia. This trial consisted of a screening phase and\r 3 treatment phases: Conversion Phase, Oral Stabilisation Phase, and\r Double-blind, Active-controlled Phase.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Six-hundred\r and sixty two patients eligible for the 38\u2011week Double-blind, Active-controlled\r Phase were randomly assigned in a 2:2:1 ratio to double\u2011blind treatment\r to one of 3 treatment groups: 1) Abilify Maintena 2) the stabilisation\r dose of oral aripiprazole 10\u201130 mg, or 3) aripiprazole Long-Acting\r Injectable 50 mg\/25 mg. The aripiprazole Long-Acting Injectable\r 50 mg\/25 mg dose was included as a low dose aripiprazole to test\r assay sensitivity for the non-inferiority design.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r results of analysis of the primary efficacy endpoint, the estimated proportion\r of patients experiencing impending relapse by end of Week 26 of the Double-blind,\r Active-controlled Phase, showed that Abilify Maintena 400 mg\/300 mg\r is non-inferior to aripiprazole oral tablets 10\u201130 mg.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r estimated relapse rate by end of Week 26 was 7.12 % for Abilify\r Maintena, and 7.76 % for oral aripiprazole tablets 10\u201130 mg, a\r difference of <\/span><\/em><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.64 %.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r 95 % CI (<\/span><\/em><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.26, 3.99) for the difference\r in the estimated proportion of patients experiencing impending relapse by end\r of Week 26 excluded the predefined non-inferiority margin, 11.5 %.\r Therefore, Abilify Maintena is non-inferior to aripiprazole oral tablets 10\u201130 mg.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r estimated proportion of patients experiencing impending relapse by end of\r Week 26 for Abilify Maintena was 7.12 %, which was statistically\r significantly lower than in aripiprazole Long-Acting Injectable 50 mg\/25 mg\r (21.80 %; p = 0.0006). Thus, superiority of Abilify Maintena\r over the aripiprazole Long-Acting Injectable 50 mg\/25 mg was\r established and the validity of the trial design was confirmed.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r Kaplan-Meier curves of the time from randomisation to impending relapse during\r the 38\u2011week, Double-blind, Active-controlled Phase for Abilify Maintena,\r oral aripiprazole 10\u201130 mg, and aripiprazole Long-Acting Injectable\r 50 mg\/25 mg are shown in Figure 1.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Figure 1      Kaplan-Meier\r Product Limit Plot for Time to Exacerbation of Psychotic Symptoms\/Impending\r Relapse<\/span><\/b><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\"><img border=\"0\" height=\"334\" id=\"Grafik 3207\" src=\"AbilifyMaintena-h-2755-e_files\/image001.png\" width=\"535\"\/><\/span><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"font-size:8.0pt;color:black;\r font-style:normal\">NOTE: ARIP IMD 400\/300 mg = Abilify Maintena;ARIP\r 10\u201130 mg = oral aripiprazole; ARIP IMD 50\/25 mg = Long-acting\r Injectable<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Further,\r the non-inferiority of Abilify Maintena compared to oral aripiprazole 10\u201130 mg\r is supported by the results of the analysis of the Positive and Negative\r Syndrome Scale score (PANSS).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Table 1       PANSS\r Total Score \u2013 Change From Baseline to Week 38-LOCF:<br\/>\r Randomised Efficacy Sample<sup>a, b<\/sup><\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.2%;margin-left:5.5pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr style=\"height:28.25pt\"> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"top\" width=\"100%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">PANSS Total Score \u2013 Change\r   From Baseline to Week 38-LOCF:<\/span><\/b><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Randomised Efficacy Sample<sup>a,\r   b<\/sup><\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr style=\"height:38.85pt\"> <td style=\"width:24.94%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:38.85pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:19.48%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:38.85pt\" valign=\"top\" width=\"19%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> 400 mg\/300 mg<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">(n = 263)<\/span><\/em><\/p> <\/td> <td style=\"width:24.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:38.85pt\" valign=\"top\" width=\"24%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Oral aripiprazole<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">10\u201130 mg\/day<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">(n = 266)<\/span><\/em><\/p> <\/td> <td style=\"width:30.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:38.85pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole Long-Acting\r   Injectable<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">50 mg\/25 mg<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">(n = 131)<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:16.55pt\"> <td style=\"width:24.94%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Mean baseline (SD)<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:19.48%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"19%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">57.9 (12.94)<\/span><\/em><\/p> <\/td> <td style=\"width:24.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"24%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">56.6 (12.65)<\/span><\/em><\/p> <\/td> <td style=\"width:30.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">56.1 (12.59)<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:16.55pt\"> <td style=\"width:24.94%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Mean change (SD)<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:19.48%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"19%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.8 (10.49)<\/span><\/em><\/p> <\/td> <td style=\"width:24.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"24%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.7 (11.60)<\/span><\/em><\/p> <\/td> <td style=\"width:30.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3.2 (14.45)<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:12.7pt\"> <td style=\"width:24.94%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.7pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">P-value<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:19.48%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.7pt\" valign=\"top\" width=\"19%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">NA<\/span><\/em><\/p> <\/td> <td style=\"width:24.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.7pt\" valign=\"top\" width=\"24%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.0272<\/span><\/em><\/p> <\/td> <td style=\"width:30.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.7pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.0002<\/span><\/em><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><em><span lang=\"EN-GB\" style=\"font-size:8.0pt;color:black;font-style:normal\">a:    Negative\r change in score indicates improvement.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><em><span lang=\"EN-GB\" style=\"font-size:8.0pt;color:black;font-style:normal\">b:   Only\r patients having both baseline and at least one post baseline were included.\r P-values were derived from comparison for change from baseline within analysis\r of covariance model with treatment as term and baseline as covariate.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r second trial was a 52\u2011week, randomised, withdrawal, double\u2011blind,\r trial conducted in US adult patients with a current diagnosis of schizophrenia.\r This trial consisted of a screening phase and 4 treatment phases:\r Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and\r Double-blind Placebo-controlled. Patients fulfilling the oral stabilisation\r requirement in the Oral Stabilisation Phase were assigned to receive, in a\r single-blind fashion, Abilify Maintena and began an Abilify Maintena\r Stabilisation Phase for a minimum of 12 weeks and a maximum of\r 36 weeks. Patients eligible for the Double-blind, Placebo-controlled Phase\r were randomly assigned in a 2:1 ratio to double\u2011blind treatment with Abilify\r Maintena or placebo, respectively.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r final efficacy analysis included 403 randomised patients and 80 exacerbations\r of psychotic symptoms\/impending relapse events. In the placebo group 39.6 %\r of the patients had progressed to impending relapse, whilst in the Abilify\r Maintena group impending relapse occurred in 10 % of the patients; thus\r patients in the placebo group had a 5.03\u2011fold greater risk of\r experiencing impending relapse.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Prolactin<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r the Double-blind, Active-controlled Phase of the 38\u2011week trial, from\r baseline to last visit there was a mean decrease in prolactin levels in Abilify\r Maintena (\u22120.33 ng\/ml) compared with a mean increase in oral\r aripiprazole tablets 10\u201130 mg (0.79 ng\/ml; p &lt; 0.01).\r The incidence of Abilify Maintena patients with prolactin levels &gt; 1\r time the upper limit of normal range (ULN) at any assessment was 5.4 %\r compared with 3.5 % of the patients on oral aripiprazole tablets 10\u201130 mg.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Male\r patients generally had a higher incidence than female patients in each\r treatment group.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r the Double-blind Placebo-controlled Phase of the 52\u2011week trial, from\r baseline to last visit there was a mean decrease in prolactin levels in Abilify\r Maintena (\u22120.38 ng\/ml) compared with a mean increase in placebo\r (1.67 ng\/ml). The incidences of Abilify Maintena patients with prolactin\r levels &gt; 1 time the upper limit of normal range (ULN) was\r 1.9 % compared to 7.1 % for placebo patients.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Acute treatment of schizophrenia in\r adults<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of Abilify Maintena in acutely\r relapsed adult patients with schizophrenia was established in a short-term\r (12-week), randomised, double\u2011blind, placebo-controlled trial\r (n = 339).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint (change in PANSS total\r score from baseline to week 10) showed superiority of Abilify Maintena\r (n = 167) over placebo (n = 172).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Similar to the PANSS Total Score, both the\r PANSS positive and negative subscale scores also showed an improvement\r (decrease) from baseline over time.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Table 2       PANSS Total\r Score \u2013 Change From Baseline to week 10: Randomised Efficacy Sample<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r avoid\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr> <td colspan=\"3\" style=\"width:458.95pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"612\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">PANSS Total Score \u2013 Change\r   From Baseline to Week 10:<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Randomised Efficacy Sample <sup>a<\/sup><\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><sup><\/sup><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">400 mg\/300 mg<\/span><\/b><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"177\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Placebo<\/span><\/b><\/p> <p class=\"MsoNormal\"><b><sup><\/sup><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">Mean baseline (SD)<\/span><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><span lang=\"EN-GB\">102.4 (11.4)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">n = 162<\/span><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"177\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><span lang=\"EN-GB\">103.4 (11.1)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><span lang=\"EN-GB\">n = 167<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">LS Mean change\r   (SE)<\/span><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">26.8\r   (1.6)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">n = 99<\/span><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"177\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">11.7\r   (1.6)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><span lang=\"EN-GB\">n = 81<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">P-value<\/span><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"177\"> <p class=\"MsoNormal\"><b><sup><\/sup><\/b><\/p> <\/td> <\/tr> <tr style=\"height:3.2pt\"> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:3.2pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Treatment difference<sup>b<\/sup>\r   (95 % CI)<\/span><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:3.2pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">15.1\r   (<\/span><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">19.4, <\/span><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">10.8)<\/span><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:3.2pt\" valign=\"top\" width=\"177\"> <p class=\"MsoNormal\"><b><sup><\/sup><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">a        <\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">Data were analysed using a mixed model repeated\r measures (MMRM) approach. The analysis included only subjects who were randomly\r assigned to treatment, given at least one injection, had baseline and at least\r one post-baseline efficacy assessment.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">b        <\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">Difference (Abilify Maintena minus placebo) in least\r squares mean change from baseline.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena also showed statistically\r significant improvement in symptoms represented by CGIS score change from\r baseline to week 10.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Personal and social functioning were\r evaluated using the Personal and Social Performance (PSP) scale. The PSP is a\r validated clinician-rated scale that measures personal and social functioning\r in four domains: socially useful activities (e.g. work and study), personal and\r social relationships, self-care, and disturbing and aggressive behaviours.\r There was a statistically significant treatment difference in favour of Abilify\r Maintena 400 mg\/300 mg compared to placebo at week 10 (+7.1,\r p &lt; 0.0001, 95 % CI: 4.1, 10.1 using an ANCOVA model (LOCF)).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The safety profile was\r consistent with that known to Abilify Maintena. Nevertheless, there were\r differences from what has been observed with maintenance use in the treatment\r of schizophrenia. In <\/span><span lang=\"EN-GB\">a short-term (12-week),\r randomised, double\u2011blind, placebo-controlled trial with <span style=\"color:black\">Abilify Maintena 400<\/span> <span style=\"color:black\">mg\/300<\/span> <span style=\"color:black\">mg treated subjects the symptoms which had at least twice\r the incidence of placebo were increased weight and akathisia. The incidence of\r weight gain of \u2265 7 % from baseline to last visit (week<\/span> <span style=\"color:black\">12) was 21.5 % for Abilify Maintena compared with the\r placebo group 8.5 %. Akathisia was the most frequently observed EPS\r symptom (Abilify Maintena 11.4<\/span> <span style=\"color:black\">% and\r placebo group 3.5 %).<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Paediatric\r population<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r European Medicines Agency has waived the obligation to submit the results of\r studies with Abilify Maintena in all subsets of the paediatric population in\r schizophrenia (see section 4.2).<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.2     Pharmacokinetic\r properties<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Absorption<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r absorption into the systemic circulation is slow and prolonged following Abilify\r Maintena administration due to low solubility of aripiprazole particles.<\/span><\/em><span lang=\"EN-GB\">The <span style=\"color:black\">average absorption half-life of <em><span style=\"font-style:normal\">Abilify Maintena<\/span><\/em> is 28 days.<\/span>Absorption of aripiprazole from\r the IM depot formulation was complete relative to the IM standard\r (immediate-release) formulation<span style=\"color:black\">. The dose adjusted C<sub>max<\/sub>\r values for the depot formulation were approximately 5% of C<sub>max<\/sub> from IM\r standard formulation.<\/span>Following a single dose administration of Abilify\r Maintena in the deltoid and gluteal muscle, the extent of absorption (AUC) was\r similar for both injection sites, but the rate of absorption (C<sub>max<\/sub>)\r was higher following administration to the deltoid muscle. Following multiple\r intramuscular doses, the plasma concentrations of aripiprazole gradually rise\r to a maximum plasma concentration at a median t<sub>max <\/sub>of 7 days\r for the gluteal muscle and 4 days for the deltoid muscle. Steady state\r concentrations for the typical subject were attained by the fourth dose for\r both sites of administration. <em><span style=\"color:black;font-style:normal\">Less\r than dose-proportional increases in aripiprazole and dehydro-aripiprazole\r concentrations and AUC parameters are observed after monthly Abilify Maintena\r injections of 300 mg to 400 mg.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Distribution<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Based\r on results from trials with oral administration of aripiprazole, aripiprazole\r is widely distributed throughout the body with an apparent volume of\r distribution of 4.9 l\/kg, indicating extensive extravascular distribution.\r At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are\r greater than 99 % bound to serum proteins, binding primarily to albumin.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Biotransformation<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r is extensively metabolised by the liver primarily by three biotransformation pathways:\r dehydrogenation, hydroxylation, and N-dealkylation. Based on <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black\">in vitro<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> studies, CYP3A4 and CYP2D6 enzymes are\r responsible for dehydrogenation and hydroxylation of aripiprazole, and\r N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal\r product moiety in systemic circulation. After multiple dose administration of Abilify\r Maintena, dehydro-aripiprazole, the active metabolite, represents about 29.1\u201132.5 %\r of aripiprazole AUC in plasma.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Elimination<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r administration of multiple dose of 400 mg or 300 mg of Abilify\r Maintena, the mean aripiprazole terminal elimination half-life is respectively\r 46.5 and 29.9 days <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">presumably\r due to absorption rate-limited kinetics.<em><span style=\"font-style:normal\"> Following\r a single oral dose of [<sup>14<\/sup>C]-labelled aripiprazole, approximately 27 %\r of the administered radioactivity was recovered in the urine and approximately 60 %\r in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the\r urine and approximately 18 % was recovered unchanged in the faeces.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pharmacokinetics\r in special patient groups<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">CYP2D6 poor\r metabolisers<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Based\r on population pharmacokinetic evaluation of Abilify Maintena, the total body\r clearance of aripiprazole was 3.71 L\/h in extensive metabolisers of CYP2D6\r and approximately 1.88 L\/h (approximately 50 % lower) in\r poor metabolisers of CYP2D6 (for dose recommendation, see section 4.2).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Elderly<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r oral administration of aripiprazole, there are no differences in the\r pharmacokinetics of aripiprazole between healthy elderly and younger adult\r subjects. Similarly, there was no detectable effect of age in a population\r pharmacokinetic analysis of Abilify Maintena in schizophrenia patients.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Gender<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r oral administration of aripiprazole, there are no differences in the\r pharmacokinetics of aripiprazole between healthy male and female subjects.\r Similarly, there was no clinically relevant effect of gender in a population\r pharmacokinetic analysis of Abilify Maintena in clinical trials in patients\r with schizophrenia.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Smoking<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Population\r pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of\r clinically relevant effects from smoking on the pharmacokinetics of\r aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Race<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Population\r pharmacokinetic evaluation showed no evidence of race-related differences on\r the pharmacokinetics of aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Renal impairment<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r a single-dose study with oral administration of aripiprazole, the\r pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were\r found to be similar in patients with severe renal disease compared to that in young\r healthy subjects.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Hepatic impairment<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">A\r single-dose study with oral administration of aripiprazole to subjects with\r varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not\r reveal a significant effect of hepatic impairment on the pharmacokinetics of\r aripiprazole and dehydro-aripiprazole, but the study included only\r 3 patients with Class C liver cirrhosis, which is insufficient to draw\r conclusions on their metabolic capacity.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.3     Preclinical safety\r data<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r toxicological profile for aripiprazole administered to experimental animals by\r intramuscular injection is generally similar to that seen following oral\r administration at comparable plasma levels. With intramuscular injection,\r however <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">an inflammatory\r response was seen at the injection site, and consisted of granulomatous\r inflammation, foci (deposited drug), cellular infiltrates, oedema (swelling)\r and, in monkeys, fibrosis. <em><span style=\"font-style:normal\">These effects\r gradually resolved with discontinuation of dosing.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Non-clinical\r safety data for orally administered aripiprazole reveal no special hazard for\r humans based on conventional studies of safety pharmacology, repeated dose\r toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and\r development.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Oral\r aripiprazole<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">For\r oral aripiprazole, toxicologically significant effects were observed only at\r doses or exposures that were sufficiently in excess of the maximum human dose\r or exposure, indicating that these effects were limited or of no relevance to\r clinical use. These included: dose-dependent adrenocortical toxicity in rats\r after 104 weeks of oral administration at approximately 3 to\r 10 times the mean steady-state AUC at the maximum recommended human dose\r and increased adrenocortical carcinomas and combined adrenocortical\r adenomas\/carcinomas in female rats at approximately 10 times the mean\r steady-state AUC at the maximum recommended human dose. The highest\r non-tumorigenic exposure in female rats was approximately 7 times the\r human exposure at the recommended dose.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">An\r additional finding was cholelithiasis as a consequence of precipitation of\r sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of\r monkeys after repeated oral dosing at 25 to 125 mg\/kg\/day or\r approximately16 to 81 times the maximum recommended human dose based on\r mg\/m<sup>2<\/sup>.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">However,\r the concentrations of the sulphate conjugates of hydroxy-aripiprazole in human\r bile at the highest dose proposed, 30 mg per day, were no more than\r 6 % of the bile concentrations found in the monkeys in the 39\u2011week\r study and are well below (6 %) their limits of <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black\">in vitro<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> solubility.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r repeated dose studies in juvenile rats and dogs, the toxicity profile of\r aripiprazole was comparable to that observed in adult animals, and there was no\r evidence of neurotoxicity or adverse events on development.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Based\r on results of a full range of standard genotoxicity tests, aripiprazole was\r considered non-genotoxic. Aripiprazole did not impair fertility in reproductive\r toxicity studies.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Developmental\r toxicity, including dose-dependent delayed foetal ossification and possible\r teratogenic effects, were observed in rats at doses resulting in\r sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in\r exposures approximately 3 and 11 times the mean steady-state AUC at\r the maximum recommended clinical dose. Maternal toxicity occurred at doses\r similar to those eliciting developmental toxicity.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.       PHARMACEUTICAL\r PARTICULARS<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.1     List of excipients<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Powder<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Carmellose\r sodium<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Mannitol<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Sodium\r dihydrogen phosphate monohydrate<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Sodium\r hydroxide<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Solvent<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Water\r for injections<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.2     Incompatibilities<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Not\r applicable<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.3     Shelf life<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3 years<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r powder and solvent for prolonged-release suspension for injection<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r suspension should be injected immediately after reconstitution but can be stored\r below 25 \u00b0C for up to 4 hours in the vial.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r powder and solvent for prolonged-release suspension for injection in pre\u2011filled syringe<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r suspension should be injected immediately after reconstitution but can be\r stored below 25 \u00b0C for up to 2 hours in the syringe.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">After reconstitution<\/span><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Chemical and physical in-use stability has\r been demonstrated for 4 hours at 25 \u00b0C. From a microbiological point\r of view, unless the method of opening\/ reconstitution precludes the risk of\r microbial contamination, the product should be used immediately. If not used\r immediately, in-use storage times and conditions are the responsibility of\r user. Do not store the reconstituted suspension in the syringe.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If the injection is not\r performed immediately after reconstitution, the syringe can be kept below 25 \u00b0C\r for up to 2 hours.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.4     Special precautions\r for storage<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not freeze.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the syringe in the outer carton in\r order to protect from light.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after reconstitution\r of the medicinal product, see section 6.3.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.5     Nature and contents of\r container<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Vial<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Type\u2011I\r glass vial stoppered with a laminated rubber stopper and sealed with a flip-off\r aluminium cap.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2 ml\r Type\u20111 glass vial stoppered with a laminated rubber stopper and sealed\r with a flip-off aluminium cap.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Single pack<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r single pack containing one vial of powder, 2 ml vial of solvent, one\r 3 ml luer lock syringe with pre-attached 38 mm (1.5 inch)\r 21 gauge, hypodermic safety needle with needle protection device, one\r 3 ml disposable syringe with luer lock tip, one vial adapter and three\r hypodermic safety needles: one 25 mm (1 inch) 23 gauge, one\r 38 mm (1.5 inch) 22 gauge and one 51 mm (2 inch)\r 21 gauge.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Multipack<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Bundle\r pack of 3 single packs.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Clear glass\r pre-filled syringe (type-I glass) with grey chlorobutyl stoppers (front-,\r middle- and end stopper), polypropylene front assembly, polypropylene finger\r grip, plunger rod, and silicone over-cap. The front chamber between front\r stopper and middle stopper contains the powder and the rear chamber between\r middle stopper and end stopper the solvent.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Single pack<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r single pack containing one pre\u2011filled syringe, and three hypodermic\r safety needles: one 25 mm (1 inch) 23 gauge, one 38 mm\r (1.5 inch) 22 gauge and one 51 mm (2 inch) 21 gauge.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Multipack<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Bundle\r pack of 3 single packs.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Not\r all pack sizes may be marketed.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.6     Special precautions\r for disposal and other handling<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify Maintena 300 mg powder and\r solvent for prolonged-release suspension for injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify Maintena 400 mg powder and\r solvent for prolonged-release suspension for injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Vertically shake the\r syringe vigorously for 20 seconds until medicine is uniformly milky-white\r and use immediately. If the injection is not performed immediately after\r reconstitution, the syringe can be kept below 25 \u00b0C for up to 2 hours.\r Shake the syringe vigorously for at least 20 seconds to re\u2011suspend\r prior to injection if the syringe has been left for more than 15 minutes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Gluteal muscle\r administration<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The recommended needle for gluteal\r administration is a 38 mm (1.5 inch), 22 gauge hypodermic safety\r needle; for obese patients (Body mass index &gt; 28 kg\/m<sup>2<\/sup>),\r a 51 mm (2 inch), 21 gauge hypodermic safety needle should be\r used. <\/span><\/em><span lang=\"EN-GB\">Gluteal injections should be alternated\r between the two gluteal muscles.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Deltoid muscle\r administration<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"font-style:normal\">The recommended\r needle for deltoid administration is a 25 mm (1 inch), 23 gauge\r hypodermic safety needle; for obese patients, a 38 mm (1.5 inch),\r 22 gauge hypodermic safety needle should be used.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Deltoid\r injections should be alternated between the two deltoid muscles.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r powder and solvent vials and the pre\u2011filled syringe are for\r single-use only.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Full instructions for\r use and handling of Abilify Maintena are provided in the package leaflet\r (information intended for healthcare professionals).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">8.       MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/001<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/003<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/002<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/004<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/005<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/007<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/006<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/008<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">9.       DATE OF FIRST\r AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Date\r of first authorisation: 15 November 2013<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Date\r of latest renewal: 27 August 2018<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">10.     DATE OF REVISION OF\r THE TEXT<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">MM\/YYYY<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency <a href=\"http:\/\/www.ema.europa.eu\/\"><u>http:\/\/www.ema.europa.eu<\/u><\/a>.<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">ANNEX II<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\" style=\"color:black\">A.      MANUFACTURER RESPONSIBLE\r FOR BATCH RELEASE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\" style=\"color:black\">B.      CONDITIONS OR\r RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\" style=\"color:black\">C.      OTHER CONDITIONS AND\r REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\" style=\"color:black\">D.      CONDITIONS OR\r RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"TitleB\"><span lang=\"EN-GB\">A.      MANUFACTURER RESPONSIBLE FOR BATCH\r RELEASE<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><u><span lang=\"EN-GB\">Name and address of the manufacturer responsible for batch release<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">H. Lundbeck A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Ottiliavej 9<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">DK2500\r Valby<\/span><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Denmark<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">Elaiapharm<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2881 Route des\r Cr\u00eates Z.I Les Bouillides Sophia Antipolis<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">06550 Valbonne<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">France<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The printed package leaflet of the\r medicinal product must state the name and address of the manufacturer\r responsible for the release of the concerned batch.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\">B.      CONDITIONS OR RESTRICTIONS REGARDING\r SUPPLY AND USE<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Medicinal\r product subject to medical prescription.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\">C.      OTHER CONDITIONS AND REQUIREMENTS OF\r THE MARKETING AUTHORISATION<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\">\u2022        Periodic <span style=\"color:black\">safety\r update reports<\/span><\/span><\/b><b><span lang=\"EN-GB\" style=\"color:black\"> (PSURs)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The requirements for submission of <\/span><span lang=\"EN-GB\">PSURs<\/span><span lang=\"EN-GB\"> for this medicinal product are set out\r in the list of Union reference dates (EURD list) provided for under Article\r 107c(7) of Directive 2001\/83\/EC and any subsequent updates published on the\r European medicines web-portal.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:34.35pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:34.35pt;text-autospace:none\"><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\">D.      CONDITIONS OR RESTRICTIONS WITH REGARD\r TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:\r avoid;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\">\u2022        Risk <\/span><\/b><b><span lang=\"EN-GB\">management\r plan<\/span><\/b><b><span lang=\"EN-GB\"> (RMP)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><span lang=\"EN-GB\">The <\/span><span lang=\"EN-GB\">marketing authorisation holder (<\/span><span lang=\"EN-GB\">MAH<\/span><span lang=\"EN-GB\">)<\/span><span lang=\"EN-GB\"> shall perform\r the required pharmacovigilance activities and interventions detailed in the\r agreed RMP presented in Module1.8.2 of\r the <\/span><span lang=\"EN-GB\">marketing authorisation<\/span><span lang=\"EN-GB\"> and\r any agreed subsequent updates of the RMP.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><span lang=\"EN-GB\">An updated RMP should be submitted:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:6.0pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\">\u2022        <\/span><\/b><span lang=\"EN-GB\">At the request\r of the European Medicines Agency;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\">\u2022        <\/span><\/b><span lang=\"EN-GB\">Whenever the\r risk management system is modified, especially as the result of new information\r being received that may lead to a significant change to the benefit\/risk\r profile or as the result of an important (pharmacovigilance or risk\r minimisation) milestone being reached.<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center;\r text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">ANNEX III<\/span><\/b><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">LABELLING AND PACKAGE LEAFLET<\/span><\/b><\/em><\/p> <em><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\"><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b><\/em> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">A. LABELLING<\/span><\/p> <em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\"><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/em> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Outer carton - Single pack 300 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\r 300 mg aripiprazole. After reconstitution each ml of suspension contains\r 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of powder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of 2 ml solvent<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Two sterile syringes, one with needle for reconstitution<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One vial adapter<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Shelf-life after\r reconstitution: 4 hours below 25 \u00b0C<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not store the\r reconstituted suspension in the syringe.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS OF\r THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/001<\/span><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Outer label (with blue box) - Multipack 300 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\r 300 mg aripiprazole.After reconstitution each ml of suspension contains\r 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Multipack: Three single packages, each containing:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of powder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of 2 ml solvent<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Two sterile syringes, one with needle for reconstitution<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One vial adapter<\/span><\/p> <p class=\"MsoCommentText\"><\/p> <p class=\"MsoCommentText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL WARNING(S),\r IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Shelf-life after\r reconstitution: 4 hours below 25 \u00b0C<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not store the\r reconstituted suspension in the syringe.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS OF\r THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/003<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL CLASSIFICATION\r FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"background:white\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Carton (without blue box) \u2013 component of\r multipack 300 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection<\/span><\/p> <p class=\"MsoNormal\">aripiprazole<\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 300 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml of suspension contains 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL FORM\r AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Single package containing:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of powder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of 2 ml solvent<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Two sterile syringes, one with needle for reconstitution<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One vial adapter<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Component of a multipack, can\u2019t be sold\r separately.<\/span><\/p> <p class=\"MsoCommentText\"><\/p> <p class=\"MsoCommentText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Shelf-life after\r reconstitution: 4 hours below 25 \u00b0C<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not store the reconstituted\r suspension in the syringe.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS OF\r THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/003<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE\r PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Vial powder 300 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder for prolonged-release injection<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">IM<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       METHOD OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">300 mg<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Outer carton - Single pack 400 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\r 400 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml of suspension contains 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of powder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of 2 ml solvent<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Two sterile syringes, one with needle for reconstitution<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One vial adapter<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Shelf-life after\r reconstitution: 4 hours below 25 \u00b0C<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not store the reconstituted\r suspension in the syringe.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS\r OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/002<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Outer label (with blue box) - Multipack 400 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF ACTIVE\r SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\r 400 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml of suspension contains 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Multipack: Three single packages, each containing:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of powder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of 2 ml solvent<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Two sterile syringes, one with needle for reconstitution<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One vial adapter<\/span><\/p> <p class=\"MsoCommentText\"><\/p> <p class=\"MsoCommentText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Shelf-life after\r reconstitution: 4 hours below 25 \u00b0C<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not store the\r reconstituted suspension in the syringe.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS\r OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/004<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL CLASSIFICATION\r FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"background:white\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Carton (without blue box) \u2013 component of\r multipack 400 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection<\/span><\/p> <p class=\"MsoNormal\">aripiprazole<\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each vial contains\r 400 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml<\/span><span lang=\"EN-GB\"> of suspension contains 200 mg\r aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Single package containing:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of powder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One vial of 2 ml solvent<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Two sterile syringes, one with needle for reconstitution<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One vial adapter<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Component of a multipack, can\u2019t be sold\r separately.<\/span><\/p> <p class=\"MsoCommentText\"><\/p> <p class=\"MsoCommentText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Shelf-life after\r reconstitution: 4 hours below 25 \u00b0C<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not store the\r reconstituted suspension in the syringe.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED\r FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS OF\r THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/004<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING\r UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Vial Powder 400 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder for prolonged-release injection<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">IM<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       METHOD OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">400 mg<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING\r UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Vial solvent<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Solvent for Abilify\r Maintena<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       METHOD OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">2 ml<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Outer carton - Single pack 300 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each pre\u2011filled\r syringe contains 300 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml of suspension contains 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One<\/span><span lang=\"EN-GB\"> pre\u2011filled syringe\r containing powder in the front chamber and solvent in the rear chamber.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Vertically shake the\r syringe vigorously for 20 seconds until medicine is uniformly milky-white\r and use immediately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If the injection is not\r performed immediately after reconstitution, the syringe can be kept below 25 \u00b0C\r for up to 2 hours. Shake the syringe vigorously for at least\r 20 seconds to re\u2011suspend prior to injection if the syringe has been\r left for more than 15 minutes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Keep the pre\u2011filled syringe\r in the outer carton in order to protect from light.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard pre\u2011filled\r syringe and needles appropriately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS OF\r THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/005<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Outer label (with blue box) - Multipack 300 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each pre\u2011filled\r syringe contains 300 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml of suspension contains 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Multipack: Three single packages, each containing:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One <\/span><span lang=\"EN-GB\">pre<span style=\"color:black\">\u2011<\/span>filled\r syringe containing powder in the front chamber and solvent in the rear chamber.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoCommentText\"><\/p> <p class=\"MsoCommentText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Vertically shake the\r syringe vigorously for 20 seconds until medicine is uniformly milky-white\r and use immediately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If the injection is not\r performed immediately after reconstitution, the syringe can be kept below\r 25 \u00b0C for up to 2 hours. Shake the syringe vigorously for at least\r 20 seconds to re\u2011suspend prior to injection if the syringe has been\r left for more than 15 minutes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Keep the pre\u2011filled syringe\r in the outer carton in order to protect from light.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard pre<\/span><span lang=\"EN-GB\">\u2011<span style=\"color:black\">filled syringe and needles\r appropriately.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS\r OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/007<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"background:white\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Carton (without blue box) \u2013 component of\r multipack 300 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/p> <p class=\"MsoNormal\">aripiprazole<\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each pre\u2011filled syringe contains\r 300 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml of suspension contains 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Single package containing:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One <\/span><span lang=\"EN-GB\">pre\u2011filled syringe\r containing powder in the front chamber and solvent in the rear chamber.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Component of a multipack, can\u2019t be sold\r separately.<\/span><\/p> <p class=\"MsoCommentText\"><\/p> <p class=\"MsoCommentText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Vertically shake the\r syringe vigorously for 20 seconds until medicine is uniformly milky-white\r and use immediately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If the injection is not\r performed immediately after reconstitution, the syringe can be kept below\r 25 \u00b0C for up to 2 hours. Shake the syringe vigorously for at least\r 20 seconds to re\u2011suspend prior to injection if the syringe has been\r left for more than 15 minutes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Keep the pre\u2011filled syringe\r in the outer carton in order to protect from light.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard pre<\/span><span lang=\"EN-GB\">\u2011<span style=\"color:black\">filled syringe and needles appropriately.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS\r OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/007<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"text-autospace:none;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE\r PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Pre\u2011filled syringe - 300 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg injection<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">IM<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       METHOD OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">300 mg<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Outer carton - Single pack 400 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each pre\u2011filled\r syringe contains 400 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml of suspension contains 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">One<\/span><span lang=\"EN-GB\"> pre<span style=\"color:black\">\u2011<\/span>filled syringe\r containing powder in the front chamber and solvent in the rear chamber.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety\r needles<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Vertically shake the\r syringe vigorously for 20 seconds until medicine is uniformly milky-white\r and use immediately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL WARNING(S),\r IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If the injection is not\r performed immediately after reconstitution, the syringe can be kept below\r 25 \u00b0C for up to 2 hours. Shake the syringe vigorously for at least\r 20 seconds to re\u2011suspend prior to injection if the syringe has been\r left for more than 15 minutes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the pre\u2011filled syringe in the\r outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard pre<\/span><span lang=\"EN-GB\">\u2011<span style=\"color:black\">filled syringe and needles\r appropriately.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS\r OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/006<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification\r for not including Braille accepted.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<\/span><\/p> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Outer label (with blue box) - Multipack\r 400 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each pre\u2011filled\r syringe contains 400 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml of suspension contains 200 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Multipack: Three single packages, each containing:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One <\/span><span lang=\"EN-GB\">pre<span style=\"color:black\">\u2011<\/span>filled\r syringe containing powder in the front chamber and solvent in the rear chamber.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety needles<\/span><\/p> <p class=\"MsoCommentText\"><\/p> <p class=\"MsoCommentText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Vertically shake the syringe\r vigorously for 20 seconds until medicine is uniformly milky-white and use\r immediately.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If the injection is not\r performed immediately after reconstitution, the syringe can be kept below\r 25 \u00b0C for up to 2 hours. Shake the syringe vigorously for at least\r 20 seconds to re\u2011suspend prior to injection if the syringe has been\r left for more than 15 minutes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the pre\u2011filled syringe in the\r outer carton in order to protect from light.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard pre<\/span><span lang=\"EN-GB\">\u2011<span style=\"color:black\">filled syringe and needles appropriately.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS\r OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/008<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"background:white\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Carton (without blue box) \u2013 component of\r multipack 400 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection\r in pre<\/span><span lang=\"EN-GB\">\u2011<span style=\"color:black\">filled syringe<\/span><\/span><\/p> <p class=\"MsoNormal\">aripiprazole<\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each pre\u2011filled\r syringe contains 400 mg aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">After reconstitution\r each ml<\/span><span lang=\"EN-GB\"> of suspension contains 200 mg\r aripiprazole.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Powder<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Carmellose sodium,\r mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Powder and solvent for prolonged-release\r suspension for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Single package containing:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">One <\/span><span lang=\"EN-GB\">pre<span style=\"color:black\">\u2011<\/span>filled\r syringe containing powder in the front chamber and solvent in the rear chamber.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Three hypodermic safety\r needles<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Component of a multipack, can\u2019t be sold\r separately.<\/span><\/p> <p class=\"MsoCommentText\"><\/p> <p class=\"MsoCommentText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Intramuscular use only<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Vertically shake the\r syringe vigorously for 20 seconds until medicine is uniformly milky-white\r and use immediately.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       SPECIAL WARNING THAT\r THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If the injection is not\r performed immediately after reconstitution, the syringe can be kept below\r 25 \u00b0C for up to 2 hours. Shake the syringe vigorously for at least\r 20 seconds to re\u2011suspend prior to injection if the syringe has been\r left for more than 15 minutes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the pre\u2011filled syringe in the\r outer carton in order to protect from light.<\/span><\/p> <p align=\"left\" class=\"BMSBodyText\" style=\"margin:0in;text-align:left;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard pre<\/span><span lang=\"EN-GB\">\u2011<span style=\"color:black\">filled syringe and needles appropriately.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.     NAME AND ADDRESS\r OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.     MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/008<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.     INSTRUCTIONS ON\r USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 1.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">16.     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black;background:silver\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING\r UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">Pre\u2011filled syringe - 400 mg<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.       NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg injection<\/span><\/p> <p class=\"MsoNormal\"><span style=\"color:black\">aripiprazole<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">IM<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.       METHOD OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lot<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.       CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">400 mg<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <em><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\"><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b><\/em> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\"><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/em> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Package leaflet: Information\r for the user<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">300 mg\r powder and solvent for prolonged-release suspension for injection<\/span><\/em><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">400 mg\r powder and solvent for prolonged-release suspension for injection<\/span><\/em><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">aripiprazole<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Read\r all of this leaflet carefully before you receive this medicine because it\r contains important information for you.<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        Keep this leaflet.\r You may need to read it again.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        If you have any\r further questions, ask your doctor or nurse.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        If you get any side\r effects, talk to your doctor or nurse. This includes any possible side effects\r not listed in this leaflet. See section 4.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">What is in this leaflet<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.       What <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">is and what it is used for<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2.       What you need to know\r before you are given <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3.       How <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">is given<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.       Possible side effects<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.       How to store <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.       Contents of the pack\r and other information<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.       What <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">is and what it is used for<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">contains the active substance aripiprazole and\r belongs to a group of medicines called antipsychotics. It is used to treat\r schizophrenia - a disease with symptoms such as hearing, seeing or sensing\r things which are not there, suspiciousness, mistaken beliefs, incoherent speech\r and behaviour and emotional flatness. People with this condition may also feel\r depressed, guilty, anxious or tense.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">is intended for adult patients with schizophrenia who\r are sufficiently stabilised during treatment with oral aripiprazole.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2.       What you need to know\r before you are given <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not use <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">        if you are allergic to\r aripiprazole or any of the other ingredients of this medicine (listed in\r section 6).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Warnings\r and precautions<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Talk\r to your doctor or nurse before you are given <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<em><span style=\"font-style:normal\">.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Suicidal\r thoughts and behaviours have been reported during aripiprazole treatment. Tell\r your doctor immediately if you are having any thoughts or feelings about\r hurting yourself.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Before\r treatment with <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<em><span style=\"font-style:normal\">, tell your doctor if you suffer\r from<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        an acutely agitated\r state or a severely psychotic state<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        heart problems or\r have a history of stroke, especially if you know that you have other risks\r factors for stroke<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        high blood sugar\r (characterised by symptoms such as excessive thirst, passing of large amounts\r of urine, increase in appetite and feeling weak) or family history of diabetes<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        fits (seizures) since\r your doctor may want to monitor you more closely<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        involuntary,\r irregular muscle movements, especially in the face<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">experience a combination of fever, sweating,\r faster breathing, muscle stiffness and drowsiness or sleepiness (may be signs\r of neuroleptic malignant syndrome)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">dementia (loss of memory and other mental\r abilities) especially if you are elderly<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        cardiovascular\r diseases (diseases of the heart and circulation), family history of\r cardiovascular disease, stroke or \"mini\" stroke, abnormal blood\r pressure<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        irregular heart beat\r or if someone else in your family has a history of irregular heart beat\r (including so called QT prolongation seen with ECG monitoring).<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        blood clots, or family\r history of blood clots, as antipsychotics have been associated with formation\r of blood clots<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">have any difficulty in swallowing<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        past experience with\r excessive gambling<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        severe liver\r problems.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you notice you are gaining weight, develop unusual movements, experience\r sleepiness that interferes with normal daily activities, any difficulty in swallowing\r or have allergic symptoms, please talk to your doctor immediately.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your\r family\/carer notices that you are developing urges or cravings to behave in\r ways that are unusual for you and you cannot resist the impulse, drive or\r temptation to carry out certain activities that could harm yourself or others.\r These are called impulse control disorders and can include behaviours such as\r addictive gambling, excessive eating or spending, an abnormally high sex drive\r or preoccupation with an increase in sexual thoughts or feelings.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Your doctor may need to adjust or stop\r your dose.<\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Aripiprazole may cause sleepiness, fall in\r blood pressure when standing up, dizziness and changes in your ability to move\r and balance, which may lead to falls. Caution should be taken, particularly if\r you are an elderly patient or have some debility.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">Children and\r adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not use this\r medicine in children and adolescents under 18 years of age. It is not\r known if it is safe and effective in these patients.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Other\r medicines and <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tell\r your doctor if you are taking, have recently taken or might take any other\r medicines.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Blood\r pressure-lowering medicines:<\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">\r Abilify Maintena <em><span style=\"font-style:normal\">may increase the effect of\r medicines used to lower the blood pressure. Be sure to tell your doctor if you\r take a medicine to keep your blood pressure under control.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Receiving\r <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">with some medicines may mean the doctor will need to\r change your dose of <\/span><\/em>Abilify Maintena <em><span style=\"font-style:\r normal\">or the other medicines. It is especially important to mention the\r following to your doctor:<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        medicines to correct\r heart rhythm (such as quinidine, amiodarone, flecainide)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        antidepressants or\r herbal remedy used to treat depression and anxiety<\/span><\/em><span class=\"berschrift4Zchn\"><\/span><span class=\"berschrift4Zchn\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;color:black;font-weight:normal'>(<\/span><\/span><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">such as fluoxetine,\r paroxetine, St. John's Wort)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        antifungal medicines\r (such as ketoconazole, itraconazole)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        certain medicines to\r treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors\r e.g. indinavir, ritonavir)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        anticonvulsants used\r to treat epilepsy (such as <\/span><\/em><span class=\"BMSHeading3Char\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;font-weight:normal'>carbamazepine,\r phenytoin,<\/span><\/span><span class=\"BMSHeading3Char\"><\/span><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">phenobarbital)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        certain antibiotics\r used to treat tuberculosis (rifabutin, rifampicin)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        medicines that are\r known to prolong QT prolongation.<\/span><\/em><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">These medicines\r may increase the risk of side effects or reduce the effect of <span style=\"color:black\">Abilify Maintena<\/span>; if you get any unusual symptom\r taking any of these medicines together with <span style=\"color:black\">Abilify\r Maintena<\/span>, you should see your doctor.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">Medicines\r that increase the level of serotonin <\/span><span class=\"BMSHeading3Char\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r font-weight:normal'>are typically used in conditions including depression,\r generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social\r phobia as well as migraine and pain<\/span><\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">:<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt\">triptans, tramadol and tryptophan used for\r conditions including depression, generalised anxiety disorder, obsessive\r compulsive disorder (OCD) and social phobia as well as migraine and pain<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">SSRI s (such as paroxetine and\r fluoxetine) used for depression, OCD, panic and anxiety<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">other anti-depressants (such as\r venlafaxine and tryptophan) used in major depression<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">tricyclic\u2019s (such as\r clomipramine and amitriptyline) used for depressive illness<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">St John\u2019s Wort (<i>Hypericum\r perforatum<\/i>) used as a herbal remedy for mild depression<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">painkillers (such as tramadol\r and pethidine) used for pain relief<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">triptans (such as sumatriptan\r and zolmitripitan) used for treating migraine.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">These medicines\r may increase the risk of side effects; if you get any unusual symptom taking\r any of these medicines together with <span style=\"color:black\">Abilify Maintena<\/span>,\r you should see your doctor.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">with alcohol<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Alcohol\r should be avoided.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pregnancy,\r breast-feeding and fertility<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you are pregnant or breast-feeding, think you may be pregnant or are planning\r to have a baby, ask your doctor for advice before receiving this medicine.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">You\r should not be given <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena <em><span style=\"font-style:normal\">if you are pregnant unless you\r have<\/span><\/em><\/span><\/b><em><span lang=\"EN-GB\" style=\"color:black;font-style:\r normal\"> discussed this with your doctor. <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Be sure to tell your doctor immediately if you are\r pregnant, think you may be pregnant, or if you are planning to become pregnant.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r following symptoms may occur in new-born babies, of mothers that have received <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">in the last trimester (last three months of their pregnancy):<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">shaking,\r muscle stiffness and\/or weakness, sleepiness, agitation, breathing problems,\r and difficulty in feeding.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r your baby develops any of these symptoms you need to contact your doctor.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you are receiving <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<em><span style=\"font-style:normal\">, your doctor will discuss with you\r whether you should breast-feed considering the benefit to you of your therapy\r and the benefit to your baby of breast-feeding. You should not do both. Talk to\r your doctor about the best way to feed your baby if you are receiving <\/span><\/em>Abilify\r Maintena<em><span style=\"font-style:normal\">.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Driving\r and using machines<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dizziness and vision problems may occur\r during treatment with this medicine (see section 4). This should be\r considered in cases where full alertness is required, e.g., when driving a car\r or handling machines.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Abilify Maintena contains sodium<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena contains less than 1 mmol\r sodium (23 mg) per dose. This means that the medicine is essentially\r \u2018sodium-free\u2019.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3.       How <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">is given<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Abilify\r Maintena comes as a powder which your doctor or nurse will make into a\r suspension.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Your doctor\r will decide on the dose of Abilify Maintena that is right for you. The\r recommended starting dose is 400 mg unless your doctor decided to give you\r a lower starting or follow up dose (300 mg, 200 mg or 160 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\">There are two ways to start\r Abilify Maintena, your doctor will decide which way is right for you.<\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span style=\"color:black;\r font-style:normal\">\u2022        <\/span><\/em>If you are given one injection of\r Abilify Maintena on your first day the <span lang=\"EN-GB\">treatment with     aripiprazole\r by mouth is continued for 14 days after the first injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span style=\"color:black;font-style:normal\">\u2022        <\/span><\/em>If\r you are given two injections of Abilify Maintena on your first day, you will\r also take one tablet of aripiprazole by mouth at this visit.<\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">After that,\r treatment is given with injections of Abilify Maintena unless your doctor\r tells you otherwise.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Your doctor\r will give it to you as a single injection into the gluteal or deltoid muscle\r (buttock or shoulder) every month. You may feel a little pain during the\r injection. Your doctor will alternate the injections between your right and\r left side. The injections will not be given intravenously.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you are given more <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena <em><span style=\"font-style:normal\">than you should<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">This\r medicine will be given to you under medical supervision; it is therefore\r unlikely that you will be given too much. If you see more than one doctor, be\r sure to tell them that you are receiving <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<em><span style=\"font-style:normal\">.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Patients\r who have been given too much aripiprazole have experienced the following\r symptoms:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        rapid heartbeat,\r agitation\/aggressiveness, problems with speech.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        unusual movements\r (especially of the face or tongue) and reduced level of consciousness.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Other\r symptoms may include:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        acute confusion,\r seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        muscle stiffness, and\r drowsiness or sleepiness, slower breathing, choking, high or low blood\r pressure, abnormal rhythms of the heart.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Contact\r your doctor or hospital immediately if you experience any of the above.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you miss an injection of <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">It\r is important not to miss your scheduled dose. You should be given an injection\r every month but not before the 26 days has passed from the last injection.\r If you miss an injection, you should contact your doctor to arrange your next\r injection as soon as you can.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you stop receiving <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not stop your treatment just because you feel better. It is important that you\r carry on receiving <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena <em><span style=\"font-style:normal\">for as long as your doctor has\r told you to.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you have any further questions on the use of this medicine, ask your doctor or\r nurse.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.       Possible side effects<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Like\r all medicines, this medicine can cause side effects, although not everybody\r gets them.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tell\r your doctor immediately if you have any of the following serious side effects:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        a combination of any\r of these symptoms: excessive sleepiness, dizziness, confusion, disorientation,\r difficulty talking, difficulty walking, muscle stiffness or shaking, fever,\r weakness, irritability, aggression, anxiety, increase in blood pressure, or seizures\r that can lead to unconsciousness.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        unusual movement\r mainly of the face or tongue, since your doctor may want to lower your dose.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        if you have symptoms\r such as swelling, pain, and redness in the leg, because this may mean you have\r a blood clot, which may travel through blood vessels to the lungs causing chest\r pain and difficulty in breathing. If you notice any of these symptoms seek\r medical advice immediately.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        a combination of\r fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness\r since this may be a sign of a condition called neuroleptic malignant syndrome\r (NMS).<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        thirstiness more than\r usual, need to urinate more than usual, feel very hungry, feel weak or tired,\r feel sick, feel confused or your breath smells fruity, since this may be a sign\r of diabetes.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r side effects listed below may also occur after receiving Abilify Maintena.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black\">Common side effects (may affect up to 1 in 10 people):<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        weight\r gain<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        diabetes\r mellitus<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        weight\r loss<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">feeling restless<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">feeling anxious<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">unable to keep still, difficulty sitting still<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">difficulty sleeping (insomnia)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">jerky resistance to passive movement as muscles\r tense and relax, abnormally increased muscle tone, slow body movement<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">akathisia (an uncomfortable feeling of inner\r restlessness and a compelling need to move constantly)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">shaking or trembling<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">uncontrollable twitching, jerking or writhing\r movements<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">changes in your level of alertness, drowsiness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">sleepiness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">dizziness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">headache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">dry mouth<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle stiffness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">inability to have or maintain an erection during\r sexual intercourse<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">pain at the injection site, hardening of the\r skin at the injection site<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">weakness, loss of strength or extreme tiredness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">during blood tests your doctor may find higher\r amounts of creatine phosphokinase in your blood (enzyme important for muscle\r function)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Uncommon side\r effects (may affect up to 1 in 100 people):<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">low level of a specific type of white blood\r cells (neutropenia), low haemoglobin or red blood cell count, low level of\r blood platelets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">allergic reactions (hypersensitivity)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        decreased\r or <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">increased blood levels of\r the hormone prolactin<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">high blood sugar<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">increased blood fats such as high cholesterol,\r high triglycerides and also low level of cholesterol and low level of\r triglycerides<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">increased levels of insulin, a hormone\r regulating blood sugar levels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">decreased or increased appetite<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">thoughts about suicide<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">mental disorder characterized by defective or\r lost contact with reality<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">hallucination<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">delusion<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">increased sexual interest<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">panic reaction<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">depression<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">affect lability<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">state of indifference with lack of emotion,\r feelings of emotional and mental discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">sleep disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">grinding of teeth or clenching of the jaw<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">reduced sexual interest (libido is decreased)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">altered mood<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle problems<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle movements that you cannot control such as\r grimacing, lip-smacking and tongue movements. They usually affect the face and\r mouth first but can affect other parts of the body. These could be signs of a\r condition called \u201ctardive dyskinesia\u201d.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">parkinsonism - medical condition with many\r various symptoms which include decreased or slow movements, slowness of\r thought, jerks when bending the limbs (cogwheel rigidity), shuffling, hurried\r steps, shaking, little or no facial expression, muscle stiffness, drooling<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">movement problems<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">extreme restlesness and restless legs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">distortion of the senses of taste and smell<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">fixation of the eyeballs in one position<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">blurred vision<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">eye pain<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">double vision<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span style=\"color:black;font-style:normal\">\u2022        eye sensitivity to light,<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">abnormal heartbeat, slow or fast heart rate,\r abnormal electrical conduction of the heart, abnormal reading (ECG) of the\r heart<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">high blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">dizziness when getting up from a lying or\r sitting position due to a drop in blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">cough<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">hiccups<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">gastroesophageal reflux disease. Excess amount\r of gastric juice flowing back (refluxes) into the esophagus (gullet or the tube\r that goes from mouth to stomach through which food passes), causing heartburn\r and possibly damaging the esophagus<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">heartburn<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">diarrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">feeling sick<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">stomach ache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">stomach discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">constipation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">frequent bowel movement<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">drooling, more saliva in mouth than normal<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">abnormal hair loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">acne, skin condition of the face where the nose\r and cheeks are unusually red, eczema,skin\r hardening<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle rigidity, muscle spasms, muscle\r twitching, muscle tightness, mucle pain (myalgia), pain in extremity<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">joint pain ( arthralgia), back pain, decreased range\r of motion of joints, stiff neck, limited opening of mouth<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">kidney stones, sugar (glucose) in urine<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">spontaneous flow of milk from the breasts\r (galactorrhoea)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">enlargement of breast in men, breast tenderness,\r vaginal dryness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">fever<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">loss of strength<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">gait disturbance<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">chest discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">injection site reactions such as redness,\r swelling discomfort and injection site itching<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">thirst<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">sluggishness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">liver function tests may show abnormal results<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">during tests your doctor may find<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of liver\r enzymes<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of alanine\r aminotransferase<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of\r gamma-glutamyl transferase<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of bilirubin\r in your blood<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of aspartate\r aminotransferase<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher or lower amounts of\r blood glucose<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of\r glycosylated haemoglobin<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        lower amounts of cholesterol\r in your blood<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        lower amounts of triglycerides\r in your blood<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        a higher waist\r circumference<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">The following side\r effects have been reported since the marketing of oral aripiprazole but the\r frequency for them to occur is not known (frequency cannot be estimated from\r the available data):<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        low levels of white\r blood cells<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        allergic reaction\r (e.g. swelling in the mouth, tongue, face and throat, itching, hives), rash<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        unusual heartbeat,\r sudden unexplained death, heart attack<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        diabetic ketoacidosis\r (ketones in the blood and urine) or coma<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        loss of appetite\r (anorexia), <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">difficulty in\r swallowing<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        low sodium level in\r the blood<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        suicide attempt and\r suicide<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\">inability to resist the impulse, drive or temptation to perform an\r action that could be harmful to you or others, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        strong impulse to gamble excessively despite\r serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        altered or increased sexual interest and\r behaviour of significant concern to you or to others, for example, an increased\r sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        uncontrollable excessive shopping<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        binge eating (eating large amounts of food in a\r short time period) or compulsive eating (eating more food than normal and more\r than is needed to satisfy your hunger)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        a tendency to wander away<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-autospace:none\"><span lang=\"EN-GB\">Tell your doctor if you experience any of these behaviours; he\/she\r will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        nervousness<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">aggression<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        neuroleptic malignant\r syndrome ( a syndrome with symptoms such as fever, muscle stiffness, faster\r breathing, sweating, reduced consciousness and sudden changes in blood pressure\r and heart rate)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        seizure (fits)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\">serotonin syndrome (a reaction which may cause feelings of great\r happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever,\r sweating or rigid muscles)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\">speech disorders<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">heart problems including torsades de pointes,\r stopping of the heart, irregularities in heart rhythm that may be due to\r abnormal nerve impulses in the heart, abnormal readings during heart\r examination (ECG) QT prolongation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        fainting<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">symptoms related to blood clots in the veins especially\r in the legs (symptoms include swelling, pain and redness in the leg), which may\r travel through blood vessels to the lungs causing chest pain and difficulty in\r breathing<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        spasm of the muscles\r around the voice box<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        accidental inhalation\r of food with risk of pneumonia (lung infection)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        inflammation of the\r pancreas<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        difficulty swallowing<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        liver failure<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        jaundice (yellowing\r of the skin and white part of eyes)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        inflammation of the\r liver<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        rash<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><em><span style=\"color:black;font-style:normal\">skin <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">sensitivity to light<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        excessive sweating<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;text-autospace:\r none\">\u2022serious allergic reactions such as Drug Reaction with Eosinophilia and\r Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a\r rash on the face and then with an extended rash, high temperature, enlarged\r lymph nodes, increased levels of liver enzymes seen in blood tests and an\r increase in a type of white blood cell (eosinophilia). <\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle weakness, tenderness or pain and\r particularly, if at the same time, you feel unwell, have a high temperature or\r have dark urine. They may be caused by an abnormal muscle breakdown which can\r be life threatening and lead to kidney problems (a condition called\r rhabdomyolysis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        difficulty in passing\r urine<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        involuntary loss of\r urine (incontinence)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        drug withdrawal symptoms\r in new-born infant<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        prolonged and\/or\r painful erection<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        difficulty\r controlling core body temperature or overheating<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        chest pain<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        swelling of hands,\r ankles or feet<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">during tests your doctor may find<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts alkaline\r phosphatase<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        fluctuating results during\r tests to measure glucose in your blood<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Reporting of side effects<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor or nurse. This includes any possible side effects not listed in this\r leaflet. You can also report side effects directly via <span style=\"background:\r silver\">the national reporting system listed in <\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><u><span style=\"background:silver\">Appendix V<\/span><\/u><\/a>. By reporting side effects,\r you can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.       How to store <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Keep\r this medicine out of the sight and reach of children.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not use this medicine after the expiry date which is stated on the carton and\r the vial. The expiry date refers to the last day of that month.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not freeze.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r reconstituted suspension should be used immediately but may be stored below\r 25\u00b0C for up to 4 hours in the vial. Do not store the reconstituted\r suspension in the syringe.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.       Contents of the pack\r and other information<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">What\r <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">contains<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        The active substance\r is aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each vial contains 300 mg\r aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After reconstitution each ml of\r suspension contains 200 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each vial contains 400 mg\r aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After reconstitution each ml of\r suspension contains 200 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        The other ingredients\r are<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Powder<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Carmellose sodium, mannitol, sodium\r dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Solvent<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Water for injections<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">What\r <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">looks like and contents of the pack<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">is a powder and solvent for prolonged-release suspension\r for injection.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">comes as a white to off-white powder in a clear glass\r vial. Your doctor or nurse will make it into a suspension that will be given as\r an injection using the vial of solvent for <\/span><\/em>Abilify Maintena <em><span style=\"font-style:normal\">that comes as a clear solution in a clear glass vial.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Single pack<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r single pack containing one vial of powder, 2 ml vial of solvent, one\r 3 ml luer lock syringe with pre-attached 38 mm (1.5 inch)\r 21 gauge, hypodermic safety needle with needle protection device, one\r 3 ml disposable syringe with luer lock tip, one vial adapter and three\r hypodermic safety needles: one 25 mm (1 inch) 23 gauge, one\r 38 mm (1.5 inch) 22 gauge and one 51 mm (2 inch)\r 21 gauge.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Multipack<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Bundle\r pack of 3 single packs.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Not\r all pack sizes may be marketed.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Marketing Authorisation Holder<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Manufacturer<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">H.\r Lundbeck A\/S<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Ottiliavej\r 9, 2500 Valby<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Denmark<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">For\r any information about this medicine, please contact the local representative of\r the Marketing Authorisation Holder:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse\" width=\"100%\"> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   S.A.\/N.V.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">T\u00e9l\/Tel: +32\r   2 535 79 79<\/span><\/em><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Lietuva<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">H. Lundbeck\r   A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +45 36301311<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Export A\/S Representative Office<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +359\r   2 962 4696<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Luxembourg\/Luxemburg<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   S.A.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">T\u00e9l: +32\r   2 535 79 79<\/span><\/em><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:38.1pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:38.1pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u010cesk\u00e1 republika<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   \u010cesk\u00e1 republika s.r.o.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +420\r   225 275 600<\/span><\/em><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:38.1pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Magyarorsz\u00e1g<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Hungaria Kft.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +36\r   1 4369980<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:46.1pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:46.1pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Danmark<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma Scandinavia AB<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +46\r   8 54528660<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:46.1pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Malta<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">H. Lundbeck\r   A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +45 36301311<\/span><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Deutschland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma GmbH<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +49\r   69 1700860<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Nederland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   B.V.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +31\r   20 697 1901<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Eesti<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">H. Lundbeck\r   A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +45 36301311<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Norge<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma Scandinavia AB<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +46\r   8 54528660<\/span><\/em><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Hellas S.A.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u03a4\u03b7\u03bb: +30\r   210 610 5036<\/span><\/em><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u00d6sterreich<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Austria GmbH<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +43\r   1 266 91 08<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Espa\u00f1a<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharmaceutical S.A.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +34\r   93 208 10 20<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Polska<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Poland Sp. z o. o.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel.: +48\r   22 626 93 00<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">France<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharmaceutical France SAS<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">T\u00e9l: +33\r   (0)1 47 08 00 00<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Portugal<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Portugal Lda<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +351\r   21 00 45 900<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Hrvatska<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Lundbeck Croatia\r   d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Tel.: +385 1 644\r   82 63<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Rom\u00e2nia<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Export\r   A\/S<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Reprezentanta\r   din <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Romania<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +40\r   21319 88 26<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Ireland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck (Ireland) Limited<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +353 1 468 9800<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Slovenija<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck Pharma d.o.o.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel.: +386 2 229 4500<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u00cdsland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">S\u00edmi: +354\r   535 7000<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Slovensk\u00e1 republika<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck Slovensko s.r.o.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +421 2 5341 42 18<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Italia<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharmaceutical Italy S.r.l<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +39\r   02 00 63 27 10<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Suomi\/Finland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma Scandinavia AB<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +46\r   8 54528660<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Hellas A.E<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u03a4\u03b7\u03bb.: +357\r   22490305<\/span><\/em><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Sverige<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma Scandinavia AB<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +46\r   8 54528660<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Latvija<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">H. Lundbeck\r   A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +45 36301311<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">United Kingdom<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharmaceuticals (UK) Ltd.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +44\r   203 747 5300<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"351\"><\/td> <td style=\"border:none\" width=\"3\"><\/td> <td style=\"border:none\" width=\"351\"><\/td> <td style=\"border:none\" width=\"3\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">This leaflet was last revised in <span style=\"color:black\">{MM\/YYYY}.<\/span><\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Detailed\r information on this medicine is available on the European Medicines Agency web\r site: <\/span><\/em><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/\"><u>http:\/\/www.ema.europa.eu<\/u><\/a><em><span style=\"color:black;font-style:normal\">.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\"><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/em> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">---------------------------------------------------------------------------------------------------------------------------<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The following information is intended for\r healthcare professionals only:<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">INSTRUCTIONS FOR HEALTH CARE\r PROFESSIONALS<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">aripiprazole<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 1:\r Preparation prior to reconstitution of the powder<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lay\r out and confirm that components listed below are provided:<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        Abilify Maintena\r package leaflet and instructions for healthcare professionals.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        Vial of powder.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        2 ml vial of\r solvent.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><b><span lang=\"EN-GB\">          Important:<\/span><\/b><span lang=\"EN-GB\"> the\r solvent vial contains an overfill.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        One 3 ml luer\r lock syringe with pre-attached 38 mm (1.5 inch) 21 gauge\r hypodermic safety needle with needle protection device.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        One 3 ml\r disposable syringe with luer lock tip.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        One vial adapter.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-        One 25 mm (1 inch) 23 gauge hypodermic\r safety needle<em><span style=\"font-style:normal\"> with needle protection device.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        One 38 mm\r (1.5 inch) 22 gauge hypodermic safety needle with needle protection\r device.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        One 51 mm\r (2 inch) 21 gauge hypodermic safety needle with needle protection\r device.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        Syringe and needle\r instructions.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 2:\r Reconstitution of the powder<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">a)       Remove the solvent\r and powder vial caps and wipe the tops with a sterile alcohol swab.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">b)      Using the syringe with\r pre-attached needle, withdraw the pre-determined solvent volume from the vial\r of the solvent into the syringe.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-autospace:none\"><span lang=\"EN-GB\">300 mg vial:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-autospace:none\"><span lang=\"EN-GB\">Add 1.5 ml solvent to reconstitute the powder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-autospace:none\"><span lang=\"EN-GB\">400 mg vial:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-autospace:none\"><span lang=\"EN-GB\">Add 1.9 ml solvent to reconstitute the powder.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">A small amount of residual solvent will\r remain in the vial following withdrawal. Any excess should be discarded.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse\" width=\"566\"> <tr style=\"height:120.55pt\"> <td style=\"width:163.05pt;padding:0in 5.4pt 0in 5.4pt;\r   height:120.55pt\" valign=\"top\" width=\"217\"> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><\/p> <\/td> <td style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt;\r   height:120.55pt\" valign=\"top\" width=\"66\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><img alt=\"Pic 1\" border=\"0\" height=\"145\" id=\"Bild 2\" src=\"AbilifyMaintena-h-2755-e_files\/image002.png\" width=\"55\"\/><\/span><\/em><\/p> <\/td> <td style=\"width:211.85pt;padding:0in 5.4pt 0in 5.4pt;\r   height:120.55pt\" valign=\"top\" width=\"282\"> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><span lang=\"EN-GB\">Water<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">c)       Slowly inject the\r solvent into the vial containing the powder.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">d)      Withdraw air to\r equalise the pressure in the vial by pulling back slightly on the plunger.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><a name=\"_Hlk498354571\"><span lang=\"EN-GB\" style=\"color:black\"><img alt=\"Pic 2\" border=\"0\" height=\"137\" id=\"Bild 3\" src=\"AbilifyMaintena-h-2755-e_files\/image003.png\" width=\"53\"\/><\/span><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">e)       Subsequently, remove\r the needle from the vial.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">          Engage the needle\r safety device by using the one-handed technique.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Gently press the sheath against a flat\r surface until the needle is firmly engaged in the needle protection sheath.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">          Visually confirm\r that the needle is fully engaged into the needle protection sheath, and\r discard.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <div align=\"center\"> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\"> <tr> <td style=\"width:134.7pt;padding:0in 5.4pt 0in 5.4pt\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"93\" id=\"Bild 4\" src=\"AbilifyMaintena-h-2755-e_files\/image004.png\" width=\"148\"\/><\/span><\/p> <\/td> <td style=\"width:120.45pt;padding:0in 5.4pt 0in 5.4pt\" width=\"161\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"97\" id=\"Bild 5\" src=\"AbilifyMaintena-h-2755-e_files\/image005.png\" width=\"123\"\/><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:134.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Cover<\/span><\/p> <\/td> <td style=\"width:120.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"161\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Discard<\/span><\/p> <\/td> <\/tr> <\/table> <\/div> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">f)       <u>Shake the vial\r vigorously for 30 seconds until the suspension appears uniform.<\/u><\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><a name=\"_Hlk498354543\"><span lang=\"EN-GB\" style=\"color:black\"><img alt=\"Pic 4\" border=\"0\" height=\"132\" id=\"Bild 6\" src=\"AbilifyMaintena-h-2755-e_files\/image006.png\" width=\"135\"\/><\/span><\/a><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">g)       Visually inspect the\r reconstituted suspension for particulate matter and discolouration prior to\r administration. The reconstituted medicine is a white to off-white, fluid\r suspension. Do not use if reconstituted suspension contains particulate matter\r or any discolouration.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">h)      If the injection is\r not performed immediately after reconstitution, keep the vial below 25 \u00b0C\r for up to 4 hours and shake it vigorously for at least 60 seconds to\r re-suspend prior to injection.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">i)       Do not store the\r reconstituted suspension in the syringe.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 3:\r Preparation prior to injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">a)       Remove the cover, but\r not the adapter from the package.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">b)      Using the vial adapter\r package to handle the vial adapter, attach the pre-packaged luer lock syringe\r to the vial adapter.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><a name=\"_Hlk498354528\"><span lang=\"EN-GB\"><img border=\"0\" height=\"133\" id=\"Grafik 11\" src=\"AbilifyMaintena-h-2755-e_files\/image007.png\" width=\"89\"\/><\/span><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-left:21.0pt;text-indent:-21.0pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">c)       Use the luer lock\r syringe to remove the vial adapter from the package and discard the vial\r adapter package. <u>Do not touch the spike tip of the adapter at any time.<\/u><\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:21.0pt;text-indent:-21.0pt\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><a name=\"_Hlk498354519\"><span lang=\"EN-GB\"><img border=\"0\" height=\"133\" id=\"Grafik 19\" src=\"AbilifyMaintena-h-2755-e_files\/image008.png\" width=\"70\"\/><\/span><\/a><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">d)      Determine the\r recommended volume for injection.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"288\"> <tr> <td colspan=\"2\" style=\"width:215.65pt;border:solid windowtext 1.0pt;\r   border-left:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify Maintena 300 mg\r   Vial<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Dose<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Volume to Inject<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">---<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">---<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">300 mg<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.5 ml<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">200 mg<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.0 ml<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">160 mg<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.8 ml<\/span><\/em><\/p> <\/td> <\/tr> <\/table> <\/div> <p class=\"MsoNormal\"><\/p> <div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"288\"> <tr> <td colspan=\"2\" style=\"width:215.65pt;border:solid windowtext 1.0pt;\r   border-left:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify Maintena 400 mg\r   Vial<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Dose<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Volume to Inject<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">400 mg<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2.0 ml<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">300 mg<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.5 ml<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">200 mg<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.0 ml<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:90.05pt;border-top:none;border-left:\r   double windowtext 1.5pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"120\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">160 mg<\/span><\/em><\/p> <\/td> <td style=\"width:125.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.8 ml<\/span><\/em><\/p> <\/td> <\/tr> <\/table> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">e)       Wipe the top of the\r vial of the reconstituted suspension with a sterile alcohol swab.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">f)       Place and hold the\r vial of the reconstituted suspension on a hard surface. Attach the adapter-syringe\r assembly to the vial by holding the outside of the adapter and pushing the\r adapter\u2019s spike firmly through the rubber stopper, until the adapter snaps in\r place.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">g)       Slowly withdraw the\r recommended volume from the vial into the luer lock syringe to allow for\r injection.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">          <u>A\r small amount of excess product will remain in the vial.<\/u><\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><a name=\"_Hlk498354506\"><span lang=\"EN-GB\"><img border=\"0\" height=\"139\" id=\"Grafik 16\" src=\"AbilifyMaintena-h-2755-e_files\/image009.png\" width=\"58\"\/><\/span><\/a><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 4:\r Injection procedure<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">a)       Detach the luer lock\r syringe containing the recommended volume of reconstituted Abilify Maintena\r suspension from the vial.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">b)      Select one of the\r following hypodermic safety needles depending on the injection site and patient\u2019s\r weight and attach the needle to the luer lock syringe containing the suspension\r for injection. Ensure the needle is firmly seated on the needle protection\r device with a push and clockwise twist and then pull the needle cap straight\r away from the needle.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse;border:none\"> <tr> <td style=\"width:120.5pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Body type<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Injection site<\/span><\/b><\/p> <\/td> <td style=\"width:198.45pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"265\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Needle size<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:120.5pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Non-obese<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Deltoid<\/span><\/b><\/p> <\/td> <td style=\"width:198.45pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"265\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">25 mm (1 inch) 23 gauge<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:120.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Gluteal<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <\/td> <td style=\"width:198.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"265\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">38 mm (1.5 inch)\r   22 gauge<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:120.5pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Obese<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Deltoid<\/span><\/b><\/p> <\/td> <td style=\"width:198.45pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"265\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">38 mm (1.5 inch)\r   22 gauge<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:120.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Gluteal<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <\/td> <td style=\"width:198.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"265\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">51 mm (2 inch) 21 gauge<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">c)       Slowly inject the recommended\r volume as a single intramuscular injection into the gluteal or deltoid muscle.\r Do not massage the injection site. Care must be taken to avoid inadvertent\r injection into the blood vessel. Do not inject into an area with signs of\r inflammation, skin damage, lumps and\/or bruises.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">For deep intramuscular gluteal or deltoid injection only.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:28.35pt;border-collapse:collapse\"> <tr> <td style=\"width:218.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"291\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><img border=\"0\" height=\"181\" id=\"Bild 10\" src=\"AbilifyMaintena-h-2755-e_files\/image010.png\" width=\"218\"\/><\/span><\/em><\/p> <\/td> <td style=\"width:218.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"291\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><img border=\"0\" height=\"181\" id=\"Bild 11\" src=\"AbilifyMaintena-h-2755-e_files\/image011.png\" width=\"180\"\/><\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:218.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"291\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">deltoid<\/span><\/em><\/p> <\/td> <td style=\"width:218.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"291\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">gluteal<\/span><\/em><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><span lang=\"EN-GB\" style=\"color:black\">Remember to rotate sites of injections between the two\r gluteal or deltoid muscles. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><span lang=\"EN-GB\" style=\"color:black\">If initiating with the two injection start, inject into two\r different sites in two different muscles. <\/span><span lang=\"EN-GB\">DO NOT inject\r both injections concomitantly into the same deltoid or gluteal muscle.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><span lang=\"EN-GB\">For known CYP2D6\r poor metabolisers administer in either<s> <\/s>two separate deltoid muscles or\r one deltoid and one gluteal muscle.<\/span><span lang=\"EN-GB\">DO NOT\r inject into two gluteal muscles.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Look for signs or symptoms of inadvertent\r intravenous administration.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 5:\r Procedures after injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Engage the\r needle safety device as described in Step 2 e). Dispose of the vials, adapter,\r needles, and syringe appropriately after injection. The powder and solvent\r vials are for single-use only.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div align=\"center\"> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\"> <tr> <td style=\"width:134.7pt;padding:0in 5.4pt 0in 5.4pt\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"93\" id=\"Bild 12\" src=\"AbilifyMaintena-h-2755-e_files\/image004.png\" width=\"148\"\/><\/span><\/p> <\/td> <td style=\"width:120.45pt;padding:0in 5.4pt 0in 5.4pt\" width=\"161\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"97\" id=\"Bild 13\" src=\"AbilifyMaintena-h-2755-e_files\/image005.png\" width=\"123\"\/><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:134.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Cover<\/span><\/p> <\/td> <td style=\"width:120.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"161\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Discard<\/span><\/p> <\/td> <\/tr> <\/table> <\/div> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><\/p> <em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\"><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/em> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Package leaflet: Information\r for the user<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">300 mg\r powder and solvent for prolonged-release suspension for injection in pre\u2011filled\r syringe<\/span><\/em><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">400 mg\r powder and solvent for prolonged-release suspension for injection in pre\u2011filled\r syringe<\/span><\/em><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">aripiprazole<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Read\r all of this leaflet carefully before you receive this medicine because it\r contains important information for you.<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        Keep this leaflet.\r You may need to read it again.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        If you have any\r further questions, ask your doctor or nurse.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        If you get any side\r effects, talk to your doctor or nurse. This includes any possible side effects\r not listed in this leaflet. See section 4.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">What is in this leaflet<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.       What <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">is and what it is used for<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2.       What you need to know\r before you are given <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3.       How <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">is given<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.       Possible side effects<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.       How to store <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.       Contents of the pack\r and other information<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.       What <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">is and what it is used for<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">contains the active substance aripiprazole and\r belongs to a group of medicines called antipsychotics. It is used to treat\r schizophrenia - a disease with symptoms such as hearing, seeing or sensing\r things which are not there, suspiciousness, mistaken beliefs, incoherent speech\r and behaviour and emotional flatness. People with this condition may also feel\r depressed, guilty, anxious or tense.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">is intended for adult patients with schizophrenia who\r are sufficiently stabilised during treatment with oral aripiprazole.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2.       What you need to know\r before you are given <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not use <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">        if you are allergic to\r aripiprazole or any of the other ingredients of this medicine (listed in\r section 6).<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Warnings\r and precautions<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Talk\r to your doctor or nurse before you are given <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<em><span style=\"font-style:normal\">.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Suicidal\r thoughts and behaviours have been reported during aripiprazole treatment. Tell\r your doctor immediately if you are having any thoughts or feelings about\r hurting yourself.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Before\r treatment with <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<em><span style=\"font-style:normal\">, tell your doctor if you suffer\r from<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        an acutely agitated\r state or a severely psychotic state<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        heart problems or\r have a history of stroke, especially if you know that you have other risks\r factors for stroke<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        high blood sugar\r (characterised by symptoms such as excessive thirst, passing of large amounts\r of urine, increase in appetite and feeling weak) or family history of diabetes<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        fits (seizures) since\r your doctor may want to monitor you more closely<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        involuntary,\r irregular muscle movements, especially in the face<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">experience a combination of fever, sweating,\r faster breathing, muscle stiffness and drowsiness or sleepiness (may be signs\r of neuroleptic malignant syndrome)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">dementia (loss of memory and other mental\r abilities) especially if you are elderly<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        cardiovascular\r diseases (diseases of the heart and circulation), family history of\r cardiovascular disease, stroke or \"mini\" stroke, abnormal blood\r pressure<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        irregular heart beat\r or if someone else in your family has a history of irregular heart beat\r (including so called QT prolongation seen with ECG monitoring).<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        blood clots, or family\r history of blood clots, as antipsychotics have been associated with formation\r of blood clots<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">have any difficulty in swallowing<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        past experience with\r excessive gambling<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        severe liver\r problems.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you notice you are gaining weight, develop unusual movements, experience\r sleepiness that interferes with normal daily activities, any difficulty in\r swallowing or have allergic symptoms, please talk to your doctor immediately.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you or your\r family\/carer notices that you are developing urges or cravings to behave in\r ways that are unusual for you and you cannot resist the impulse, drive or\r temptation to carry out certain activities that could harm yourself or others.\r These are called impulse control disorders and can include behaviours such as\r addictive gambling, excessive eating or spending, an abnormally high sex drive\r or preoccupation with an increase in sexual thoughts or feelings.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Your doctor may need to adjust or stop\r your dose.<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"background:white\"><span style=\"color:#212121\">Aripiprazole<\/span><span style=\"color:#212121\"> may cause sleepiness, fall in blood pressure when\r standing up, dizziness and changes in your ability to move and balance, which\r may lead to falls. Caution should be taken, particularly if you are an elderly\r patient or have some debility.<\/span><\/p> <p class=\"MsoNormal\" style=\"background:white\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">Children and\r adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not use this\r medicine in children and adolescents under 18 years of age. It is not known\r if it is safe and effective in these patients.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Other\r medicines and <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tell\r your doctor if you are taking, have recently taken or might take any other\r medicines.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Blood\r pressure-lowering medicines:<\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">\r Abilify Maintena <em><span style=\"font-style:normal\">may increase the effect of\r medicines used to lower the blood pressure. Be sure to tell your doctor if you\r take a medicine to keep your blood pressure under control.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Receiving\r <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">with some medicines may mean the doctor will need to\r change your dose of <\/span><\/em>Abilify Maintena <em><span style=\"font-style:\r normal\">or the other medicines. It is especially important to mention the\r following to your doctor:<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        medicines to correct\r heart rhythm (such as quinidine, amiodarone, flecainide)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        antidepressants or\r herbal remedy used to treat depression and anxiety<\/span><\/em><span class=\"berschrift4Zchn\"><\/span><span class=\"berschrift4Zchn\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;color:black;font-weight:normal'>(<\/span><\/span><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">such as fluoxetine,\r paroxetine, St. John's Wort)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        antifungal medicines\r (such as ketoconazole, itraconazole)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        certain medicines to\r treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors e.g.\r indinavir, ritonavir)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        anticonvulsants used\r to treat epilepsy (such as <\/span><\/em><span class=\"BMSHeading3Char\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;font-weight:normal'>carbamazepine,\r phenytoin,<\/span><\/span><span class=\"BMSHeading3Char\"><\/span><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">phenobarbital)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        certain antibiotics\r used to treat tuberculosis (rifabutin, rifampicin)<\/span><\/em><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        medicines\r that are known to prolong QT prolongation.<\/span><\/em><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">These medicines\r may increase the risk of side effects or reduce the effect of <span style=\"color:black\">Abilify Maintena<\/span>; if you get any unusual symptom\r taking any of these medicines together with <span style=\"color:black\">Abilify\r Maintena<\/span>, you should see your doctor.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">Medicines\r that increase the level of serotonin <\/span><span class=\"BMSHeading3Char\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r font-weight:normal'>are typically used in conditions including depression, generalised\r anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well\r as migraine and pain<\/span><\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;\r color:black\">:<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt\">triptans, tramadol and tryptophan used for\r conditions including depression, generalised anxiety disorder, obsessive\r compulsive disorder (OCD) and social phobia as well as migraine and pain<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">SSRI s (such as paroxetine and\r fluoxetine) used for depression, OCD, panic and anxiety<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">other anti-depressants (such as\r venlafaxine and tryptophan) used in major depression<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">tricyclic\u2019s (such as clomipramine\r and amitriptyline) used for depressive illness<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">St John\u2019s Wort (<i>Hypericum\r perforatum<\/i>) used as a herbal remedy for mild depression<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">painkillers (such as tramadol\r and pethidine) used for pain relief<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">triptans (such as sumatriptan\r and zolmitripitan) used for treating migraine.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">These medicines\r may increase the risk of side effects; if you get any unusual symptom taking\r any of these medicines together with <span style=\"color:black\">Abilify Maintena<\/span>,\r you should see your doctor.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">with alcohol<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Alcohol\r should be avoided.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pregnancy,\r breast-feeding and fertility<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you are pregnant or breast-feeding, think you may be pregnant or are planning\r to have a baby, ask your doctor for advice before receiving this medicine.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">You\r should not be given <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena <em><span style=\"font-style:normal\">if you are pregnant unless you\r have<\/span><\/em><\/span><\/b><em><span lang=\"EN-GB\" style=\"color:black;font-style:\r normal\"> discussed this with your doctor. <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Be sure to tell your doctor immediately if you are\r pregnant, think you may be pregnant, or if you are planning to become pregnant.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r following symptoms may occur in new-born babies, of mothers that have received <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">in the last trimester (last three months of their pregnancy):<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">shaking,\r muscle stiffness and\/or weakness, sleepiness, agitation, breathing problems,\r and difficulty in feeding.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r your baby develops any of these symptoms you need to contact your doctor.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you are receiving <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<em><span style=\"font-style:normal\">, your doctor will discuss with you\r whether you should breast-feed considering the benefit to you of your therapy\r and the benefit to your baby of breast-feeding. You should not do both. Talk to\r your doctor about the best way to feed your baby if you are receiving <\/span><\/em>Abilify\r Maintena<em><span style=\"font-style:normal\">.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Driving\r and using machines<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dizziness and vision problems may occur\r during treatment with this medicine (see section 4). This should be\r considered in cases where full alertness is required, e.g., when driving a car\r or handling machines.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Abilify Maintena contains sodium<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena contains less than 1 mmol\r sodium (23 mg) per dose. This means that the medicine is essentially\r \u2018sodium-free\u2019.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3.       How <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:\r normal\">is given<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Abilify\r Maintena comes as a pre\u2011filled syringe.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Your doctor\r will decide on the dose of Abilify Maintena that is right for you. The\r recommended starting dose is 400 mg unless your doctor decided to give you\r a lower starting or follow up dose (300 mg, 200 mg or 160 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\">There are two ways to start\r Abilify Maintena, your doctor will decide which way is right for you.<\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><em><span style=\"color:black;font-style:normal\">If you are given one injection of Abilify\r Maintena on your first day the <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">treatment with aripiprazole by <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">mouth<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> is continued for 14 days\r after the first injection.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\">If you are given two injections of Abilify Maintena on your first\r day, you will also take one tablet of aripiprazole by mouth at this visit.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">After that,\r treatment is given with injections of Abilify Maintena unless your doctor\r tells you otherwise.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Your doctor\r will give it to you as a single injection into the gluteal or deltoid muscle\r (buttock or shoulder) every month. You may feel a little pain during the\r injection. Your doctor will alternate the injections between your right and\r left side. The injections will not be given intravenously.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you are given more <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena <em><span style=\"font-style:normal\">than you should<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">This\r medicine will be given to you under medical supervision; it is therefore\r unlikely that you will be given too much. If you see more than one doctor, be\r sure to tell them that you are receiving <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<em><span style=\"font-style:normal\">.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Patients\r who have been given too much aripiprazole have experienced the following\r symptoms:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        rapid heartbeat,\r agitation\/aggressiveness, problems with speech.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        unusual movements\r (especially of the face or tongue) and reduced level of consciousness.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Other\r symptoms may include:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        acute confusion,\r seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        muscle stiffness, and\r drowsiness or sleepiness, slower breathing, choking, high or low blood\r pressure, abnormal rhythms of the heart.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Contact\r your doctor or hospital immediately if you experience any of the above.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you miss an injection of <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">It\r is important not to miss your scheduled dose. You should be given an injection\r every month but not before the 26 days has passed from the last injection.\r If you miss an injection, you should contact your doctor to arrange your next\r injection as soon as you can.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you stop receiving <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not stop your treatment just because you feel better. It is important that you\r carry on receiving <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">Abilify\r Maintena <em><span style=\"font-style:normal\">for as long as your doctor has\r told you to.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r you have any further questions on the use of this medicine, ask your doctor or\r nurse.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.       Possible side effects<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Like\r all medicines, this medicine can cause side effects, although not everybody\r gets them.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tell\r your doctor immediately if you have any of the following serious side effects:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        a combination of any\r of these symptoms: excessive sleepiness, dizziness, confusion, disorientation,\r difficulty talking, difficulty walking, muscle stiffness or shaking, fever,\r weakness, irritability, aggression, anxiety, increase in blood pressure, or\r seizures that can lead to unconsciousness.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        unusual movement\r mainly of the face or tongue, since your doctor may want to lower your dose.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        if you have symptoms\r such as swelling, pain, and redness in the leg, because this may mean you have\r a blood clot, which may travel through blood vessels to the lungs causing chest\r pain and difficulty in breathing. If you notice any of these symptoms seek\r medical advice immediately.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        a combination of\r fever, faster breathing, sweating, muscle stiffness and drowsiness or\r sleepiness since this may be a sign of a condition called neuroleptic malignant\r syndrome (NMS).<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        thirstiness more than\r usual, need to urinate more than usual, feel very hungry, feel weak or tired,\r feel sick, feel confused or your breath smells fruity, since this may be a sign\r of diabetes.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r side effects listed below may also occur after receiving Abilify Maintena.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black\">Common side effects (may affect up to 1 in\r 10 people):<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        weight\r gain<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        diabetes\r mellitus<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        weight\r loss<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">feeling restless<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">feeling anxious<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">unable to keep still, difficulty sitting still<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">difficulty sleeping (insomnia)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">jerky resistance to passive movement as muscles\r tense and relax, abnormally increased muscle tone, slow body movement<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">akathisia (an uncomfortable feeling of inner\r restlessness and a compelling need to move constantly)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">shaking or trembling<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">uncontrollable twitching, jerking or writhing\r movements<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">changes in your level of alertness, drowsiness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">sleepiness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">dizziness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">headache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">dry mouth<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle stiffness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">inability to have or maintain an erection during\r sexual intercourse<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">pain at the injection site, hardening of the\r skin at the injection site<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">weakness, loss of strength or extreme tiredness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">during blood tests your doctor may find higher\r amounts of creatine phosphokinase in your blood (enzyme important for muscle\r function)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Uncommon side\r effects (may affect up to 1 in 100 people):<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">low level of a specific type of white blood\r cells (neutropenia), low haemoglobin or red blood cell count, low level of\r blood platelets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">allergic reactions (hypersensitivity)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        decreased\r or <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">increased blood levels of\r the hormone prolactin<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">high blood sugar<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">increased blood fats such as high cholesterol,\r high triglycerides and also low level of cholesterol and low level of\r triglycerides<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">increased levels of insulin, a hormone\r regulating blood sugar levels<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">decreased or increased appetite<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">thoughts about suicide<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">mental disorder characterized by defective or\r lost contact with reality<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">hallucination<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">delusion<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">increased sexual interest<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">panic reaction<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">depression<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">affect lability<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">state of indifference with lack of emotion,\r feelings of emotional and mental discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">sleep disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">grinding of teeth or clenching of the jaw<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">reduced sexual interest (libido is decreased)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">altered mood<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle problems<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle movements that you cannot control such as\r grimacing, lip-smacking and tongue movements. They usually affect the face and\r mouth first but can affect other parts of the body. These could be signs of a\r condition called \u201ctardive dyskinesia\u201d.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">parkinsonism - medical condition with many\r various symptoms which include decreased or slow movements, slowness of\r thought, jerks when bending the limbs (cogwheel rigidity), shuffling, hurried\r steps, shaking, little or no facial expression, muscle stiffness, drooling<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">movement problems<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">extreme restlesness and restless legs<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">distortion of the senses of taste and smell<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">fixation of the eyeballs in one position<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">blurred vision<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">eye pain<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">double vision<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span style=\"color:black;font-style:normal\">\u2022        eye sensitivity to light,<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">abnormal heartbeat, slow or fast heart rate,\r abnormal electrical conduction of the heart, abnormal reading (ECG) of the\r heart<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">high blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">dizziness when getting up from a lying or\r sitting position due to a drop in blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">cough<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">hiccups<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">gastroesophageal reflux disease. Excess amount\r of gastric juice flowing back (refluxes) into the esophagus (gullet or the tube\r that goes from mouth to stomach through which food passes), causing heartburn\r and possibly damaging the esophagus<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">heartburn<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">diarrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">feeling sick<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">stomach ache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">stomach discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">constipation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">frequent bowel movement<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">drooling, more saliva in mouth than normal<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">abnormal hair loss<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">acne, skin condition of the face where the nose\r and cheeks are unusually red, eczema,skin\r hardening<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle rigidity, muscle spasms, muscle\r twitching, muscle tightness, mucle pain (myalgia), pain in extremity<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">joint pain ( arthralgia), back pain, decreased\r range of motion of joints, stiff neck, limited opening of mouth<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">kidney stones, sugar (glucose) in urine<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">spontaneous flow of milk from the breasts\r (galactorrhoea)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">enlargement of breast in men, breast tenderness,\r vaginal dryness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">fever<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">loss of strength<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">gait disturbance<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">chest discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">injection site reactions such as redness,\r swelling discomfort and injection site itching<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">thirst<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">sluggishness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">liver function tests may show abnormal results<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">during tests your doctor may find<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of liver\r enzymes<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of alanine\r aminotransferase<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of\r gamma-glutamyl transferase<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of bilirubin\r in your blood<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of aspartate\r aminotransferase<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher or lower amounts of\r blood glucose<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts of\r glycosylated haemoglobin<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        lower amounts of\r cholesterol in your blood<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        lower amounts of triglycerides\r in your blood<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        a higher waist\r circumference<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">The following side\r effects have been reported since the marketing of oral aripiprazole but the\r frequency for them to occur is not known (frequency cannot be estimated from\r the available data):<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        low levels of white\r blood cells<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        allergic reaction\r (e.g. swelling in the mouth, tongue, face and throat, itching, hives), rash<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        unusual heartbeat,\r sudden unexplained death, heart attack<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        diabetic ketoacidosis\r (ketones in the blood and urine) or coma<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        loss of appetite\r (anorexia), <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">difficulty in\r swallowing<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        low sodium level in\r the blood<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        suicide attempt and\r suicide<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\">inability to resist the impulse, drive or temptation to perform an\r action that could be harmful to you or others, which may include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        strong impulse to gamble excessively despite\r serious personal or family consequences<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        altered or increased sexual interest and\r behaviour of significant concern to you or to others, for example, an increased\r sexual drive<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        uncontrollable excessive shopping<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        binge eating (eating large amounts of food in a\r short time period) or compulsive eating (eating more food than normal and more\r than is needed to satisfy your hunger)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\">-        a tendency to wander away<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-autospace:none\"><span lang=\"EN-GB\">Tell your doctor if you experience any of these behaviours; he\/she\r will discuss ways of managing or reducing the symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        nervousness<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">aggression<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        neuroleptic malignant\r syndrome ( a syndrome with symptoms such as fever, muscle stiffness, faster\r breathing, sweating, reduced consciousness and sudden changes in blood pressure\r and heart rate)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        seizure (fits)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\">serotonin syndrome (a reaction which may cause feelings of great\r happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever,\r sweating or rigid muscles)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\">speech disorders<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">heart problems including torsades de pointes,\r stopping of the heart, irregularities in heart rhythm that may be due to\r abnormal nerve impulses in the heart, abnormal readings during heart\r examination (ECG) QT prolongation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        fainting<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">symptoms related to blood clots in the veins\r especially in the legs (symptoms include swelling, pain and redness in the\r leg), which may travel through blood vessels to the lungs causing chest pain\r and difficulty in breathing<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        spasm of the muscles\r around the voice box<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        accidental inhalation\r of food with risk of pneumonia (lung infection)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        inflammation of the\r pancreas<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        difficulty swallowing<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        liver failure<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        jaundice (yellowing\r of the skin and white part of eyes)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        inflammation of the\r liver<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        rash<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><em><span style=\"color:black;font-style:normal\">skin <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">sensitivity to light<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        excessive sweating<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;text-autospace:\r none\">\u2022serious allergic reactions such as Drug Reaction with Eosinophilia and\r Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a\r rash on the face and then with an extended rash, high temperature, enlarged\r lymph nodes, increased levels of liver enzymes seen in blood tests and an\r increase in a type of white blood cell (eosinophilia). <\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">muscle weakness, tenderness or pain and\r particularly, if at the same time, you feel unwell, have a high temperature or\r have dark urine. They may be caused by an abnormal muscle breakdown which can\r be life threatening and lead to kidney problems (a condition called\r rhabdomyolysis)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        difficulty in passing\r urine<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        involuntary loss of\r urine (incontinence)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        drug withdrawal\r symptoms in new-born infant<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        prolonged and\/or\r painful erection<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        difficulty\r controlling core body temperature or overheating<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        chest pain<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        swelling of hands,\r ankles or feet<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">during tests your doctor may find<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        higher amounts alkaline\r phosphatase<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">-        fluctuating results during\r tests to measure glucose in your blood<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Reporting\r of side effects<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor or nurse. This includes any possible side effects not listed in this\r leaflet. You can also report side effects directly via <span style=\"background:\r silver\">the national reporting system listed in <\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><u><span style=\"background:silver\">Appendix V<\/span><\/u><\/a>. By reporting side effects,\r you can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.       How to store <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Keep\r this medicine out of the sight and reach of children.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not use this medicine after the expiry date which is stated on the carton and\r the pre-filled syringe. The expiry date refers to the last day of that month.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not freeze.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the pre\u2011filled syringe in the\r outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution, the syringe can be kept <em><span style=\"font-style:normal\">below 25 \u00b0C <\/span><\/em>for up to 2 hours.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.       Contents of the pack\r and other information<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">What\r <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">contains<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        The active substance\r is aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each pre\u2011filled syringe contains\r 300 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After reconstitution each ml of\r suspension contains 200 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each pre\u2011filled syringe contains\r 400 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After reconstitution each ml of\r suspension contains 200 mg aripiprazole.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        The other ingredients\r are<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Powder<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Carmellose sodium, mannitol, sodium\r dihydrogen phosphate monohydrate, sodium hydroxide<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Solvent<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Water for injections<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">What\r <\/span><\/b><\/em><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena <em><span style=\"font-style:normal\">looks like and contents of the pack<\/span><\/em><\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena <em><span style=\"font-style:normal\">comes in a pre\u2011filled syringe containing a\r white to off-white powder in the front chamber and a clear solvent in the rear\r chamber. Your doctor will make it into a suspension that will be given as an\r injection.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Single pack<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r single pack containing one pre\u2011filled syringe and three hypodermic safety\r needles: one 25 mm (1 inch) 23 gauge, one 38 mm\r (1.5 inch) 22 gauge and one 51 mm (2 inch) 21 gauge.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Multipack<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Bundle\r pack of 3 single packs.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Not\r all pack sizes may be marketed.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Marketing Authorisation Holder<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Manufacturer<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">H.\r Lundbeck A\/S<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Ottiliavej\r 9, 2500 Valby<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Denmark<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">Elaiapharm<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2881 Route des\r Cr\u00eates Z.I Les Bouillides Sophia Antipolis<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">06550 Valbonne<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">France<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">For\r any information about this medicine, please contact the local representative of\r the Marketing Authorisation Holder:<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse\" width=\"100%\"> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   S.A.\/N.V.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">T\u00e9l\/Tel: +32\r   2 535 79 79<\/span><\/em><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Lietuva<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">H. Lundbeck\r   A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +45 36301311<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Export A\/S Representative Office<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +359\r   2 962 4696<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Luxembourg\/Luxemburg<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   S.A.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">T\u00e9l: +32\r   2 535 79 79<\/span><\/em><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:38.1pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:38.1pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u010cesk\u00e1 republika<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   \u010cesk\u00e1 republika s.r.o.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +420\r   225 275 600<\/span><\/em><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:38.1pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Magyarorsz\u00e1g<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Hungaria Kft.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +36\r   1 4369980<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:46.1pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:46.1pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Danmark<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma Scandinavia AB<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +46\r   8 54528660<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:46.1pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Malta<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">H. Lundbeck\r   A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +45 36301311<\/span><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Deutschland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma GmbH<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +49\r   69 1700860<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Nederland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   B.V.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +31\r   20 697 1901<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Eesti<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">H. Lundbeck\r   A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +45 36301311<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Norge<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma Scandinavia AB<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +46\r   8 54528660<\/span><\/em><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td style=\"width:49.64%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"49%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Hellas S.A.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u03a4\u03b7\u03bb: +30\r   210 610 5036<\/span><\/em><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u00d6sterreich<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Austria GmbH<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +43\r   1 266 91 08<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Espa\u00f1a<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharmaceutical S.A.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +34\r   93 208 10 20<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Polska<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Poland Sp. z o. o.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel.: +48\r   22 626 93 00<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">France<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharmaceutical France SAS<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">T\u00e9l: +33\r   (0)1 47 08 00 00<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Portugal<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Portugal Lda<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +351\r   21 00 45 900<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hrvatska<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Lundbeck Croatia d.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Tel.: +385 1 644 82 63<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Rom\u00e2nia<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Export A\/S<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Reprezentanta din <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Romania<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +40 21319 88 26<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Ireland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   (Ireland) Limited<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +353\r   1 468 9800<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Slovenija<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Pharma d.o.o.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel.: +386\r   2 229 4500<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u00cdsland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi: +354 535 7000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Slovensk\u00e1 republika<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Slovensko s.r.o.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +421\r   2 5341 42 18<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Italia<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharmaceutical Italy S.r.l<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +39\r   02 00 63 27 10<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Suomi\/Finland<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma Scandinavia AB<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +46\r   8 54528660<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lundbeck\r   Hellas A.E<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u03a4\u03b7\u03bb.: +357\r   22490305<\/span><\/em><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Sverige<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharma Scandinavia AB<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +46\r   8 54528660<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"height:6.85pt\"> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Latvija<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">H. Lundbeck\r   A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +45 36301311<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:50.0%;padding:0in 5.4pt 0in 5.4pt;\r   height:6.85pt\" valign=\"top\" width=\"50%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">United Kingdom<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Otsuka\r   Pharmaceuticals (UK) Ltd.<\/span><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tel: +44\r   203 747 5300<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"351\"><\/td> <td style=\"border:none\" width=\"3\"><\/td> <td style=\"border:none\" width=\"351\"><\/td> <td style=\"border:none\" width=\"3\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">This leaflet was last revised in <span style=\"color:black\">{MM\/YYYY}.<\/span><\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Detailed\r information on this medicine is available on the European Medicines Agency web\r site: <\/span><\/em><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/\"><u>http:\/\/www.ema.europa.eu<\/u><\/a><em><span style=\"color:black;font-style:normal\">.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <em><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black;font-style:normal\"><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/em> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">---------------------------------------------------------------------------------------------------------------------------<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The following information is intended for\r healthcare professionals only:<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">INSTRUCTIONS FOR HEALTH CARE\r PROFESSIONALS<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/b><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">aripiprazole<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 1: Preparation prior\r to reconstitution of the powder<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Lay\r out and confirm that components listed below are provided:<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        Abilify Maintena\r package leaflet and instructions for healthcare professionals.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        One Abilify Maintena\r pre\u2011filled syringe.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-        One 25 mm (1 inch) 23 gauge hypodermic\r safety needle<em><span style=\"font-style:normal\"> with needle protection device.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        One 38 mm\r (1.5 inch) 22 gauge hypodermic safety needle with needle protection\r device.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        One 51 mm\r (2 inch) 21 gauge hypodermic safety needle with needle protection\r device.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">-        Syringe and needle\r instructions.<\/span><\/em><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 2:\r Reconstitution of the powder<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">a)       Push plunger rod slightly\r to engage threads. And then, rotate plunger rod until the rod stops rotating to\r release diluent. After plunger rod is at complete stop, middle stopper will be\r at the indicator line.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse\" width=\"566\"> <tr style=\"height:90.7pt\"> <td rowspan=\"2\" style=\"width:92.15pt;padding:0in 5.4pt 0in 5.4pt;\r   height:90.7pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\"><\/p> <\/td> <td rowspan=\"2\" style=\"width:59.4pt;padding:0in 5.4pt 0in 5.4pt;\r   height:90.7pt\" valign=\"top\" width=\"79\"> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"177\" id=\"Picture 10\" src=\"AbilifyMaintena-h-2755-e_files\/image012.png\" width=\"73\"\/><\/span><\/p> <\/td> <td style=\"width:70.2pt;padding:0in 5.4pt 0in 5.4pt;\r   height:90.7pt\" valign=\"top\" width=\"94\"> <p align=\"right\" class=\"MsoNormal\" style=\"margin-left:-5.4pt;text-align:right\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"margin-left:-5.4pt;text-align:right\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"margin-left:-5.4pt;text-align:right\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"margin-left:-5.4pt;text-align:right\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"margin-left:-5.4pt;text-align:right\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\" style=\"color:black\">Indicator line<\/span><\/p> <\/td> <td rowspan=\"2\" style=\"width:49.1pt;padding:0in 5.4pt 0in 5.4pt;\r   height:90.7pt\" valign=\"top\" width=\"65\"> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt;text-align:justify\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"177\" src=\"AbilifyMaintena-h-2755-e_files\/image013.png\" width=\"57\"\/><\/span><\/p> <\/td> <td rowspan=\"2\" style=\"width:153.65pt;padding:0in 5.4pt 0in 5.4pt;\r   height:90.7pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"height:31.2pt\"> <td style=\"width:70.2pt;padding:0in 5.4pt 0in 5.4pt;\r   height:31.2pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><span lang=\"EN-GB\">Plunger Rod<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">b)      Vertically shake the syringe\r vigorously for 20 seconds until the reconstituted suspension appears\r uniform<em><span style=\"font-style:normal\">. The suspension should be injected\r immediately after reconstitution.<\/span><\/em><\/span><\/p> <p class=\"MsoNormal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse\" width=\"566\"> <tr style=\"height:67.65pt\"> <td rowspan=\"2\" style=\"width:78.0pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"104\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:70.85pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"94\"> <p align=\"right\" class=\"MsoNormal\" style=\"margin-left:-5.4pt;text-align:right\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"95\" id=\"Picture 14\" src=\"AbilifyMaintena-h-2755-e_files\/image014.png\" width=\"77\"\/><\/span><\/p> <\/td> <td rowspan=\"2\" style=\"width:106.3pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"176\" src=\"AbilifyMaintena-h-2755-e_files\/image015.png\" width=\"132\"\/><\/span><\/p> <\/td> <td rowspan=\"2\" style=\"width:169.35pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">uniform<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">milky white<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:70.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><b><span lang=\"EN-GB\">20 seconds<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">c)       Visually inspect the\r syringe for particulate matter and discoloration prior to administration. The\r reconstituted product suspension should appear to be a uniform, homogeneous\r suspension that is opaque and milky-white in colour.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">d)      If the injection is not performed\r immediately after reconstitution, the syringe can be kept below 25 \u00b0C for\r up to 2 hours. Shake the syringe vigorously for at least 20 seconds\r to re-suspend prior to injection if the syringe has been left for more than\r 15 minutes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 3:\r Injection procedure<\/span><\/u><\/em><\/p> <p class=\"Default\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a)       Twist and pull off Over-cap and\r Tip-cap.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse\" width=\"566\"> <tr style=\"height:67.65pt\"> <td rowspan=\"2\" style=\"width:92.15pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\"><\/p> <\/td> <td rowspan=\"2\" style=\"width:56.7pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"76\"> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\"><img border=\"0\" height=\"210\" id=\"Picture 17\" src=\"AbilifyMaintena-h-2755-e_files\/image016.png\" width=\"64\"\/><\/span><\/p> <\/td> <td style=\"width:70.9pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"95\"> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><span lang=\"EN-GB\">Twist +<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><span lang=\"EN-GB\">Pull Off<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><span lang=\"EN-GB\">Over-cap<\/span><\/p> <\/td> <td rowspan=\"2\" style=\"width:49.6pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"66\"> <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-GB\"><img border=\"0\" height=\"210\" src=\"AbilifyMaintena-h-2755-e_files\/image017.png\" width=\"61\"\/><\/span><\/p> <\/td> <td style=\"width:155.15pt;padding:0in 5.4pt 0in 5.4pt;\r   height:67.65pt\" valign=\"top\" width=\"207\"> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:70.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"95\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Tip-cap<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <\/td> <td style=\"width:155.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"207\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Twist + Pull Off<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">b)      Select one of the\r following hypodermic safety needles depending on the injection site and\r patient\u2019s weight.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:131.75pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"176\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Body type<\/span><\/b><\/p> <\/td> <td style=\"width:84.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Injection site<\/span><\/b><\/p> <\/td> <td style=\"width:184.85pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Needle size<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:131.75pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"176\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Non-obese<\/span><\/b><\/p> <\/td> <td style=\"width:84.5pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Deltoid<\/span><\/b><\/p> <\/td> <td style=\"width:184.85pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">25 mm (1 inch) 23 gauge<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:131.75pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"176\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:84.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Gluteal<\/span><\/b><\/p> <\/td> <td style=\"width:184.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">38 mm (1.5 inch) 22 gauge<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:131.75pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"176\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Obese<\/span><\/b><\/p> <\/td> <td style=\"width:84.5pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Deltoid<\/span><\/b><\/p> <\/td> <td style=\"width:184.85pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">38 mm (1.5 inch)\r   22 gauge<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:131.75pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"176\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:84.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Gluteal<\/span><\/b><\/p> <\/td> <td style=\"width:184.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">51 mm (2 inch) 21 gauge<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <\/div> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">c)       While holding the needle\r cap, ensure the needle is firmly seated on the safety device with a push. Twist\r clockwise until snugly fitted.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse\" width=\"566\"> <tr style=\"height:120.55pt\"> <td style=\"width:163.05pt;padding:0in 5.4pt 0in 5.4pt;\r   height:120.55pt\" valign=\"top\" width=\"217\"> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><\/p> <\/td> <td style=\"width:85.05pt;padding:0in 5.4pt 0in 5.4pt;\r   height:120.55pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"157\" id=\"Picture 21\" src=\"AbilifyMaintena-h-2755-e_files\/image018.png\" width=\"108\"\/><\/span><\/p> <\/td> <td style=\"width:2.45in;padding:0in 5.4pt 0in 5.4pt;\r   height:120.55pt\" valign=\"top\" width=\"235\"> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Needle cap<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"color:black\">d)      Then <b>pull <\/b>needle-cap\r straight up.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse\" width=\"566\"> <tr style=\"height:106.35pt\"> <td style=\"width:163.05pt;padding:0in 5.4pt 0in 5.4pt;\r   height:106.35pt\" valign=\"top\" width=\"217\"> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Needle\r   cap<\/span><\/p> <\/td> <td style=\"width:70.85pt;padding:0in 5.4pt 0in 5.4pt;\r   height:106.35pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"margin-left:-5.4pt\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"148\" id=\"Picture 24\" src=\"AbilifyMaintena-h-2755-e_files\/image019.png\" width=\"89\"\/><\/span><\/p> <\/td> <td style=\"width:190.6pt;padding:0in 5.4pt 0in 5.4pt;\r   height:106.35pt\" valign=\"top\" width=\"254\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pull<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">e)       Hold syringe <b>upright and advance\r plunger rod slowly to expel the air<\/b>. If it's not possible to advance\r plunger rod to expel the air, check that plunger rod is rotated to a complete\r stop. It is not possible to re-suspend after the air in the syringe is\r expelled.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse\" width=\"566\"> <tr style=\"height:107.65pt\"> <td style=\"width:163.05pt;padding:0in 5.4pt 0in 5.4pt;\r   height:107.65pt\" valign=\"bottom\" width=\"217\"> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><b><span lang=\"EN-GB\">*If\r   there\u2019s resistance or difficulty expelling air,<\/span><\/b><span lang=\"EN-GB\">\r   check that plunger rod is rotated to a complete stop.<\/span><\/p> <\/td> <td style=\"width:70.85pt;padding:0in 5.4pt 0in 5.4pt;\r   height:107.65pt\" valign=\"top\" width=\"94\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"140\" id=\"Picture 27\" src=\"AbilifyMaintena-h-2755-e_files\/image020.png\" width=\"89\"\/><\/span><\/p> <\/td> <td style=\"width:190.6pt;padding:0in 5.4pt 0in 5.4pt;\r   height:107.65pt\" valign=\"top\" width=\"254\"> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Expel air until suspension fills needle\r   base*<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">f)       Slowly inject into\r the gluteal or deltoid muscle. Do not massage the injection site. Care must be\r taken to avoid inadvertent injection into the blood vessel. Do not inject into\r an area with signs of inflammation, skin damage, lumps and\/or bruises. <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">For deep intramuscular gluteal or deltoid injection\r only.<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:424.85pt;margin-left:33.75pt;border-collapse:collapse\" width=\"566\"> <tr> <td colspan=\"2\" style=\"width:424.85pt;padding:0in 5.4pt 0in 5.4pt\" width=\"566\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"color:black\"><img alt=\"ws\" border=\"0\" height=\"202\" id=\"Bild 23\" src=\"AbilifyMaintena-h-2755-e_files\/image021.jpg\" width=\"443\"\/><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:194.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"260\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">deltoid<\/span><\/em><\/p> <\/td> <td style=\"width:230.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"307\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">gluteal<\/span><\/em><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><span lang=\"EN-GB\" style=\"color:black\">Remember to rotate sites of injections between the two\r gluteal or deltoid muscles. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><span lang=\"EN-GB\" style=\"color:black\">If initiating with the two injection start, inject into two\r different sites in two different muscles. <\/span><span lang=\"EN-GB\">DO NOT inject\r both injections concomitantly into the same deltoid or gluteal muscle.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><span lang=\"EN-GB\">For known CYP2D6\r poor metabolisers administer in either<s> <\/s>two separate deltoid muscles or\r one deltoid and one gluteal muscle.<\/span><span lang=\"EN-GB\">DO NOT\r inject into two gluteal muscles.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Look for signs or symptoms of inadvertent\r intravenous administration.<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"margin-left:31.5pt\"><\/p> <p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Step 4:\r Procedures after injection<\/span><\/u><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Engage the needle safety device. Dispose of the needle and\r pre\u2011filled syringe appropriately after injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <div align=\"center\"> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\"> <tr> <td style=\"width:313.35pt;padding:0in 5.4pt 0in 5.4pt\" width=\"418\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\"><img border=\"0\" height=\"123\" id=\"Bild 24\" src=\"AbilifyMaintena-h-2755-e_files\/image022.png\" width=\"291\"\/><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:313.35pt;padding:0in 5.4pt 0in 5.4pt\" width=\"418\"> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:33.75pt;border-collapse:collapse\"> <tr> <td style=\"width:196.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"262\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Cover<\/span><\/p> <\/td> <td style=\"width:230.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"307\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Discard<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <\/table> <\/div> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;text-autospace:none\"><\/p> <\/div>","ID":"8e0a973f-8e00-498e-8624-cc02780a0c28","Styles":"None","Classes":"['WordSection1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ","ParentId":"15e25fa7-af1c-4c8d-872e-3d88dd81e800"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><strong><\/strong><\/p>","ID":"fffa02a7-dd0f-4f64-bc09-17f1afc4d8d9","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"8a536276-5728-4df2-bd91-3e46cefec7f2","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"d996aebe-779a-4f40-b3ad-5586113fc530","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"d8663acd-5c61-4aa8-ac5f-620b23ceb7ae","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"770a094a-724a-40b3-87ab-f545d66ba820","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"f6c9dc04-6ae6-466f-88a9-d1eb81c50d96","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"57e3c3fe-4d37-411c-8021-8944105b8f76","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"9a115196-ed19-42f3-9b70-c567655a594d","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"380557de-1dff-452b-a930-7f29048fde6a","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"36780bdc-c667-4f61-aba2-d38117cf3d71","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"f00079f4-2451-40d8-a964-aa444a170bba","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"96358888-939f-45b4-a6a0-8f3143eba53d","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"904d5d5c-b29f-4235-bdd9-1ba120021106","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"b604343b-bd94-449c-b83a-2b323a1ca602","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"86347ee6-285e-4248-bbed-5ea8be0ef85e","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"2c668047-8ce5-4aca-a114-5f167cda07e0","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"4f3a92d1-2099-46a4-afc3-145f7f85af31","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"96388441-77dc-4037-85d8-65c62435f4fe","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"d095972c-649f-4405-9b3a-f0e3fcf7ac6e","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"70895bfa-62db-4a3d-8284-b410f8c65068","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"3612f6d6-b36e-47b0-b63e-89256cfbd362","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"c0bdac82-8934-412d-9448-085c3dda35eb","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center\"><\/p>","ID":"d0286139-bd11-46c2-bd4e-46dd9302e256","Styles":"margin-right:4.25pt;text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center;\r text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">ANNEX I<\/span><\/b><\/p>","ID":"6fe7a8e7-645f-4f7e-8b22-5df45d79657d","Styles":"margin-right:4.25pt;text-align:center;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":null,"Text":"ANNEX I","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-right:4.25pt;text-align:center;\r text-autospace:none\"><\/p>","ID":"37c9235e-750d-4c01-b138-715828d90c48","Styles":"margin-right:4.25pt;text-align:center;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p>","ID":"a827af4f-dbc0-41cc-8e3c-f00288efa550","Styles":"None","Classes":"['TitleA']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"SUMMARY OF PRODUCT CHARACTERISTICS","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"90b92dd7-b199-402a-80ba-ab5f0f0f2562","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"77456e5c-ac4d-42bc-a697-3522198a2d34","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"90b92dd7-b199-402a-80ba-ab5f0f0f2562"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.       NAME OF THE MEDICINAL\r PRODUCT<\/span><\/b><\/em><\/p>","ID":"442c6025-03ed-4bfe-9872-cfa3dc542de0","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"1.       NAME OF THE MEDICINAL\r PRODUCT","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2184acd2-f11a-4394-8837-50699e1b5f6a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/em><\/p>","ID":"1c68c80d-17d8-417f-a088-0272292de790","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/em><\/p>","ID":"6abbe59a-87fe-4872-a89f-1dd4df9a64b5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/em><\/p>","ID":"93ff696d-9181-4490-8944-eaa2b639c4b2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/em><\/p>","ID":"7c40f5ff-0349-42b0-9ad6-1eead972dd7d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"53006c02-69be-493a-b72b-24387e5ec485","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"eefda17c-25aa-4041-a2cb-eae27b43c13a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION<\/span><\/b><\/em><\/p>","ID":"dbcddba5-b87d-4473-870e-e1789b1c2295","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2831a106-c92a-4e50-9917-15ab5bfcc16b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"9207ead6-c704-4884-bc66-ef4e2a9bf09a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"04d9f63f-abff-4689-a46b-ebcbc9072b65","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r vial contains 300 mg aripiprazole.<\/span><\/em><\/p>","ID":"915d6764-15fb-4263-80de-0d8f26ab512c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Each\r vial contains 300 mg aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b6a0cd4f-4f89-4d99-bdb8-85f49590f1a1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"c6f1bfa5-07f9-410c-a5e8-d50c8ed29238","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"add97d70-ba3c-4a64-a020-3ac325de8b05","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r vial contains 400 mg aripiprazole.<\/span><\/em><\/p>","ID":"7dbc7614-353d-414b-a496-5e6cc3fe689a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Each\r vial contains 400 mg aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ca4f46ac-c22a-47b5-9720-212b0df617fa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"9497294e-f465-4fa9-8a1b-6033fcd29a43","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"73126695-96aa-436a-8d5b-92c19744b7bc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r pre\u2011filled syringe contains 300 mg aripiprazole.<\/span><\/em><\/p>","ID":"6d313b2a-b7cf-45d5-a893-b4cf5396dab5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Each\r pre\u2011filled syringe contains 300 mg aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b0e96971-1789-483c-aa06-ee3788e0d29f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"1772069d-ac5b-41c4-8be1-c3e21efbef58","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f2ee107c-58e7-4940-960c-1b67ab559f9b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r pre\u2011filled syringe contains 400 mg aripiprazole.<\/span><\/em><\/p>","ID":"63b8313e-f839-4319-879b-ede49830f66a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Each\r pre\u2011filled syringe contains 400 mg aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"dcad9b5e-cbef-4b69-823c-8eee31809848","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r reconstitution each ml of suspension contains 200 mg aripiprazole.<\/span><\/em><\/p>","ID":"c8fa1c9c-0a99-44fd-b15b-e5b95423a734","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"After\r reconstitution each ml of suspension contains 200 mg aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b45bf199-a7ad-4120-aa42-4f5d659d3744","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">For\r the full list of excipients, see section 6.1.<\/span><\/em><\/p>","ID":"398b7df3-e7f5-4d07-9954-c1e0f9adb8a7","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"For\r the full list of excipients, see section 6.1.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9c5fbf43-498e-4471-ab7c-126655d98ab3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1f6d8786-2fee-4f4f-839c-b36d68b471aa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3.       PHARMACEUTICAL FORM<\/span><\/b><\/em><\/p>","ID":"5db3f8a1-8e61-4e3d-9088-b929b66db27b","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"3.       PHARMACEUTICAL FORM","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"23a97d3c-61e9-4105-b229-8d564e019a58","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Powder\r and solvent for prolonged-release suspension for injection<\/span><\/em><\/p>","ID":"41a161f2-4bfe-4617-966e-51ba8562916e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Powder\r and solvent for prolonged-release suspension for injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1148d992-b299-4af2-9a48-44a56f33c723","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Powder:\r white to off-white<\/span><\/em><\/p>","ID":"60274a8a-67dd-4f54-b3cd-55cfd44a54c2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Powder:\r white to off-white","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Solvent:\r clear solution<\/span><\/em><\/p>","ID":"0929da31-5344-4fc6-8c6f-58c52d4e960f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Solvent:\r clear solution","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bd14b765-5692-4531-bbb2-990786079392","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"33ad2abf-79e2-41af-ace2-554a9d42090a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.       CLINICAL PARTICULARS<\/span><\/b><\/em><\/p>","ID":"714c12b5-c1f6-4cc3-ba35-aa03e05b7bc3","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"4.       CLINICAL PARTICULARS","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"48b46a64-c31a-4cb4-869a-cae14f499b69","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.1     Therapeutic\r indications<\/span><\/b><\/em><\/p>","ID":"2b29e30a-3454-43d4-b710-001a4a8e1b75","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.1     Therapeutic\r indications","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c151a768-beb1-4cfa-9dc0-a4e3dfc1ca32","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena is indicated for maintenance treatment of schizophrenia in adult\r patients stabilised with oral aripiprazole.<\/span><\/em><\/p>","ID":"186fafcf-2be8-4023-9f52-2dd29074574a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena is indicated for maintenance treatment of schizophrenia in adult\r patients stabilised with oral aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3f5297a4-662e-4d51-abba-0610e8519698","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.2     Posology and method of\r administration<\/span><\/b><\/em><\/p>","ID":"de995972-65f6-4555-8aa2-f7cbe9471878","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.2     Posology and method of\r administration","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2018ef9f-9a7e-4ed2-9891-b4e57f2fee98","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Posology<\/span><\/u><\/em><\/p>","ID":"d1b38ea2-95c2-4e48-90cf-1f013685dbb7","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Posology","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"fe75338f-a419-4429-8ec5-a3e549169613","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">For\r patients who have never taken aripiprazole, tolerability with oral aripiprazole\r must occur prior to initiating treatment with Abilify Maintena.<\/span><\/em><\/p>","ID":"dce4c77b-e526-43f6-8750-5e7c64619cbd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"For\r patients who have never taken aripiprazole, tolerability with oral aripiprazole\r must occur prior to initiating treatment with Abilify Maintena.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"da943a59-55fd-41f9-bf73-769da0c3785d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a7fd1494-338d-478c-a5e4-926e2edc5013","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Titration\r of the dose <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:\r normal\">for Abilify Maintena is not required. <\/span><\/em><\/p>","ID":"ba6ad26e-28f2-4a19-b222-15d24a5b7452","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Titration\r of the dose for Abilify Maintena is not required. ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d8376bf5-fb8e-4da6-97b4-fd12e8e6ac8a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">starting\r dose can be administered by following one of two regimens: <\/span><\/em><\/p>","ID":"4e8f7551-0a38-4064-b850-55b09557dde6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The\r starting\r dose can be administered by following one of two regimens: ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"11642e4b-2fcd-4a93-a4d4-41cf278aaa7b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        One injection start: On\r the day of initiation, administer one injection of 400 mg Abilify Maintena\r and continue treatment with 10 mg to 20 mg oral aripiprazole per day for\r 14 consecutive days to maintain therapeutic aripiprazole concentrations\r during initiation of therapy. <\/span><\/em><\/p>","ID":"75c73c0a-a616-4044-b496-281d87472c53","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"\u2022        One injection start: On\r the day of initiation, administer one injection of 400 mg Abilify Maintena\r and continue treatment with 10 mg to 20 mg oral aripiprazole per day for\r 14 consecutive days to maintain therapeutic aripiprazole concentrations\r during initiation of therapy. ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        Two injection start:\r On the day of initiation, administer two separate injections of 400 mg\r Abilify Maintena at separate injection sites (see method of administration), along\r with one 20 mg dose of oral aripiprazole. <\/span><\/em><\/p>","ID":"76bd438f-2653-4a74-a0af-5cc7c3daab5e","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"\u2022        Two injection start:\r On the day of initiation, administer two separate injections of 400 mg\r Abilify Maintena at separate injection sites (see method of administration), along\r with one 20 mg dose of oral aripiprazole. ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e9ecaf39-7e62-48cc-b73d-8406cbf4ea49","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r the <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">injection\r start, the <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">recommended\r maintenance dose of Abilify Maintena is 400 mg.<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> Abilify Maintena<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> should be administered once\r monthly as a single injection (no sooner than 26 days after the previous\r injection).<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If there\r are adverse reactions with the 400 mg dosage, reduction of the dose to\r 300 mg once monthly should be considered.<\/span><\/em><\/p>","ID":"6090c333-ac6a-4a54-8847-0c056a610494","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"After\r the injection\r start, the recommended\r maintenance dose of Abilify Maintena is 400 mg. Abilify Maintena should be administered once\r monthly as a single injection (no sooner than 26 days after the previous\r injection).If there\r are adverse reactions with the 400 mg dosage, reduction of the dose to\r 300 mg once monthly should be considered.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"dc28c289-96b9-4cc5-9765-5cf9fd067dc9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Missed\r doses<\/span><\/u><\/em><\/p>","ID":"c8255fc6-5f55-472c-9bb2-dcc5733a844d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Missed\r doses","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.5in\"><\/p>","ID":"2c9c3a44-3138-44d0-bee4-a8cbbac92329","Styles":"margin-left:.5in","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"614\"> <tr> <td colspan=\"2\" style=\"width:460.7pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"614\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Missed doses<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Timing of Missed Dose<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Action<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">If 2<sup>nd<\/sup> or 3<sup>rd<\/sup> dose is missed and time\r   since last injection is:<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">&gt; 4 weeks\r   and &lt; 5 weeks <\/span><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r   injection should be administered as soon as possible and then the monthly\r   injection schedule should be resumed.<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">&gt; 5 weeks\r   <\/span><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Concomitant\r   oral aripiprazole should be restarted for 14 days with next administered\r   injection<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\r   or two separate injections given at one time, along with a single dose of 20 mg\r   oral aripiprazole. Monthly injection schedule should then resume<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">.<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">If 4<sup>th<\/sup> or subsequent doses are missed (i.e., after\r   attainment of steady state) and time since last injection is:<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">&gt; 4 weeks\r   and &lt; 6 weeks<\/span><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r   injection should be administered as soon as possible and then the monthly\r   injection schedule should be resumed.<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:184.3pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"246\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">&gt; 6 weeks<\/span><\/em><\/p> <\/td> <td style=\"width:276.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"369\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Concomitant\r   oral aripiprazole should be restarted for 14 days with next administered\r   injection <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">or two separate injections given at one time, along with a single\r   dose of 20 mg oral aripiprazole. Monthly<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> injection schedule<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> should then resume<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">.<\/span><\/em><\/p> <\/td> <\/tr> <\/table>","ID":"8b3f97f1-ee1a-45b1-94c8-73b51f99e32f","Styles":"width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"   Missed doses     Timing of Missed Dose   Action     If 2nd or 3rd dose is missed and time\r   since last injection is:        > 4 weeks\r   and < 5 weeks    The\r   injection should be administered as soon as possible and then the monthly\r   injection schedule should be resumed.     > 5 weeks\r      Concomitant\r   oral aripiprazole should be restarted for 14 days with next administered\r   injection\r   or two separate injections given at one time, along with a single dose of 20 mg\r   oral aripiprazole. Monthly injection schedule should then resume.     If 4th or subsequent doses are missed (i.e., after\r   attainment of steady state) and time since last injection is:        > 4 weeks\r   and < 6 weeks   The\r   injection should be administered as soon as possible and then the monthly\r   injection schedule should be resumed.     > 6 weeks   Concomitant\r   oral aripiprazole should be restarted for 14 days with next administered\r   injection or two separate injections given at one time, along with a single\r   dose of 20 mg oral aripiprazole. Monthly injection schedule should then resume.   ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"8f0b577d-f78e-4eff-b658-e74bc12756de","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Special\r populations<\/span><\/u><\/em><\/p>","ID":"a8711340-2ace-48a4-b242-da47d6f54e19","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Special\r populations","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3672a9fb-79c8-4f75-9a0b-2408c3e49ef8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Elderly<\/span><\/em><\/p>","ID":"5b9987b5-fddd-4c84-a0bf-d946e3adc2a4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Elderly","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of <em><span style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em> in the\r treatment of schizophrenia in patients 65 years of age or older has not\r been established (see section 4.4).<\/span><\/p>","ID":"a79cbfd1-8e6c-4e7a-ab1c-8598b52a9dac","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The safety and efficacy of Abilify Maintena in the\r treatment of schizophrenia in patients 65 years of age or older has not\r been established (see section 4.4).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"30d3eeeb-3f2a-4a4b-9996-f0c1a95cb85b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Renal impairment<\/span><\/em><\/p>","ID":"1337f93e-4344-4f75-ba7d-e5eac3be17fc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Renal impairment","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">No\r dosage adjustment is required for patients with renal impairment (see section 5.2).<\/span><\/em><\/p>","ID":"02540c15-cba2-4f98-8ba0-44bd05cabc0a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"No\r dosage adjustment is required for patients with renal impairment (see section 5.2).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1c55ff57-3865-4fa6-b62a-d6eb7b5e1070","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Hepatic impairment<\/span><\/em><\/p>","ID":"d152fa8d-88ab-4e95-a72e-d3309b69d6f2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Hepatic impairment","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">No\r dosage adjustment is required for patients with mild or moderate hepatic\r impairment. In patients with severe hepatic impairment, the data available are\r insufficient to establish recommendations. In these patients dosing should be\r managed cautiously. Oral formulation should be preferred (see\r section 5.2).<\/span><\/em><\/p>","ID":"97e1e92f-f8c7-467e-aece-11c7471261fa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"No\r dosage adjustment is required for patients with mild or moderate hepatic\r impairment. In patients with severe hepatic impairment, the data available are\r insufficient to establish recommendations. In these patients dosing should be\r managed cautiously. Oral formulation should be preferred (see\r section 5.2).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"16941916-c718-427c-b4cc-ffe522cb54b6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><a name=\"_Hlk23773509\"><em><span lang=\"EN-GB\" style=\"color:black\">Known CYP2D6 poor metabolisers<\/span><\/em><\/a><\/p>","ID":"64ee6691-e944-4481-8f39-6618e33a0002","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Known CYP2D6 poor metabolisers","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r patients who are known to be CYP2D6 poor metabolisers<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">: <\/span><\/em><\/p>","ID":"79f63919-88c3-4c58-912e-09b4a929b281","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"In\r patients who are known to be CYP2D6 poor metabolisers: ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5da476db-e131-4e75-9ddb-95825517a9ce","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        One injection start: The\r starting dose should be 300 mg Abilify Maintena and continue treatment with\r prescribed dose of oral aripiprazole per day for 14 consecutive days. <\/span><\/em><\/p>","ID":"52ed3148-3268-4f12-b8db-6ed050ad4057","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"\u2022        One injection start: The\r starting dose should be 300 mg Abilify Maintena and continue treatment with\r prescribed dose of oral aripiprazole per day for 14 consecutive days. ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        Two injection start:\r The starting dose should be 2 separate injections of 300 mg Abilify\r Maintena (see method of administration) along with one single dose of the previous\r prescribed dose of oral aripiprazole. <\/span><\/em><\/p>","ID":"29dd882e-1ac2-4c27-9672-8f19a664b641","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"\u2022        Two injection start:\r The starting dose should be 2 separate injections of 300 mg Abilify\r Maintena (see method of administration) along with one single dose of the previous\r prescribed dose of oral aripiprazole. ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p>","ID":"537ddac9-2373-4297-a8c8-a869ee71401f","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r patients who are known to be CYP2D6 poor metabolisers and concomitantly use a\r strong CYP3A4 inhibitor:<\/span><\/em><\/p>","ID":"5ff745da-8e4c-43c0-9cf9-0d9b8e5cf3d8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"In\r patients who are known to be CYP2D6 poor metabolisers and concomitantly use a\r strong CYP3A4 inhibitor:","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ac05eef1-c317-42f3-bedd-3afa046aa9bf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        The one injection\r start: The starting dose should be reduced to 200 mg (see section 4.5)\r and continue treatment with the prescribed dose of oral aripiprazole per day\r for 14 consecutive days.<\/span><\/em><\/p>","ID":"a13dd531-c09c-42ec-a53a-40cd351b3a86","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"\u2022        The one injection\r start: The starting dose should be reduced to 200 mg (see section 4.5)\r and continue treatment with the prescribed dose of oral aripiprazole per day\r for 14 consecutive days.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\u2022        Two injection start\r is not to be used in patients who are known to be CYP2D6 poor metabolisers and\r concomitantly use a strong CYP3A4 inhibitor.<\/span><\/em><\/p>","ID":"52fe6fc0-fe24-4ca4-99c8-01a81c7f8b93","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"\u2022        Two injection start\r is not to be used in patients who are known to be CYP2D6 poor metabolisers and\r concomitantly use a strong CYP3A4 inhibitor.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a20e2aa3-7ccd-4e44-8a9e-3208a622ace3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r the injection start, see table below for the recommended maintenance dose of\r Abilify Maintena. Abilify Maintena should be administered once monthly as a\r single injection (no sooner than 26 days after the previous injection).<\/span><\/em><\/p>","ID":"46403013-5682-4d92-ad67-8e8e82fbe271","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"After\r the injection start, see table below for the recommended maintenance dose of\r Abilify Maintena. Abilify Maintena should be administered once monthly as a\r single injection (no sooner than 26 days after the previous injection).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.25in\"><\/p>","ID":"7edc2de0-8aab-487c-b89b-8e698a75ddb1","Styles":"margin-left:.25in","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Maintenance dose<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black\"> adjustments due to interactions <\/span><\/em><i><span lang=\"EN-GB\" style=\"color:black\">with CYP2D6 and\/or CYP3A4 inhibitors and\/or\r CYP3A4 inducers<\/span><\/i><\/p>","ID":"c1b2e8ff-09d7-4806-8755-47421f029536","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Maintenance dose adjustments due to interactions with CYP2D6 and\/or CYP3A4 inhibitors and\/or\r CYP3A4 inducers","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Maintenance\r dosage<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">\r adjustments should be made in patients taking concomitant strong CYP3A4\r inhibitors or strong CYP2D6 inhibitors for more than 14 days. If the\r CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the dosage may need to be\r increased to the previous dose (see section 4.5). In case of adverse\r reactions despite dose adjustments of Abilify Maintena, the necessity of\r concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed.<\/span><\/em><\/p>","ID":"41df0d36-0d88-4b73-a31b-b2098d668696","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Maintenance\r dosage\r adjustments should be made in patients taking concomitant strong CYP3A4\r inhibitors or strong CYP2D6 inhibitors for more than 14 days. If the\r CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the dosage may need to be\r increased to the previous dose (see section 4.5). In case of adverse\r reactions despite dose adjustments of Abilify Maintena, the necessity of\r concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7c628731-1d17-43c9-a3a1-bebfea2479bd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Concomitant\r use of CYP3A4 inducers with Abilify Maintena should be avoided for more than\r 14 days because the blood levels of aripiprazole are decreased and may be\r below the effective levels (see section 4.5).<\/span><\/em><\/p>","ID":"c2cc48a0-69bf-426f-953c-d0a007d17571","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Concomitant\r use of CYP3A4 inducers with Abilify Maintena should be avoided for more than\r 14 days because the blood levels of aripiprazole are decreased and may be\r below the effective levels (see section 4.5).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"58e9cec7-2182-4956-86dc-fa20be025ae3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Maintenance dose<\/span><\/b><\/em><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> adjustments of Abilify Maintena\r in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4\r inhibitors, and\/or CYP3A4 inducers for more than 14 days<\/span><\/b><\/em><\/p>","ID":"5f9e9140-dc8c-4fd8-ace7-9d389fb3534a","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Maintenance dose adjustments of Abilify Maintena\r in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4\r inhibitors, and\/or CYP3A4 inducers for more than 14 days","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"614\"> <tr style=\"height:22.45pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:22.45pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:177.2pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.45pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Adjusted dose<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr style=\"height:11.2pt\"> <td colspan=\"2\" style=\"width:460.7pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.2pt\" valign=\"top\" width=\"614\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Patients taking 400 mg of Abilify Maintena<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr style=\"height:11.2pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.2pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Strong\r   CYP2D6 or strong CYP3A4 inhibitors<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.2pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">300 mg<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.0pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Strong\r   CYP2D6 and strong CYP3A4 inhibitors<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.0pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">200 mg*<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:11.65pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">CYP3A4\r   inducers<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.65pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Avoid use<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:8.95pt\"> <td colspan=\"2\" style=\"width:460.7pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.95pt\" valign=\"top\" width=\"614\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Patients taking 300 mg of Abilify Maintena<\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr style=\"height:8.5pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Strong\r   CYP2D6 or strong CYP3A4 inhibitors<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">200 mg*<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:8.95pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.95pt\" valign=\"top\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Strong\r   CYP2D6 and strong CYP3A4 inhibitors<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.95pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">160 mg*<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:283.5pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" width=\"378\"> <p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">CYP3A4\r   inducers<\/span><\/em><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"236\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Avoid use<\/span><\/em><\/p> <\/td> <\/tr> <\/table>","ID":"7654ca68-b76a-4638-a5b4-ed35f0dc0585","Styles":"width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"      Adjusted dose     Patients taking 400 mg of Abilify Maintena     Strong\r   CYP2D6 or strong CYP3A4 inhibitors   300 mg     Strong\r   CYP2D6 and strong CYP3A4 inhibitors   200 mg*     CYP3A4\r   inducers   Avoid use     Patients taking 300 mg of Abilify Maintena     Strong\r   CYP2D6 or strong CYP3A4 inhibitors   200 mg*     Strong\r   CYP2D6 and strong CYP3A4 inhibitors   160 mg*     CYP3A4\r   inducers   Avoid use   ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><em><span lang=\"EN-GB\" style=\"font-size:8.0pt;font-style:normal\">*    <\/span><\/em><span lang=\"EN-GB\" style=\"font-size:8.0pt\">200 mg and 160 mg can be achieved via\r adjustment of the injection volume only by using Abilify Maintena powder and\r solvent for <\/span><span lang=\"EN-GB\" style=\"font-size:8.0pt\">prolonged-release suspension for injection.<\/span><\/p>","ID":"a2866931-9eb5-433f-b5e8-750f8b36ec19","Styles":"margin-left:14.2pt;text-indent:-14.2pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"*    200 mg and 160 mg can be achieved via\r adjustment of the injection volume only by using Abilify Maintena powder and\r solvent for prolonged-release suspension for injection.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"df39d7b0-57eb-4d6c-a2a3-98c4d0438b1a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Paediatric\r population<\/span><\/em><\/p>","ID":"005307ca-2864-4a51-bf18-cbefa7b974cb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Paediatric\r population","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r safety and efficacy of Abilify Maintena in children and adolescents aged 0\u201117 years\r have not been established. No data are available.<\/span><\/em><\/p>","ID":"4dc98076-a2a5-44ee-9220-ee082123db30","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The\r safety and efficacy of Abilify Maintena in children and adolescents aged 0\u201117 years\r have not been established. No data are available.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"60b81732-5788-4745-8b66-13c5d45215e2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Method\r of administration<\/span><\/u><\/em><\/p>","ID":"29d25daf-1e4c-4b72-acd8-ea0002989a79","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Method\r of administration","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"e79756c1-9584-4767-a6c6-a1b9e610b72a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena is only intended for intramuscular use and should not be administered\r intravenously or subcutaneously. It should only be administered by a healthcare\r professional.<\/span><\/em><\/p>","ID":"e4db9732-25ce-4502-9f32-30d91e3898ca","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena is only intended for intramuscular use and should not be administered\r intravenously or subcutaneously. It should only be administered by a healthcare\r professional.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a87dc7cb-d7f2-4406-9a86-f89ac96230d2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r suspension should be injected slowly as a single injection (doses must not be\r divided) into the gluteal or deltoid muscle. Care should be taken to avoid\r inadvertent injection into a blood vessel.<\/span><\/em><\/p>","ID":"e0badd04-8236-48be-8c27-8ad1e5a59132","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r suspension should be injected slowly as a single injection (doses must not be\r divided) into the gluteal or deltoid muscle. Care should be taken to avoid\r inadvertent injection into a blood vessel.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7433ea22-c3d2-40f2-9d12-ae6efb1ab1d3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If initiating with the\r two injection start, inject into two different sites in two different muscles.\r DO NOT inject both injections concomitantly into the same deltoid or gluteal\r muscle.<\/span><span lang=\"EN-GB\">For\r known CYP2D6 poor metabolisers administer in either two separate deltoid\r muscles or one deltoid and one gluteal muscle. DO NOT inject into two gluteal\r muscles.<\/span><\/p>","ID":"85c8d282-f963-4be8-9dfb-9e304fe21c0c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"If initiating with the\r two injection start, inject into two different sites in two different muscles.\r DO NOT inject both injections concomitantly into the same deltoid or gluteal\r muscle.For\r known CYP2D6 poor metabolisers administer in either two separate deltoid\r muscles or one deltoid and one gluteal muscle. DO NOT inject into two gluteal\r muscles.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3e79664a-1704-4af5-8cc0-3da6a30afd9e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Full instructions for\r use and handling of Abilify Maintena are provided in the package leaflet\r (information intended for healthcare professionals).<\/span><\/p>","ID":"f3c01793-0f58-4376-8700-240acfc32aad","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Full instructions for\r use and handling of Abilify Maintena are provided in the package leaflet\r (information intended for healthcare professionals).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"35b270d9-b1e5-43cd-a697-01e2a1e5cbe5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">For instructions on\r reconstitution of the medicinal product before administration, see section 6.6.<\/span><\/p>","ID":"cca43b2a-a6ae-4660-a907-25c9b663e804","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For instructions on\r reconstitution of the medicinal product before administration, see section 6.6.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"db0d37e1-04dd-4ff3-8c12-7e46d73d1f68","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.3     Contraindications<\/span><\/b><\/em><\/p>","ID":"20693000-fce0-41a5-a10d-bf1dcccd3f6b","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.3     Contraindications","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"14c32b81-1e0c-4f17-8898-1f3a819886a1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/em><\/p>","ID":"f3e3db33-7cc5-4ee1-a48f-92e50e50e1ba","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1aff8b71-9936-43a0-bda0-2fbe46dac810","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.4     Special\r warnings and precautions for use<\/span><\/b><\/em><\/p>","ID":"5629e695-12ee-4915-a5c0-2d318ddb2774","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.4     Special\r warnings and precautions for use","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"c19449ba-7871-42eb-b709-5b72cc873dd8","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"font-style:normal\">During antipsychotic treatment, improvement in the\r patient's clinical condition may take several days to some weeks. Patients\r should be closely monitored throughout this period.<\/span><\/em><\/p>","ID":"bfc2e143-3842-4007-84ef-cee1fafa1740","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"During antipsychotic treatment, improvement in the\r patient's clinical condition may take several days to some weeks. Patients\r should be closely monitored throughout this period.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"b1e1e82c-231b-4df4-92b6-821e32f1b0a6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Use in patients who are in an acutely\r agitated or severely psychotic state<\/span><\/u><\/p>","ID":"03220815-5ffe-4386-b093-32e0df072f26","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","Text":"Use in patients who are in an acutely\r agitated or severely psychotic state","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"bcf34e44-7300-42e7-a90b-b7aca58b8ca5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena should not be used to\r manage acutely agitated or severely psychotic states when immediate symptom\r control is warranted.<\/span><\/p>","ID":"2c8724dc-0b6c-4b03-a873-22a9b629ffbe","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Abilify Maintena should not be used to\r manage acutely agitated or severely psychotic states when immediate symptom\r control is warranted.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d5865f33-7621-4013-86ee-e0c4f6c88ed8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Suicidality<\/span><\/u><\/em><\/p>","ID":"f73da531-11ad-46c0-9e3b-f97208ca7d15","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Suicidality","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"97a95a6d-9c26-42ee-abcb-52c937c21ed8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r occurrence of suicidal behaviour is inherent in psychotic illnesses, and in\r some cases has been reported early after initiation or switch of antipsychotic\r treatment, including treatment with aripiprazole (see section 4.8). Close\r supervision of high risk patients should accompany antipsychotic treatment.<\/span><\/em><\/p>","ID":"7df1ab0f-8afb-4cbd-8ea2-aef88eaba519","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r occurrence of suicidal behaviour is inherent in psychotic illnesses, and in\r some cases has been reported early after initiation or switch of antipsychotic\r treatment, including treatment with aripiprazole (see section 4.8). Close\r supervision of high risk patients should accompany antipsychotic treatment.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7d4bfd0a-4edb-4e0e-93da-957ce631c74e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Cardiovascular disorders<\/span><\/u><\/em><\/p>","ID":"78bfef1b-6a54-463e-8dd1-56bf5a1cb632","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Cardiovascular disorders","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"852d2a15-a757-455e-a377-d94ed34175f8","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r should be used with caution in patients with known cardiovascular disease\r (history of myocardial infarction or ischaemic heart disease, heart failure, or\r conduction abnormalities), cerebrovascular disease, conditions which would\r predispose patients to hypotension (dehydration, hypovolemia, and treatment with\r antihypertensive medicinal products) or hypertension, including accelerated or\r malignant. Cases of venous thromboembolism (VTE) have been reported with\r antipsychotic medicinal products. Since patients treated with antipsychotics\r often present with acquired risk factors for VTE, all possible risk factors for\r VTE should be identified before and during treatment with aripiprazole and\r preventive measures undertaken (see section 4.8).<\/span><\/em><\/p>","ID":"86a8c1a9-bbf4-4320-af3e-7637559284c9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole\r should be used with caution in patients with known cardiovascular disease\r (history of myocardial infarction or ischaemic heart disease, heart failure, or\r conduction abnormalities), cerebrovascular disease, conditions which would\r predispose patients to hypotension (dehydration, hypovolemia, and treatment with\r antihypertensive medicinal products) or hypertension, including accelerated or\r malignant. Cases of venous thromboembolism (VTE) have been reported with\r antipsychotic medicinal products. Since patients treated with antipsychotics\r often present with acquired risk factors for VTE, all possible risk factors for\r VTE should be identified before and during treatment with aripiprazole and\r preventive measures undertaken (see section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"195ecc55-e4f0-4e5d-938a-53f3169a1895","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">QT\r prolongation<\/span><\/u><\/em><\/p>","ID":"2f2d4c3d-6710-4764-b138-c1243698342c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"QT\r prolongation","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"19f37c90-d1a3-4fa5-b55a-8081cf216dfa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r clinical trials of treatment with oral aripiprazole, the incidence of QT\r prolongation was comparable to placebo. Aripiprazole should be used with\r caution in patients with a family history of QT prolongation (see\r section 4.8).<\/span><\/em><\/p>","ID":"e4a2bfd8-7bec-49a2-b35a-10f41e88ef3e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r clinical trials of treatment with oral aripiprazole, the incidence of QT\r prolongation was comparable to placebo. Aripiprazole should be used with\r caution in patients with a family history of QT prolongation (see\r section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1a700b86-8e45-4f7e-a01d-4aa0cade4290","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tardive\r dyskinesia<\/span><\/u><\/em><\/p>","ID":"1d62c2d3-7f67-411d-8c24-c186ef071007","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Tardive\r dyskinesia","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"56efaad8-034f-4f3c-adc4-45f6e24d1d34","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r clinical trials of one year or less duration, there were uncommon reports of\r treatment emergent dyskinesia during treatment with aripiprazole. If signs and\r symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose\r reduction or discontinuation should be considered (see section 4.8). These\r symptoms can temporally deteriorate or can even arise after discontinuation of\r treatment.<\/span><\/em><\/p>","ID":"13973b1e-5ad8-4f07-a4b6-edb2b53ea159","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r clinical trials of one year or less duration, there were uncommon reports of\r treatment emergent dyskinesia during treatment with aripiprazole. If signs and\r symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose\r reduction or discontinuation should be considered (see section 4.8). These\r symptoms can temporally deteriorate or can even arise after discontinuation of\r treatment.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"44b2fcec-553a-4542-a570-d2bdc273eff8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Neuroleptic\r Malignant Syndrome (NMS)<\/span><\/u><\/em><\/p>","ID":"9aad7414-f3ad-45a9-875b-8a7cfd4406d9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Neuroleptic\r Malignant Syndrome (NMS)","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"12b54410-1c01-475b-a5c0-b1fc7b82ba77","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">NMS\r is a potentially fatal symptom complex associated with antipsychotics. In\r clinical trials, rare cases of NMS were reported during treatment with\r aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity,\r altered mental status and evidence of autonomic instability (irregular pulse or\r blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs\r may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis),\r and acute renal failure. However, elevated creatine phosphokinase and\r rhabdomyolysis, not necessarily in association with NMS, have also been\r reported. If a patient develops signs and symptoms indicative of NMS, or\r presents with unexplained high fever without additional clinical manifestations\r of NMS, all antipsychotics, including aripiprazole, must be discontinued (see\r section 4.8).<\/span><\/em><\/p>","ID":"5035df6b-2367-4efe-b1ec-954920043c7e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"NMS\r is a potentially fatal symptom complex associated with antipsychotics. In\r clinical trials, rare cases of NMS were reported during treatment with\r aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity,\r altered mental status and evidence of autonomic instability (irregular pulse or\r blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs\r may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis),\r and acute renal failure. However, elevated creatine phosphokinase and\r rhabdomyolysis, not necessarily in association with NMS, have also been\r reported. If a patient develops signs and symptoms indicative of NMS, or\r presents with unexplained high fever without additional clinical manifestations\r of NMS, all antipsychotics, including aripiprazole, must be discontinued (see\r section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"95ed55f6-fc08-4ac8-8ac7-af67ce0c44f4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Seizure<\/span><\/u><\/em><\/p>","ID":"01dcdd8f-cf96-49f9-baa5-a697435507a0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Seizure","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"aa4ffcd9-2a5c-455b-af1b-92b2fa0d121c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r clinical trials, uncommon cases of seizure were reported during treatment with\r aripiprazole. Therefore, aripiprazole should be used with caution in patients\r who have a history of seizure disorder or have conditions associated with\r seizures (see section 4.8).<\/span><\/em><\/p>","ID":"0285041c-babf-4188-a2e1-e720b53c038a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r clinical trials, uncommon cases of seizure were reported during treatment with\r aripiprazole. Therefore, aripiprazole should be used with caution in patients\r who have a history of seizure disorder or have conditions associated with\r seizures (see section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"b385f118-1f12-4400-b7d8-e48b35b495b7","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Elderly patients with dementia-related\r psychosis<\/span><\/u><\/p>","ID":"505b03d1-7176-4d20-9c91-ad8bc97c33d5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","Text":"Elderly patients with dementia-related\r psychosis","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e6cb5ff0-37d7-4cba-bd20-9d38941acbbb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Increased mortality<\/span><\/i><\/p>","ID":"60554f97-8525-421d-a4db-06de80101568","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Increased mortality","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In three\r placebo-controlled trials of oral aripiprazole in elderly patients with\r psychosis associated with Alzheimer's disease (n = 938; mean age:\r 82.4 years; range: 56\u201199 years), patients treated with\r aripiprazole were at an increased risk of death compared to placebo. The rate\r of death in oral aripiprazole-treated patients was 3.5 % compared to\r 1.7 % in placebo. Although the causes of deaths were varied, most of the\r deaths appeared to be either cardiovascular (e.g. heart failure, sudden death)\r or infectious (e.g. pneumonia) in nature (see section 4.8).<\/span><\/p>","ID":"7371d50d-e70f-41ab-aa4b-055029493b0b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In three\r placebo-controlled trials of oral aripiprazole in elderly patients with\r psychosis associated with Alzheimer's disease (n = 938; mean age:\r 82.4 years; range: 56\u201199 years), patients treated with\r aripiprazole were at an increased risk of death compared to placebo. The rate\r of death in oral aripiprazole-treated patients was 3.5 % compared to\r 1.7 % in placebo. Although the causes of deaths were varied, most of the\r deaths appeared to be either cardiovascular (e.g. heart failure, sudden death)\r or infectious (e.g. pneumonia) in nature (see section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"ce082216-4904-495b-98f4-08afbdbffcce","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Cerebrovascular adverse reactions<\/span><\/i><\/p>","ID":"f4a1fc5a-1f95-449d-81cd-09c4076bc53b","Styles":"page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Cerebrovascular adverse reactions","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In the same\r trials with oral aripiprazole, cerebrovascular adverse reactions (e.g. stroke,\r transient ischaemic attack), including fatalities, were reported in patients\r (mean age: 84 years; range: 78\u201188 years). Overall, 1.3 %\r of oral aripiprazole-treated patients reported cerebrovascular adverse\r reactions compared with 0.6 % of placebo-treated patients in these trials.\r This difference was not statistically significant. However, in one of these\r trials, a fixed-dose trial, there was a significant dose- response relationship\r for cerebrovascular adverse reactions in patients treated with aripiprazole\r (see section 4.8).<\/span><\/p>","ID":"8253f32d-7240-4112-9a79-989c2212bbf6","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In the same\r trials with oral aripiprazole, cerebrovascular adverse reactions (e.g. stroke,\r transient ischaemic attack), including fatalities, were reported in patients\r (mean age: 84 years; range: 78\u201188 years). Overall, 1.3 %\r of oral aripiprazole-treated patients reported cerebrovascular adverse\r reactions compared with 0.6 % of placebo-treated patients in these trials.\r This difference was not statistically significant. However, in one of these\r trials, a fixed-dose trial, there was a significant dose- response relationship\r for cerebrovascular adverse reactions in patients treated with aripiprazole\r (see section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"6661082f-cd62-47a1-b491-a974839c4ad8","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole<\/span><\/em><span lang=\"EN-GB\" style=\"color:black\"> is not indicated for the treatment of patients\r with dementia-related psychosis.<\/span><\/p>","ID":"3e1992f5-5c92-42cc-bf99-27f86a808131","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole is not indicated for the treatment of patients\r with dementia-related psychosis.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"57feab58-68ab-4c2f-8670-e76f35bc1384","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hyperglycaemia\r and diabetes mellitus<\/span><\/u><\/em><\/p>","ID":"97cda223-20c5-4bb0-9ed3-3faa66703a9b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Hyperglycaemia\r and diabetes mellitus","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"0f7e3465-87b7-4ed3-9757-05b370447889","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hyperglycaemia,\r in some cases extreme and associated with ketoacidosis or hyperosmolar coma or\r death, has been reported in patients treated with aripiprazole. Risk factors\r that may predispose patients to severe complications include obesity and family\r history of diabetes. Patients treated with aripiprazole should be observed for\r signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia\r and weakness) and patients with diabetes mellitus or with risk factors for\r diabetes mellitus should be monitored regularly for worsening of glucose\r control (see section 4.8).<\/span><\/em><\/p>","ID":"0b596e69-cdff-4a25-8f6d-74874052ed4e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hyperglycaemia,\r in some cases extreme and associated with ketoacidosis or hyperosmolar coma or\r death, has been reported in patients treated with aripiprazole. Risk factors\r that may predispose patients to severe complications include obesity and family\r history of diabetes. Patients treated with aripiprazole should be observed for\r signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia\r and weakness) and patients with diabetes mellitus or with risk factors for\r diabetes mellitus should be monitored regularly for worsening of glucose\r control (see section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"98306447-3428-4942-87c4-a0e6b7e01204","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hypersensitivity<\/span><\/u><\/em><\/p>","ID":"74eff693-a98f-4a8a-9bdc-e24090bb2638","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Hypersensitivity","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"4e271be3-ca68-47ad-8c11-b6e24bb56428","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hypersensitivity\r reactions, characterised by allergic symptoms, may occur with aripiprazole (see\r section 4.8).<\/span><\/em><\/p>","ID":"3230d90d-3c66-46a6-9661-f9a27d0f7689","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Hypersensitivity\r reactions, characterised by allergic symptoms, may occur with aripiprazole (see\r section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"97a7ab34-2d89-47f8-8f4b-cbb2b49ef511","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Weight gain<\/span><\/u><\/em><\/p>","ID":"4e0e70e4-da1c-4c17-9c32-82b6030830be","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Weight gain","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;background:yellow;\r font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"94ec129e-5518-43d1-8185-56d5e25e80af","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Weight gain is commonly\r seen in schizophrenic patients due to use of antipsychotics known to cause\r weight gain, co-morbidities, poorly managed life-style and might lead to severe\r complications. <em><span style=\"font-style:normal\">Weight gain has been\r reported post-marketing among patients prescribed oral aripiprazole. When seen,\r it is usually in those with significant risk factors such as history of\r diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole\r has not been shown to induce clinically relevant weight gain (see section 4.8).<\/span><\/em><\/span><\/p>","ID":"a1a1c81a-44e6-45aa-8a8c-41e9e22ae798","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Weight gain is commonly\r seen in schizophrenic patients due to use of antipsychotics known to cause\r weight gain, co-morbidities, poorly managed life-style and might lead to severe\r complications. Weight gain has been\r reported post-marketing among patients prescribed oral aripiprazole. When seen,\r it is usually in those with significant risk factors such as history of\r diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole\r has not been shown to induce clinically relevant weight gain (see section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5fe4388f-1260-4bbe-876e-4c2ae98e09dc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Dysphagia<\/span><\/u><\/em><\/p>","ID":"67998347-7a9a-4f46-9f4e-5aebad1d7437","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Dysphagia","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"03007fbf-3382-48b8-ba07-d9c7270efb9d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Oesophageal\r dysmotility and aspiration have been associated with the use of aripiprazole.\r Aripiprazole should be used cautiously in patients at risk for aspiration\r pneumonia.<\/span><\/em><\/p>","ID":"4d04dcc0-83a9-4477-b12f-57c556b170e6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Oesophageal\r dysmotility and aspiration have been associated with the use of aripiprazole.\r Aripiprazole should be used cautiously in patients at risk for aspiration\r pneumonia.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bcc8872a-cfa4-4f88-88ad-ad855016e0c8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\">Pathological\r gambling and other impulse control disorders<\/span><\/u><\/p>","ID":"387d67c4-8914-4a78-81f1-f91433312581","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","Text":"Pathological\r gambling and other impulse control disorders","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ec83fc0f-ebe9-41c8-b7aa-de1dadbcb029","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Patients can experience increased urges,\r particularly for gambling, and the inability to control these urges while\r taking aripiprazole. Other urges, reported, include: increased sexual urges,\r compulsive shopping, binge or compulsive eating, and other impulsive and\r compulsive behaviours. It is important for prescribers to ask patients or their\r caregivers specifically about the development of new or increased gambling\r urges, sexual urges, compulsive shopping, binge or compulsive eating, or other\r urges while being treated with aripiprazole. It should be noted that\r impulse-control symptoms can be associated with the underlying disorder;\r however, in some cases, urges were reported to have stopped when the dose was\r reduced or the medicinal productation was discontinued. Impulse control\r disorders may result in harm to the patient and others if not recognised. <\/span><\/em><span lang=\"EN-GB\">A dose reduction or stopping of the medicinal product should be\r considered if a patient develops such urges <em><span style=\"color:black;\r font-style:normal\">(see section 4.8<\/span><\/em>).<\/span><\/p>","ID":"0d2ddb0f-61e3-4cbc-b603-825d1539e113","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients can experience increased urges,\r particularly for gambling, and the inability to control these urges while\r taking aripiprazole. Other urges, reported, include: increased sexual urges,\r compulsive shopping, binge or compulsive eating, and other impulsive and\r compulsive behaviours. It is important for prescribers to ask patients or their\r caregivers specifically about the development of new or increased gambling\r urges, sexual urges, compulsive shopping, binge or compulsive eating, or other\r urges while being treated with aripiprazole. It should be noted that\r impulse-control symptoms can be associated with the underlying disorder;\r however, in some cases, urges were reported to have stopped when the dose was\r reduced or the medicinal productation was discontinued. Impulse control\r disorders may result in harm to the patient and others if not recognised. A dose reduction or stopping of the medicinal product should be\r considered if a patient develops such urges (see section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"21af0d4b-28d2-48a1-b611-1bf8563294a2","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\">Falls<\/span><\/u><\/p>","ID":"6049a8d0-afd9-4d8f-afa9-25ff35c42e13","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","Text":"Falls","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"f959fee0-d33e-442b-a32d-b40f160ccf7d","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Aripiprazole\r may cause somnolence, postural hypotension, motor and sensory instability,\r which may lead to falls. Caution should be taken when treating patients at\r higher risk, and a lower starting dose should be considered (e.g., elderly or\r debilitated patients; see section 4.2).<\/span><\/p>","ID":"ab2a444f-0b44-4165-a046-b1f95fa0bacf","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole\r may cause somnolence, postural hypotension, motor and sensory instability,\r which may lead to falls. Caution should be taken when treating patients at\r higher risk, and a lower starting dose should be considered (e.g., elderly or\r debilitated patients; see section 4.2).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"db5dca13-f615-4257-a0a2-0503509d0a5e","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Sodium<\/span><\/u><\/p>","ID":"7eec9373-1651-49d0-88dd-a6a636d5da5d","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","Text":"Sodium","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"48b7bc50-d691-4c75-a63f-3e5b8673503b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena contains less than 1 mmol\r of sodium (23 mg) per dose.<\/span><\/p>","ID":"ad10656a-a9b7-4755-aa9e-12d40057035d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Abilify Maintena contains less than 1 mmol\r of sodium (23 mg) per dose.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f7657cf7-b149-4d01-8cb9-afc4570abd39","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.5     Interaction\r with other medicinal products and other forms of interaction<\/span><\/b><\/em><\/p>","ID":"7aa5776c-167b-405b-801d-e5f138fa73f1","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.5     Interaction\r with other medicinal products and other forms of interaction","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"b77fb43c-07e4-4c50-8093-a8fcdc71f079","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">No\r interaction studies have been performed with Abilify Maintena. The information\r below is obtained from studies with oral aripiprazole.<\/span><\/em><\/p>","ID":"0aab30e0-a231-4e68-b11f-9c9da4490e3d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"No\r interaction studies have been performed with Abilify Maintena. The information\r below is obtained from studies with oral aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"43673a9e-968f-4bf7-9d61-147d74c8ba97","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Due\r to its \u03b11-adrenergic receptor antagonism, aripiprazole has the potential\r to enhance the effect of certain antihypertensive medicinal products.<\/span><\/em><\/p>","ID":"9b43be67-515f-44dc-a92f-e60a48d4fc47","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Due\r to its \u03b11-adrenergic receptor antagonism, aripiprazole has the potential\r to enhance the effect of certain antihypertensive medicinal products.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"4c452c78-5081-47a3-9150-37054538d0bf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Given\r the primary CNS effects of aripiprazole, caution should be used when\r aripiprazole is administered in combination with alcohol or other CNS medicinal\r products with overlapping adverse reactions such as sedation (see\r section 4.8).<\/span><\/em><\/p>","ID":"55377baf-dd3d-4df8-ad72-bfb56681fbc3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Given\r the primary CNS effects of aripiprazole, caution should be used when\r aripiprazole is administered in combination with alcohol or other CNS medicinal\r products with overlapping adverse reactions such as sedation (see\r section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a5c395f0-749e-41c7-815b-8a4aa38581c3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">If\r aripiprazole is administered concomitantly with medicinal products known to\r cause QT prolongation or electrolyte imbalance, caution should be used.<\/span><\/em><\/p>","ID":"bc8d6f33-a4fb-42fc-80f9-bbff1a5b004b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"If\r aripiprazole is administered concomitantly with medicinal products known to\r cause QT prolongation or electrolyte imbalance, caution should be used.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cd405776-a4b1-4f3b-8616-52ae6ae79099","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Potential\r for other medicinal products to affect aripiprazole<\/span><\/u><\/em><\/p>","ID":"48e1fa50-9065-4db3-9510-6582523f116f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Potential\r for other medicinal products to affect aripiprazole","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6fd606a0-79dd-407f-a330-cdc9c0c06dfc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Quinidine and other\r strong CYP2D6 inhibitors<\/span><\/em><\/p>","ID":"a619feac-1dcc-44af-82ca-2ad4e758d04a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Quinidine and other\r strong CYP2D6 inhibitors","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor\r of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while C<sub>max<\/sub>\r was unchanged. The AUC and C<sub>max<\/sub> of dehydro-aripiprazole, the active\r metabolite, decreased by 32 % and 47 %, respectively. Other strong\r inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to\r have similar effects and similar dose reduction should, therefore, be applied\r (see section 4.2).<\/span><\/em><\/p>","ID":"e15ab4ec-e58c-4e2c-b41a-946f5001fcab","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor\r of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax\r was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active\r metabolite, decreased by 32 % and 47 %, respectively. Other strong\r inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to\r have similar effects and similar dose reduction should, therefore, be applied\r (see section 4.2).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"965cd60e-f265-40e7-abc0-0d7875c6ce9e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Ketoconazole and\r other strong CYP3A4 inhibitors<\/span><\/em><\/p>","ID":"4dcc87ae-3e78-4e20-ab8c-bb3b014d413f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Ketoconazole and\r other strong CYP3A4 inhibitors","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor\r of CYP3A4 (ketoconazole) increased aripiprazole AUC and C<sub>max<\/sub> by\r 63 % and 37 %, respectively. The AUC and C<sub>max<\/sub> of\r dehydro-aripiprazole increased by 77 % and 43 %, respectively. In\r CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may\r result in higher plasma concentrations of aripiprazole compared to that in\r CYP2D6 extensive metabolisers (see section 4.2). When considering\r concomitant administration of ketoconazole or other potent CYP3A4 inhibitors\r with aripiprazole, potential benefits should outweigh the potential risks to\r the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV\r protease inhibitors may be expected to have similar effects and similar dose\r reductions should, therefore, be applied (see section 4.2). Upon\r discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should\r be increased to the dose prior to the initiation of the concomitant therapy.\r When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram)\r are used concomitantly with aripiprazole, modest increases in plasma\r aripiprazole concentrations may be expected.<\/span><\/em><\/p>","ID":"37afbffe-2d5c-425f-b94e-bdb66a3647ca","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor\r of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by\r 63 % and 37 %, respectively. The AUC and Cmax of\r dehydro-aripiprazole increased by 77 % and 43 %, respectively. In\r CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may\r result in higher plasma concentrations of aripiprazole compared to that in\r CYP2D6 extensive metabolisers (see section 4.2). When considering\r concomitant administration of ketoconazole or other potent CYP3A4 inhibitors\r with aripiprazole, potential benefits should outweigh the potential risks to\r the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV\r protease inhibitors may be expected to have similar effects and similar dose\r reductions should, therefore, be applied (see section 4.2). Upon\r discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should\r be increased to the dose prior to the initiation of the concomitant therapy.\r When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram)\r are used concomitantly with aripiprazole, modest increases in plasma\r aripiprazole concentrations may be expected.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2845d058-f4d8-414c-86de-c790dfcef07f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Carbamazepine and\r other CYP3A4 inducers<\/span><\/em><\/p>","ID":"f898ab4d-3b1f-41c3-9075-5205d68c16d1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Carbamazepine and\r other CYP3A4 inducers","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span class=\"BMSHeading3Char\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;font-weight:normal'>Following\r concomitant administration of carbamazepine, a strong inducer of CYP3A4, and\r oral aripiprazole<\/span><\/span><span class=\"BMSHeading3Char\"><\/span><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">to patients with schizophrenia\r or schizoaffective disorder, the geometric means of C<sub>max<\/sub> and AUC for\r aripiprazole were 68 % and 73 % lower, respectively, compared to when\r oral aripiprazole (30 mg) was administered alone. Similarly, for\r dehydro-aripiprazole the geometric means of C<sub>max<\/sub> and AUC after\r carbamazepine co-administration were 69 % and 71 % lower,\r respectively, than those following treatment with oral aripiprazole alone. Concomitant\r administration of Abilify Maintena and other inducers of CYP3A4 (such as\r rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz,\r nevirapine and St. John's Wort) may be expected to have similar effects. The\r concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided\r because the blood levels of aripiprazole are decreased and may be below the\r effective levels.<\/span><\/em><\/p>","ID":"40daa96d-cb7f-41be-ab19-129467e3331b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Following\r concomitant administration of carbamazepine, a strong inducer of CYP3A4, and\r oral aripiprazoleto patients with schizophrenia\r or schizoaffective disorder, the geometric means of Cmax and AUC for\r aripiprazole were 68 % and 73 % lower, respectively, compared to when\r oral aripiprazole (30 mg) was administered alone. Similarly, for\r dehydro-aripiprazole the geometric means of Cmax and AUC after\r carbamazepine co-administration were 69 % and 71 % lower,\r respectively, than those following treatment with oral aripiprazole alone. Concomitant\r administration of Abilify Maintena and other inducers of CYP3A4 (such as\r rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz,\r nevirapine and St. John's Wort) may be expected to have similar effects. The\r concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided\r because the blood levels of aripiprazole are decreased and may be below the\r effective levels.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"02cdd07a-1dbf-4cb7-95a1-43e3051bd064","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Serotonin syndrome<\/span><\/i><\/p>","ID":"572ae7b1-56da-49c5-81a1-1b4c01d75c71","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Serotonin syndrome","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cases of serotonin syndrome have been\r reported in patients taking aripiprazole, and possible signs and symptoms for\r this condition can occur especially in cases of concomitant use with other\r serotonergic medicinal products, such as SSRI\/SNRI, or with medicinal products\r that are known to increase aripiprazole concentrations (see section 4.8).<\/span><\/p>","ID":"59f021ac-122b-4a90-9138-935a2249a47c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Cases of serotonin syndrome have been\r reported in patients taking aripiprazole, and possible signs and symptoms for\r this condition can occur especially in cases of concomitant use with other\r serotonergic medicinal products, such as SSRI\/SNRI, or with medicinal products\r that are known to increase aripiprazole concentrations (see section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"92f2ec80-1e43-4224-970f-178c760f27f8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.6     Fertility,\r pregnancy and lactation<\/span><\/b><\/em><\/p>","ID":"9f50cdb7-78eb-4c26-9ee1-3899d83c1bbd","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.6     Fertility,\r pregnancy and lactation","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"deffd227-bcc0-4365-8ab6-9865fe4900b8","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pregnancy<\/span><\/u><\/em><\/p>","ID":"5bd53103-0708-4dca-a39f-745d76d390c8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Pregnancy","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"50f262f0-3076-4ebd-b7fb-2460c86dc660","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">There are no adequate and well-controlled trials of\r aripiprazole in pregnant women. Congenital anomalies have been reported;\r however, causal relationship with aripiprazole could not be established. Animal\r studies could not exclude potential developmental toxicity (see\r section 5.3). Patients must be advised to notify their physician if they\r become pregnant or intend to become pregnant during treatment with <em><span style=\"font-style:normal\">aripiprazole<\/span><\/em>. Due to insufficient safety\r information in humans and concerns raised by animal reproductive studies, this\r medicinal product should not be used in pregnancy unless the expected benefit\r clearly justifies the potential risk to the foetus.<\/span><\/p>","ID":"854a303a-4e32-4710-9b62-662e3003d3eb","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"There are no adequate and well-controlled trials of\r aripiprazole in pregnant women. Congenital anomalies have been reported;\r however, causal relationship with aripiprazole could not be established. Animal\r studies could not exclude potential developmental toxicity (see\r section 5.3). Patients must be advised to notify their physician if they\r become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety\r information in humans and concerns raised by animal reproductive studies, this\r medicinal product should not be used in pregnancy unless the expected benefit\r clearly justifies the potential risk to the foetus.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"121dc20d-208a-401d-9f62-51199cf4bf10","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Prescribers\r need to be aware of the long-acting properties of <em><span style=\"color:black;\r font-style:normal\">Abilify Maintena<\/span><\/em>.<\/span><\/p>","ID":"a822022a-b8e9-44c0-bee7-0af33504d0d3","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Prescribers\r need to be aware of the long-acting properties of Abilify Maintena.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"409de6a0-e40a-4f15-bf7d-dc255d881d9b","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">New-born\r infants exposed to antipsychotics (including aripiprazole) during the third\r trimester of pregnancy are at risk of adverse reactions including\r extrapyramidal and\/or withdrawal symptoms that may vary in severity and\r duration following delivery. There have been reports of agitation, hypertonia,\r hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.\r Consequently, new-born infants should be monitored carefully (see\r section 4.8).<\/span><\/em><\/p>","ID":"2beea287-f3c8-4986-9e76-fefda0976d8d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"New-born\r infants exposed to antipsychotics (including aripiprazole) during the third\r trimester of pregnancy are at risk of adverse reactions including\r extrapyramidal and\/or withdrawal symptoms that may vary in severity and\r duration following delivery. There have been reports of agitation, hypertonia,\r hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.\r Consequently, new-born infants should be monitored carefully (see\r section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"ec441b65-2d4f-461b-b3e8-ee630461fd39","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Breast-feeding<\/span><\/u><\/em><\/p>","ID":"1f960571-a86f-40e7-b273-0df20a04647d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Breast-feeding","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"aec8d811-6c2b-4174-9fb9-ee7905889658","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r is excreted in human milk. A decision must be made whether to discontinue\r breast-feeding or to discontinue\/abstain from aripiprazole therapy taking into\r account the benefit of breast feeding for the child and the benefit of therapy\r for the woman.<\/span><\/em><\/p>","ID":"8ebaf389-9424-43d5-b071-837a9c9ae4da","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole\r is excreted in human milk. A decision must be made whether to discontinue\r breast-feeding or to discontinue\/abstain from aripiprazole therapy taking into\r account the benefit of breast feeding for the child and the benefit of therapy\r for the woman.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2c35051c-a30e-44ed-bd48-740e1c507271","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Fertility<\/span><\/u><\/em><\/p>","ID":"894b5625-c6bb-4df6-a431-76ef8fc3e51d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Fertility","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"dfab1829-b84a-4da0-bc79-fc0f117acf6a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p><span lang=\"EN-GB\">Aripiprazole did not impair fertility based on data from\r reproductive toxicity studies.<\/span><\/p>","ID":"c08c48fa-a890-4b7e-b4b1-dbabfcf1165f","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole did not impair fertility based on data from\r reproductive toxicity studies.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p><\/p>","ID":"622c29cd-e8e3-48ea-b35e-deeddada5ba4","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.7     Effects on ability to\r drive and use machines<\/span><\/b><\/em><\/p>","ID":"c7803e6b-f6e2-4d6b-83e9-fedcdd0cb754","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.7     Effects on ability to\r drive and use machines","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ace7f6d3-fc82-4239-8cb1-d9c37e19ef0a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r <\/span><\/em><span lang=\"EN-GB\">has minor to moderate influence on the ability to\r drive and use machines due to potential nervous system and visual effects, such\r as sedation, somnolence, syncope, vision blurred, diplopia (see\r section 4.8).<\/span><\/p>","ID":"0b63fb6d-f32a-4a07-8061-c807265abf24","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole\r has minor to moderate influence on the ability to\r drive and use machines due to potential nervous system and visual effects, such\r as sedation, somnolence, syncope, vision blurred, diplopia (see\r section 4.8).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"062f9605-60ba-4972-bb87-2b62173b11df","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.8     Undesirable effects<\/span><\/b><\/em><\/p>","ID":"8d988b1b-f03c-4cc0-85d1-0e854349cd61","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.8     Undesirable effects","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6a7add6f-67c1-4830-8226-cfbbf7ebc8ee","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Summary\r of the safety profile<\/span><\/u><\/em><\/p>","ID":"fbfb15ca-5ba2-4a4c-a6e8-a598945c757e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Summary\r of the safety profile","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"7d71b788-54c9-4521-965a-88f7914bd62a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r most frequently observed adverse drug reactions (ADRs) reported in \u2265 5 %\r of patients in two double\u2011blind, long-term trials of Abilify Maintena\r were weight increased (9.0 %), akathisia (7.9 %), insomnia\r (5.8 %), and injection site pain (5.1 %).<\/span><\/em><\/p>","ID":"995263a7-5d30-41c5-bfe4-2808e8c94a3f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r most frequently observed adverse drug reactions (ADRs) reported in \u2265 5 %\r of patients in two double\u2011blind, long-term trials of Abilify Maintena\r were weight increased (9.0 %), akathisia (7.9 %), insomnia\r (5.8 %), and injection site pain (5.1 %).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"ec601e4c-d0ac-48e1-9815-10e8c42fe1fe","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Tabulated\r list of adverse reactions<\/span><\/u><\/em><\/p>","ID":"5867134e-ff3c-4c41-b383-12d3afa4076d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Tabulated\r list of adverse reactions","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"99135f83-ee6f-4a1c-8c3f-305a8e8d56e6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">The incidences of the ADRs associated with aripiprazole\r therapy are tabulated below. The table is based on adverse reactions reported\r during clinical trials and\/or post-marketing use.<\/span><\/p>","ID":"0e15db96-5a5d-4fda-9ad3-e89a64c912d1","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The incidences of the ADRs associated with aripiprazole\r therapy are tabulated below. The table is based on adverse reactions reported\r during clinical trials and\/or post-marketing use.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"0c9888a5-ae6e-42ff-b861-ad8c8dfbc258","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">All ADRs are listed by system organ class and frequency;\r very common (\u2265 1\/10), common (\u2265 1\/100 to &lt; 1\/10),\r uncommon (\u2265 1\/1,000 to &lt; 1\/100), rare\r (\u2265 1\/10,000 to &lt; 1\/1,000), very rare\r (&lt; 1\/10,000) and not known (cannot be estimated from the available\r data). Within each frequency grouping, adverse reactions are presented in order\r of decreasing seriousness.<\/span><\/p>","ID":"9f165e04-8402-454f-93f9-3705a93b5a32","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"All ADRs are listed by system organ class and frequency;\r very common (\u2265 1\/10), common (\u2265 1\/100 to < 1\/10),\r uncommon (\u2265 1\/1,000 to < 1\/100), rare\r (\u2265 1\/10,000 to < 1\/1,000), very rare\r (< 1\/10,000) and not known (cannot be estimated from the available\r data). Within each frequency grouping, adverse reactions are presented in order\r of decreasing seriousness.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"ad284a8e-3776-4c51-8b7d-8d97160e717e","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">The frequency of adverse reactions reported during post-marketing\r use cannot be determined as they are derived from spontaneous reports.\r Consequently, the frequency of these adverse events is qualified as \"not\r known\".<\/span><\/p>","ID":"fbeba7bc-189a-4b3d-b8d6-31c5594678c2","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The frequency of adverse reactions reported during post-marketing\r use cannot be determined as they are derived from spontaneous reports.\r Consequently, the frequency of these adverse events is qualified as \"not\r known\".","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"c57a2b40-3ecb-4a21-a7e1-9929a9275807","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"614\"> <thead> <tr style=\"height:27.4pt\"> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:27.4pt\" valign=\"top\" width=\"104\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:85.05pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Common<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Uncommon<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Not known<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Blood and lymphatic system\r   disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Neutropenia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Anaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Thrombocytopenia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Neutrophil count decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">White blood cell count decreased<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Leukopenia<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Immune system disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypersensitivity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Allergic reaction (e.g. anaphylactic\r   reaction, angioedema including swollen tongue, tongue oedema, face oedema,\r   pruritus, or urticaria)<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Endocrine disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood prolactin decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hyperprolactinaemia<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Diabetic hyperosmolar coma<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Diabetic ketoacidosis<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Metabolism and nutrition disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Weight increased<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Diabetes mellitus<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Weight decreased<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hyperglycaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypercholesterolaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hyperinsulinaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hyperlipidaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypertriglyceridaemia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Appetite disorder<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Anorexia<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hyponatraemia<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Psychiatric disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Agitation<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Anxiety<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Restlessness<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Insomnia<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Suicidal ideation<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Psychotic disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hallucination<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Delusion<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypersexuality<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Panic reaction<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Depression<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Affect lability<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Apathy<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dysphoria<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Sleep disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Bruxism<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Libido decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Mood altered<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Completed suicide<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Suicide attempt<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pathological gambling<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Impulse-control disorders<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Binge eating<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Compulsive shopping<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Poriomania<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Nervousness<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aggression<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Extrapyramidal disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Akathisia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Tremor<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dyskinesia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Sedation<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Somnolence<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dizziness<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Headache<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dystonia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Tardive dyskinesia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Parkinsonism<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Movement disorder<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Psychomotor hyperactivity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Restless legs syndrome<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cogwheel rigidity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypertonia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Bradykinesia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Drooling<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dysgeusia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Parosmia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Neuroleptic malignant syndrome<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Grand mal convulsion<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Serotonin syndrome<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Speech disorder<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Eye disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Oculogyric crisis<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Vision blurred<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Eye pain<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Diplopia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span style=\"color:black\">Photophobia<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Cardiac disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ventricular extrasystoles<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Bradycardia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Tachycardia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Electrocardiogram T wave amplitude decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Electrocardiogram abnormal<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Electrocardiogram T wave inversion<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Sudden unexplained death<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Cardiac arrest<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Torsades de pointes<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Ventricular arrhythmias<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">QT prolongation<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hypertension<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Orthostatic hypotension<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood pressure increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Syncope<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Venous thromboembolism (including\r   pulmonary embolism and deep vein thrombosis)<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and\r   mediastinal disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cough<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Hiccups<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Oropharyngeal spasm<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Laryngospasm<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aspiration pneumonia<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dry mouth<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Gastrooesophageal reflux disease<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Dyspepsia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Diarrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Nausea<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Abdominal pain upper<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Abdominal discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Constipation<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Frequent bowel movement<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Salivary hypersecretion<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pancreatitis<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Dysphagia<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Hepatobiliary disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Liver function test abnormal Hepatic enzyme increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Alanine aminotransferase increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Gamma-glutamyl transferase increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood bilirubin increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Aspartate aminotransferase increased<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hepatic failure<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Jaundice<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Hepatitis<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Alkaline phosphatase increased<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Alopecia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Acne<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Rosacea<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Eczema<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Skin induration<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span style=\"color:black;\r   font-style:normal\">Rash<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span style=\"color:black;\r   font-style:normal\">Photosensitivity reaction<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span style=\"color:black;\r   font-style:normal\">Hyperhidrosis<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\">Drug Reaction with\r   Eosinophilia and Systemic Symptoms (DRESS)<\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective\r   tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal stiffness<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Muscle rigidity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Muscle spasms<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Muscle twitching<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Muscle tightness<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Myalgia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Pain in extremity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Arthralgia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Back pain<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Joint range of motion decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Nuchal rigidity<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Trismus<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Rhabdomyolysis<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Nephrolithiasis<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Glycosuria<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Urinary retention<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Urinary incontinence<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Pregnancy, puerperium and perinatal conditions<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Drug withdrawal syndrome neonatal (see\r   section 4.6)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Reproductive system and breast\r   disorders<\/span><\/b><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Erectile dysfunction<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Galactorrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Gynaecomastia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Breast tenderness<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Vulvovaginal dryness<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Priapism<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">General disorders and\r   administration site conditions<\/span><\/b><\/p> <p><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site pain<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site induration Fatigue<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Pyrexia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Asthenia<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Gait disturbance<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Chest discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site reaction<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site erythema<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site swelling<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Injection site pruritus<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Thirst<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Sluggishness <\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Temperature regulation disorder (e.g.\r   hypothermia, pyrexia)<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Chest pain<\/span><\/em><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Peripheral oedema<\/span><\/em><\/p> <\/td> <\/tr> <tr> <td style=\"width:78.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\"> <p><b><span lang=\"EN-GB\" style=\"color:black\">Investigations<\/span><\/b><\/p> <p><\/p> <\/td> <td style=\"width:85.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"113\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood creatine phosphokinase increased<\/span><\/p> <\/td> <td style=\"width:141.75pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"189\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood glucose increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood glucose decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Glycosylated haemoglobin increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Waist circumference increased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood cholesterol decreased<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Blood triglycerides decreased<\/span><\/p> <\/td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"208\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Blood glucose fluctuation<\/span><\/em><\/p> <\/td> <\/tr> <\/table>","ID":"4edd070e-8700-45d6-b5e7-17a48968fe7b","Styles":"margin-left:5.4pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"       Common    Uncommon    Not known      Blood and lymphatic system\r   disorders      Neutropenia Anaemia Thrombocytopenia Neutrophil count decreased White blood cell count decreased   Leukopenia     Immune system disorders      Hypersensitivity    Allergic reaction (e.g. anaphylactic\r   reaction, angioedema including swollen tongue, tongue oedema, face oedema,\r   pruritus, or urticaria)     Endocrine disorders      Blood prolactin decreased Hyperprolactinaemia   Diabetic hyperosmolar coma Diabetic ketoacidosis     Metabolism and nutrition disorders   Weight increased Diabetes mellitus Weight decreased    Hyperglycaemia Hypercholesterolaemia Hyperinsulinaemia Hyperlipidaemia Hypertriglyceridaemia Appetite disorder   Anorexia Hyponatraemia     Psychiatric disorders   Agitation Anxiety Restlessness Insomnia   Suicidal ideation Psychotic disorder Hallucination Delusion Hypersexuality Panic reaction Depression Affect lability Apathy Dysphoria Sleep disorder Bruxism Libido decreased Mood altered   Completed suicide Suicide attempt Pathological gambling Impulse-control disorders Binge eating Compulsive shopping Poriomania Nervousness Aggression      Nervous system disorders   Extrapyramidal disorder Akathisia Tremor Dyskinesia Sedation Somnolence Dizziness Headache   Dystonia Tardive dyskinesia Parkinsonism Movement disorder Psychomotor hyperactivity Restless legs syndrome Cogwheel rigidity Hypertonia Bradykinesia Drooling Dysgeusia Parosmia    Neuroleptic malignant syndrome Grand mal convulsion Serotonin syndrome Speech disorder      Eye disorders      Oculogyric crisis Vision blurred Eye pain Diplopia Photophobia        Cardiac disorders      Ventricular extrasystoles Bradycardia Tachycardia Electrocardiogram T wave amplitude decreased Electrocardiogram abnormal Electrocardiogram T wave inversion   Sudden unexplained death Cardiac arrest Torsades de pointes Ventricular arrhythmias QT prolongation      Vascular disorders      Hypertension Orthostatic hypotension Blood pressure increased    Syncope Venous thromboembolism (including\r   pulmonary embolism and deep vein thrombosis)     Respiratory, thoracic and\r   mediastinal disorders      Cough Hiccups   Oropharyngeal spasm Laryngospasm Aspiration pneumonia     Gastrointestinal disorders   Dry mouth   Gastrooesophageal reflux disease Dyspepsia Vomiting Diarrhoea Nausea Abdominal pain upper Abdominal discomfort Constipation Frequent bowel movement Salivary hypersecretion   Pancreatitis Dysphagia     Hepatobiliary disorders      Liver function test abnormal Hepatic enzyme increased Alanine aminotransferase increased Gamma-glutamyl transferase increased Blood bilirubin increased Aspartate aminotransferase increased   Hepatic failure Jaundice Hepatitis Alkaline phosphatase increased      Skin and subcutaneous tissue disorders      Alopecia Acne Rosacea Eczema Skin induration   Rash Photosensitivity reaction Hyperhidrosis Drug Reaction with\r   Eosinophilia and Systemic Symptoms (DRESS)     Musculoskeletal and connective\r   tissue disorders   Musculoskeletal stiffness   Muscle rigidity Muscle spasms Muscle twitching Muscle tightness Myalgia Pain in extremity Arthralgia Back pain Joint range of motion decreased Nuchal rigidity Trismus   Rhabdomyolysis     Renal and urinary disorders      Nephrolithiasis Glycosuria    Urinary retention Urinary incontinence      Pregnancy, puerperium and perinatal conditions         Drug withdrawal syndrome neonatal (see\r   section 4.6)      Reproductive system and breast\r   disorders   Erectile dysfunction   Galactorrhoea Gynaecomastia Breast tenderness Vulvovaginal dryness   Priapism     General disorders and\r   administration site conditions    Injection site pain Injection site induration Fatigue   Pyrexia Asthenia Gait disturbance Chest discomfort Injection site reaction Injection site erythema Injection site swelling Injection site discomfort Injection site pruritus Thirst Sluggishness    Temperature regulation disorder (e.g.\r   hypothermia, pyrexia) Chest pain Peripheral oedema     Investigations    Blood creatine phosphokinase increased   Blood glucose increased Blood glucose decreased Glycosylated haemoglobin increased Waist circumference increased Blood cholesterol decreased Blood triglycerides decreased   Blood glucose fluctuation   ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"bced1a81-e8a6-4ec2-b567-af4e5b769fa1","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Description\r of selected adverse reactions<\/span><\/u><\/em><\/p>","ID":"1a9cce04-61e8-4238-ae75-88137236179c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Description\r of selected adverse reactions","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ad811951-fa22-4a9c-8f9b-02277e741e66","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Injection site\r reactions<\/span><\/em><\/p>","ID":"bd5ad674-5a93-46b4-b492-f0d5b95ecb41","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Injection site\r reactions","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">During\r the double\u2011blind, controlled phases of the two long-term trials,\r injection site reactions were observed; those seen were generally mild to\r moderate in severity, and resolved over time. <\/span><\/em><span lang=\"EN-GB\">Injection\r site pain (incidence 5.1 %), had a median onset on day 2 after the\r injection and a median duration of 4 days.<\/span><\/p>","ID":"3d61c2b8-1478-44e0-b8b2-ab39ffaf64ed","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"During\r the double\u2011blind, controlled phases of the two long-term trials,\r injection site reactions were observed; those seen were generally mild to\r moderate in severity, and resolved over time. Injection\r site pain (incidence 5.1 %), had a median onset on day 2 after the\r injection and a median duration of 4 days.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"70350d4b-e3ed-427a-9802-ceac177fdb7f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">In an open label study comparing\r bioavailability of Abilify Maintena administered in the deltoid or gluteal\r muscle, injection site related reactions were slightly more frequent in the\r deltoid muscle. The majority were mild and improved on subsequent injections.\r When compared to studies where Abilify Maintena was injected in the gluteal\r muscle, repeated occurrence of injection site pain was more frequent in the\r deltoid muscle.<\/span><\/p>","ID":"d4763616-1db4-4728-83fe-d374900dfcca","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In an open label study comparing\r bioavailability of Abilify Maintena administered in the deltoid or gluteal\r muscle, injection site related reactions were slightly more frequent in the\r deltoid muscle. The majority were mild and improved on subsequent injections.\r When compared to studies where Abilify Maintena was injected in the gluteal\r muscle, repeated occurrence of injection site pain was more frequent in the\r deltoid muscle.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"24607aaf-8973-4c89-8ea3-0a42e2a30a1d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Leukopenia<\/span><\/i><\/p>","ID":"576a2bec-cb3b-4cd7-aad8-42850cbff8a6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Leukopenia","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia has been reported in the\r clinical program with <em><span style=\"color:black;font-style:normal\">Abilify\r Maintena<\/span><\/em> and typically started around day 16 after first\r injection, and lasted a median of 18 days.<\/span><\/p>","ID":"23f820b3-983d-4591-b326-74c46ca90f4a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Neutropenia has been reported in the\r clinical program with Abilify\r Maintena and typically started around day 16 after first\r injection, and lasted a median of 18 days.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f144050c-d379-491a-b264-81b64e42a1a5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Extrapyramidal\r Symptoms (EPS)<\/span><\/em><\/p>","ID":"02f57632-d0f7-44d0-922b-7f20ee1508ed","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Extrapyramidal\r Symptoms (EPS)","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">In trials in stable patients with\r schizophrenia, <em><span style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em>\r was associated with a higher frequency of EPS symptoms (18.4 %) than oral\r aripiprazole treatment (11.7 %). Akathisia was the most frequently\r observed symptom (8.2 %) and typically started around day 10 after\r first injection, and lasted a median of 56 days. Subjects with akathisia\r typically received anti-cholinergic medicines as treatment, primarily\r benzatropine mesilate and trihexyphenidyl. Less often substances such as\r propranolol and benzodiazepines (clonazepam and diazepam) were administered to\r control akathisia. Parkinsonism events followed in frequency of 6.9 % for <em><span style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em>, 4.15 %\r for oral aripiprazole 10\u201130 mg tablets and 3.0 % for placebo,\r respectively.<\/span><\/p>","ID":"02159513-0d3b-4913-a349-77146b9ebc96","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In trials in stable patients with\r schizophrenia, Abilify Maintena\r was associated with a higher frequency of EPS symptoms (18.4 %) than oral\r aripiprazole treatment (11.7 %). Akathisia was the most frequently\r observed symptom (8.2 %) and typically started around day 10 after\r first injection, and lasted a median of 56 days. Subjects with akathisia\r typically received anti-cholinergic medicines as treatment, primarily\r benzatropine mesilate and trihexyphenidyl. Less often substances such as\r propranolol and benzodiazepines (clonazepam and diazepam) were administered to\r control akathisia. Parkinsonism events followed in frequency of 6.9 % for Abilify Maintena, 4.15 %\r for oral aripiprazole 10\u201130 mg tablets and 3.0 % for placebo,\r respectively.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"caae5966-2d03-4bee-be80-bb0d6bf600e2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Dystonia<\/span><\/em><\/p>","ID":"6edadb97-6f6c-4bd4-9e97-7c35ee27930e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Dystonia","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Class\r effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups,\r may occur in susceptible individuals during the first few days of treatment.\r Dystonic symptoms include spasm of the neck muscles, sometimes progressing to\r tightness of the throat, swallowing difficulty, difficulty breathing, and\/or\r protrusion of the tongue. While these symptoms can occur at low doses, they\r occur more frequently and with greater severity with high potency and at higher\r doses of first generation antipsychotic medicinal products. An elevated risk of\r acute dystonia is observed in males and younger age groups.<\/span><\/em><\/p>","ID":"13feafbd-9863-4371-82a8-f6ad83b5184c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Class\r effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups,\r may occur in susceptible individuals during the first few days of treatment.\r Dystonic symptoms include spasm of the neck muscles, sometimes progressing to\r tightness of the throat, swallowing difficulty, difficulty breathing, and\/or\r protrusion of the tongue. While these symptoms can occur at low doses, they\r occur more frequently and with greater severity with high potency and at higher\r doses of first generation antipsychotic medicinal products. An elevated risk of\r acute dystonia is observed in males and younger age groups.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"66e0e427-0bfb-4e76-aa5b-378b48756739","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Weight<\/span><\/em><\/p>","ID":"00a9c4ee-2de7-4a8d-9a08-edc9f0e89f9f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Weight","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">During\r the Double-blind, Active-controlled Phase of the 38\u2011week long-term trial,\r the incidence of weight gain of <\/span><\/em><em><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black;font-style:normal\">\u00b3<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> 7 % from baseline\r to last visit was 9.5 % for Abilify Maintena and 11.7 % for the oral\r aripiprazole tablets 10\u201130 mg. The incidence of weight loss of \u2265 7 %\r from baseline to last visit was 10.2 % for Abilify Maintena and 4.5 %\r for oral aripiprazole tablets 10\u201130 mg. During the Double-blind, Placebo-controlled\r Phase of the 52\u2011week long-term trial, the incidence of weight gain of <\/span><\/em><em><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black;font-style:normal\">\u00b3<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> 7 % from baseline\r to last visit was 6.4 % for Abilify Maintena and 5.2 % for placebo. The\r incidence of weight loss of \u2265 7 % from baseline to last\r visit was 6.4 % for Abilify Maintena and 6.7 % for placebo. During\r double\u2011blind treatment, mean change in body weight from baseline to last\r visit was \u20110.2 kg for Abilify Maintena and \u20110.4 kg for\r placebo (p = 0.812).<\/span><\/em><\/p>","ID":"b29a3bb0-d2a0-4e53-8079-54c744146f17","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"During\r the Double-blind, Active-controlled Phase of the 38\u2011week long-term trial,\r the incidence of weight gain of \u00b3 7 % from baseline\r to last visit was 9.5 % for Abilify Maintena and 11.7 % for the oral\r aripiprazole tablets 10\u201130 mg. The incidence of weight loss of \u2265 7 %\r from baseline to last visit was 10.2 % for Abilify Maintena and 4.5 %\r for oral aripiprazole tablets 10\u201130 mg. During the Double-blind, Placebo-controlled\r Phase of the 52\u2011week long-term trial, the incidence of weight gain of \u00b3 7 % from baseline\r to last visit was 6.4 % for Abilify Maintena and 5.2 % for placebo. The\r incidence of weight loss of \u2265 7 % from baseline to last\r visit was 6.4 % for Abilify Maintena and 6.7 % for placebo. During\r double\u2011blind treatment, mean change in body weight from baseline to last\r visit was \u20110.2 kg for Abilify Maintena and \u20110.4 kg for\r placebo (p = 0.812).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c03ad8bc-bdcc-4cb7-8909-7791cf8b7375","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><i><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Prolactin<\/span><\/i><\/p>","ID":"7ec2ba15-6265-4470-a513-874f59d6cfe8","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Prolactin","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>In\r clinical trials for the approved indications and post-marketing, both increase\r and decrease in serum prolactin as compared to baseline was observed with\r aripiprazole (section 5.1).<\/span><\/p>","ID":"69c9646e-98bc-47b7-b0bd-4ba4415ff6fd","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r clinical trials for the approved indications and post-marketing, both increase\r and decrease in serum prolactin as compared to baseline was observed with\r aripiprazole (section 5.1).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"437ed8b0-860b-42ca-ade0-322c92428e1f","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><i><span lang=\"EN-GB\">Pathological\r gambling and other impulse control disorders<\/span><\/i><\/p>","ID":"6ec46202-8072-4eb6-b964-f11bff35e95b","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Pathological\r gambling and other impulse control disorders","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pathological gambling, hypersexuality,\r compulsive shopping and binge or compulsive eating can occur in patients\r treated with aripiprazole (see section 4.4).<\/span><\/p>","ID":"77593f7d-d242-4c4a-8266-18107b1eb3ec","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pathological gambling, hypersexuality,\r compulsive shopping and binge or compulsive eating can occur in patients\r treated with aripiprazole (see section 4.4).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1a12a20b-05df-4530-866e-82a5ab105fa5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Reporting\r of suspected adverse reactions<\/span><\/u><\/em><\/p>","ID":"fe4a5e9a-fb0d-465e-9af7-284e51a74e4f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Reporting\r of suspected adverse reactions","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"ec2605a8-9c36-41dc-aa3b-c76f8f0ecf75","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Reporting\r suspected adverse reactions after authorisation of the medicinal product is\r important. It allows continued monitoring of the benefit\/risk balance of the\r medicinal product. Healthcare professionals are asked to report any suspected\r adverse reactions via <\/span><\/em><span lang=\"EN-GB\" style=\"background:silver\">the\r national reporting system listed in <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><u><span style=\"background:silver\">Appendix V<\/span><\/u><\/a>.<\/span><\/p>","ID":"dd83dfa3-8041-4a5f-b32d-811f356040e8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Reporting\r suspected adverse reactions after authorisation of the medicinal product is\r important. It allows continued monitoring of the benefit\/risk balance of the\r medicinal product. Healthcare professionals are asked to report any suspected\r adverse reactions via the\r national reporting system listed in Appendix V.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"4ca4b696-d72f-4c1e-b150-fc3be549f5d0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">4.9     Overdose<\/span><\/b><\/em><\/p>","ID":"1728d0de-4bcd-4b36-b838-5ef65be9b022","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"4.9     Overdose","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0b6950ec-94c9-4aa7-aae4-8b8eead9dded","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">No cases of overdose associated with\r adverse reactions were reported in clinical studies with <em><span style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em>. Care must\r be taken to avoid inadvertent injection of this medicinal product into a blood\r vessel. Following any confirmed or suspected accidental overdose\/inadvertent\r intravenous administration, close observation of the patient is needed and if\r any potentially medically serious sign or symptom develops, monitoring, which\r should include continuous electrocardiographic monitoring, is required. The\r medical supervision and monitoring should continue until the patient recovers.<\/span><\/p>","ID":"b6553490-efa5-4f8b-b1ba-b3335a813108","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"No cases of overdose associated with\r adverse reactions were reported in clinical studies with Abilify Maintena. Care must\r be taken to avoid inadvertent injection of this medicinal product into a blood\r vessel. Following any confirmed or suspected accidental overdose\/inadvertent\r intravenous administration, close observation of the patient is needed and if\r any potentially medically serious sign or symptom develops, monitoring, which\r should include continuous electrocardiographic monitoring, is required. The\r medical supervision and monitoring should continue until the patient recovers.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ec4a2abe-9a44-4fab-bba7-aeec2bcda0d8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">A simulation of dose dumping showed that\r the predicted median aripiprazole concentration reaches a peak of 4,500 ng\/ml\r or approximately 9 times the upper therapeutic range. In case of dose\r dumping, aripiprazole concentrations are predicted to descend rapidly to the\r upper limit of the therapeutic window after approximately 3 days. By\r the 7th day, the median aripiprazole concentrations further decline to\r concentrations following an IM depot dose with no dose dumping. <span style=\"color:black\">While overdose is less likely with parenteral than oral\r medicinal products, reference information for oral aripiprazole overdose is\r presented below.<\/span><\/span><\/p>","ID":"f8f7b6de-6667-49f5-845e-03619f65986f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A simulation of dose dumping showed that\r the predicted median aripiprazole concentration reaches a peak of 4,500 ng\/ml\r or approximately 9 times the upper therapeutic range. In case of dose\r dumping, aripiprazole concentrations are predicted to descend rapidly to the\r upper limit of the therapeutic window after approximately 3 days. By\r the 7th day, the median aripiprazole concentrations further decline to\r concentrations following an IM depot dose with no dose dumping. While overdose is less likely with parenteral than oral\r medicinal products, reference information for oral aripiprazole overdose is\r presented below.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"09cd718b-2a38-4d7e-a87b-0fc0045423ae","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Signs\r and symptoms<\/span><\/u><\/em><\/p>","ID":"8452ff8d-fc62-4a6f-818d-6bd3c37d0692","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Signs\r and symptoms","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"01e34027-cb10-4f67-ad4d-678242a25542","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r clinical trials and post-marketing experience, accidental or intentional acute\r overdose of aripiprazole alone was identified in adult patients with reported\r estimated doses up to 1,260 mg (41 times highest recommended daily\r aripiprazole dose) with no fatalities. The potentially medically important\r signs and symptoms observed included lethargy, increased blood pressure,\r somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports\r of accidental overdose with aripiprazole alone (up to 195 mg) in children\r have been received with no fatalities. The potentially medically serious signs\r and symptoms reported included somnolence, transient loss of consciousness and\r extrapyramidal symptoms.<\/span><\/em><\/p>","ID":"ff365ab1-4611-4d5d-80c4-efb8ad7efef4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r clinical trials and post-marketing experience, accidental or intentional acute\r overdose of aripiprazole alone was identified in adult patients with reported\r estimated doses up to 1,260 mg (41 times highest recommended daily\r aripiprazole dose) with no fatalities. The potentially medically important\r signs and symptoms observed included lethargy, increased blood pressure,\r somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports\r of accidental overdose with aripiprazole alone (up to 195 mg) in children\r have been received with no fatalities. The potentially medically serious signs\r and symptoms reported included somnolence, transient loss of consciousness and\r extrapyramidal symptoms.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3f4ba3bd-4bb4-403f-92df-31f78989af6d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Management\r of overdose<\/span><\/u><\/em><\/p>","ID":"12675455-d1cd-4a8f-9c8c-f3b1d26531b5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Management\r of overdose","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"60fb5d26-34f2-491a-a089-057122979fbc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Management\r of overdose should concentrate on supportive therapy, maintaining an adequate\r airway, oxygenation and ventilation, and management of symptoms. The\r possibility of multiple medicinal product involvement should be considered.\r Therefore, cardiovascular monitoring should be started immediately and should\r include continuous electrocardiographic monitoring to detect possible arrhythmias.\r Following any confirmed or suspected overdose with aripiprazole, close medical\r supervision and monitoring should continue until the patient recovers.<\/span><\/em><\/p>","ID":"5fd14b93-ff62-42ba-8bc1-18f035890ec0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Management\r of overdose should concentrate on supportive therapy, maintaining an adequate\r airway, oxygenation and ventilation, and management of symptoms. The\r possibility of multiple medicinal product involvement should be considered.\r Therefore, cardiovascular monitoring should be started immediately and should\r include continuous electrocardiographic monitoring to detect possible arrhythmias.\r Following any confirmed or suspected overdose with aripiprazole, close medical\r supervision and monitoring should continue until the patient recovers.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"51ade6c2-2dbf-48d7-a9b4-f9a0d2ebd737","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Haemodialysis<\/span><\/u><\/em><\/p>","ID":"c658c722-b7e3-42ce-9cbc-9aa074cf6266","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Haemodialysis","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"ccef0d01-8037-486c-9d47-98bff22d0b93","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Although\r there is no information on the effect of haemodialysis in treating an overdose\r with aripiprazole, haemodialysis is unlikely to be useful in overdose\r management since aripiprazole is highly bound to plasma proteins.<\/span><\/em><\/p>","ID":"ec6e185f-ad9f-485d-88dd-534672edfde9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Although\r there is no information on the effect of haemodialysis in treating an overdose\r with aripiprazole, haemodialysis is unlikely to be useful in overdose\r management since aripiprazole is highly bound to plasma proteins.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c4c5e395-b8c6-45a4-84b5-985163345a26","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"32813d18-2718-4dd0-bfca-f475c7bc86b1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.       PHARMACOLOGICAL\r PROPERTIES<\/span><\/b><\/em><\/p>","ID":"51bba9b2-cd65-4341-8fc2-787e2f602f4e","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"5.       PHARMACOLOGICAL\r PROPERTIES","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e4264b97-846b-41e0-999d-96abef36d37e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.1     Pharmacodynamic\r properties<\/span><\/b><\/em><\/p>","ID":"ac677f14-bac8-43ac-a4c2-075fa42290ee","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"5.1     Pharmacodynamic\r properties","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"95178b0b-714a-4963-8108-602df61d5f89","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pharmacotherapeutic\r group: Psycholeptics, other antipsychotics, ATC code: N05AX12<\/span><\/em><\/p>","ID":"b3e447cc-25ce-409b-a6ed-6af6b31f39cc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Pharmacotherapeutic\r group: Psycholeptics, other antipsychotics, ATC code: N05AX12","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6241049c-1704-48a8-8ba8-e3c7bece2a01","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Mechanism\r of action<\/span><\/u><\/em><\/p>","ID":"dd30eae2-5f89-41c8-90bb-06dbb9ca5341","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Mechanism\r of action","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"cabaed55-c6bd-4ccf-86db-5434869196e8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">It\r has been proposed that aripiprazole\u2019s efficacy in schizophrenia is mediated\r through a combination of partial agonism at dopamine D<sub>2<\/sub> and\r serotonin 5\u2011HT<sub>1A<\/sub> receptors and antagonism at serotonin 5\u2011HT<sub>2A<\/sub>\r receptors. Aripiprazole exhibited antagonist properties in animal models of\r dopaminergic hyperactivity and agonist properties of dopaminergic hypoactivity.\r Aripiprazole exhibits high binding affinity <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black\">in vitro<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> for dopamine D<sub>2<\/sub> and D<sub>3<\/sub>,\r serotonin 5\u2011HT<sub>1A<\/sub> and 5\u2011HT<sub>2A<\/sub> receptors and has\r moderate affinity for dopamine D<sub>4<\/sub>, serotonin 5\u2011HT<sub>2C<\/sub>\r and 5\u2011HT<sub>7<\/sub>, alpha-1 adrenergic, and histamine H<sub>1<\/sub>\r receptors. Aripiprazole also exhibited moderate binding affinity for the\r serotonin reuptake site and no appreciable affinity for cholinergic muscarinic\r receptors. Interaction with receptors other than dopamine and serotonin\r subtypes may explain some of the other clinical effects of aripiprazole.<\/span><\/em><\/p>","ID":"4acdeb4d-296e-4078-8f6b-32da330259e8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"It\r has been proposed that aripiprazole\u2019s efficacy in schizophrenia is mediated\r through a combination of partial agonism at dopamine D2 and\r serotonin 5\u2011HT1A receptors and antagonism at serotonin 5\u2011HT2A\r receptors. Aripiprazole exhibited antagonist properties in animal models of\r dopaminergic hyperactivity and agonist properties of dopaminergic hypoactivity.\r Aripiprazole exhibits high binding affinity in vitro for dopamine D2 and D3,\r serotonin 5\u2011HT1A and 5\u2011HT2A receptors and has\r moderate affinity for dopamine D4, serotonin 5\u2011HT2C\r and 5\u2011HT7, alpha-1 adrenergic, and histamine H1\r receptors. Aripiprazole also exhibited moderate binding affinity for the\r serotonin reuptake site and no appreciable affinity for cholinergic muscarinic\r receptors. Interaction with receptors other than dopamine and serotonin\r subtypes may explain some of the other clinical effects of aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b0085f74-6db1-4828-b9f3-42a2e1e05d76","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r oral doses ranging from 0.5 to 30 mg administered once a day to healthy\r subjects for 2 weeks produced a dose-dependent reduction in the binding of\r <sup>11<\/sup>C\u2011raclopride, a D<sub>2<\/sub>\/D<sub>3<\/sub> receptor ligand,\r to the caudate and putamen detected by positron emission tomography.<\/span><\/em><\/p>","ID":"e86b4ca8-4959-4c21-9e8b-3261e28cd894","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole\r oral doses ranging from 0.5 to 30 mg administered once a day to healthy\r subjects for 2 weeks produced a dose-dependent reduction in the binding of\r 11C\u2011raclopride, a D2\/D3 receptor ligand,\r to the caudate and putamen detected by positron emission tomography.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6cef6516-e78c-4735-b71d-3ab7084a10f8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Clinical\r efficacy and safety<\/span><\/u><\/em><\/p>","ID":"4bec307f-95a7-4add-b7e7-ce3b65aececf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Clinical\r efficacy and safety","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"319bf4d5-3650-41e2-8828-90b68a8eb40d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Maintenance\r treatment of schizophrenia in adults<\/span><\/em><\/p>","ID":"32382b41-151b-48c5-bc7c-27aa9beaa067","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Maintenance\r treatment of schizophrenia in adults","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r efficacy of Abilify Maintena in the maintenance treatment of patients with\r schizophrenia was established in two randomised, double\u2011blind, long-term trials.<\/span><\/em><\/p>","ID":"9baba776-c4db-4c09-b3f4-da2450371eae","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The\r efficacy of Abilify Maintena in the maintenance treatment of patients with\r schizophrenia was established in two randomised, double\u2011blind, long-term trials.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2b0f0cda-1abb-4717-8e16-e186c39fa8c4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r pivotal trial was a 38 week, randomised, double\u2011blind, active\u2011controlled\r trial designed to establish the efficacy, safety, and tolerability of this\r medicinal product administered as monthly injections compared to once daily\r oral aripiprazole tablets 10\u201130 mg as maintenance treatment in adult\r patients with schizophrenia. This trial consisted of a screening phase and\r 3 treatment phases: Conversion Phase, Oral Stabilisation Phase, and\r Double-blind, Active-controlled Phase.<\/span><\/em><\/p>","ID":"2310fb65-e3e8-49d6-8d3c-c8e572330e71","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r pivotal trial was a 38 week, randomised, double\u2011blind, active\u2011controlled\r trial designed to establish the efficacy, safety, and tolerability of this\r medicinal product administered as monthly injections compared to once daily\r oral aripiprazole tablets 10\u201130 mg as maintenance treatment in adult\r patients with schizophrenia. This trial consisted of a screening phase and\r 3 treatment phases: Conversion Phase, Oral Stabilisation Phase, and\r Double-blind, Active-controlled Phase.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9b70dbb5-1967-4a66-ac0f-527a53f9cbc2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Six-hundred\r and sixty two patients eligible for the 38\u2011week Double-blind, Active-controlled\r Phase were randomly assigned in a 2:2:1 ratio to double\u2011blind treatment\r to one of 3 treatment groups: 1) Abilify Maintena 2) the stabilisation\r dose of oral aripiprazole 10\u201130 mg, or 3) aripiprazole Long-Acting\r Injectable 50 mg\/25 mg. The aripiprazole Long-Acting Injectable\r 50 mg\/25 mg dose was included as a low dose aripiprazole to test\r assay sensitivity for the non-inferiority design.<\/span><\/em><\/p>","ID":"42ba48e8-cafb-4375-8e7f-c8aba496a8ae","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Six-hundred\r and sixty two patients eligible for the 38\u2011week Double-blind, Active-controlled\r Phase were randomly assigned in a 2:2:1 ratio to double\u2011blind treatment\r to one of 3 treatment groups: 1) Abilify Maintena 2) the stabilisation\r dose of oral aripiprazole 10\u201130 mg, or 3) aripiprazole Long-Acting\r Injectable 50 mg\/25 mg. The aripiprazole Long-Acting Injectable\r 50 mg\/25 mg dose was included as a low dose aripiprazole to test\r assay sensitivity for the non-inferiority design.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"4f9752c5-f22f-46c2-bcf3-58fb0e9b4fdb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r results of analysis of the primary efficacy endpoint, the estimated proportion\r of patients experiencing impending relapse by end of Week 26 of the Double-blind,\r Active-controlled Phase, showed that Abilify Maintena 400 mg\/300 mg\r is non-inferior to aripiprazole oral tablets 10\u201130 mg.<\/span><\/em><\/p>","ID":"6bc7f25a-2ba8-4772-95a8-c11d447c838f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r results of analysis of the primary efficacy endpoint, the estimated proportion\r of patients experiencing impending relapse by end of Week 26 of the Double-blind,\r Active-controlled Phase, showed that Abilify Maintena 400 mg\/300 mg\r is non-inferior to aripiprazole oral tablets 10\u201130 mg.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r estimated relapse rate by end of Week 26 was 7.12 % for Abilify\r Maintena, and 7.76 % for oral aripiprazole tablets 10\u201130 mg, a\r difference of <\/span><\/em><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.64 %.<\/span><\/em><\/p>","ID":"b1688135-0eba-47ff-ad76-0a9a8ae490e4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The\r estimated relapse rate by end of Week 26 was 7.12 % for Abilify\r Maintena, and 7.76 % for oral aripiprazole tablets 10\u201130 mg, a\r difference of \u22120.64 %.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"26903078-3195-4324-be04-eba1e4c4650a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r 95 % CI (<\/span><\/em><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.26, 3.99) for the difference\r in the estimated proportion of patients experiencing impending relapse by end\r of Week 26 excluded the predefined non-inferiority margin, 11.5 %.\r Therefore, Abilify Maintena is non-inferior to aripiprazole oral tablets 10\u201130 mg.<\/span><\/em><\/p>","ID":"37da1961-7a99-42b3-a6fb-dc60cc2d9dbf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r 95 % CI (\u22125.26, 3.99) for the difference\r in the estimated proportion of patients experiencing impending relapse by end\r of Week 26 excluded the predefined non-inferiority margin, 11.5 %.\r Therefore, Abilify Maintena is non-inferior to aripiprazole oral tablets 10\u201130 mg.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c6956a40-5d15-4519-86e1-7cae27799f61","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r estimated proportion of patients experiencing impending relapse by end of\r Week 26 for Abilify Maintena was 7.12 %, which was statistically\r significantly lower than in aripiprazole Long-Acting Injectable 50 mg\/25 mg\r (21.80 %; p = 0.0006). Thus, superiority of Abilify Maintena\r over the aripiprazole Long-Acting Injectable 50 mg\/25 mg was\r established and the validity of the trial design was confirmed.<\/span><\/em><\/p>","ID":"03501fe7-bcec-4b58-a593-4b90e1702ae6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r estimated proportion of patients experiencing impending relapse by end of\r Week 26 for Abilify Maintena was 7.12 %, which was statistically\r significantly lower than in aripiprazole Long-Acting Injectable 50 mg\/25 mg\r (21.80 %; p = 0.0006). Thus, superiority of Abilify Maintena\r over the aripiprazole Long-Acting Injectable 50 mg\/25 mg was\r established and the validity of the trial design was confirmed.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1da45b31-c958-48bd-856b-92208b44cbbc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r Kaplan-Meier curves of the time from randomisation to impending relapse during\r the 38\u2011week, Double-blind, Active-controlled Phase for Abilify Maintena,\r oral aripiprazole 10\u201130 mg, and aripiprazole Long-Acting Injectable\r 50 mg\/25 mg are shown in Figure 1.<\/span><\/em><\/p>","ID":"7aeb03c0-2528-49a3-ba48-6a1ef5e4e870","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r Kaplan-Meier curves of the time from randomisation to impending relapse during\r the 38\u2011week, Double-blind, Active-controlled Phase for Abilify Maintena,\r oral aripiprazole 10\u201130 mg, and aripiprazole Long-Acting Injectable\r 50 mg\/25 mg are shown in Figure 1.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"12613484-f17c-46a1-b3ab-c6a1884e4f12","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Figure 1      Kaplan-Meier\r Product Limit Plot for Time to Exacerbation of Psychotic Symptoms\/Impending\r Relapse<\/span><\/b><\/em><\/p>","ID":"c544b4ec-e0c7-41cc-a157-9ef80636d2e8","Styles":"margin-left:56.7pt;text-indent:-56.7pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Figure 1      Kaplan-Meier\r Product Limit Plot for Time to Exacerbation of Psychotic Symptoms\/Impending\r Relapse","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\"><img border=\"0\" height=\"334\" id=\"Grafik 3207\" src=\"AbilifyMaintena-h-2755-e_files\/image001.png\" width=\"535\"\/><\/span><\/p>","ID":"f1158653-dc54-4f0a-a2dd-eb2916f6bd01","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"font-size:8.0pt;color:black;\r font-style:normal\">NOTE: ARIP IMD 400\/300 mg = Abilify Maintena;ARIP\r 10\u201130 mg = oral aripiprazole; ARIP IMD 50\/25 mg = Long-acting\r Injectable<\/span><\/em><\/p>","ID":"1e77b0cb-3c93-45a1-8db6-b9c9f5a611d4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"NOTE: ARIP IMD 400\/300 mg = Abilify Maintena;ARIP\r 10\u201130 mg = oral aripiprazole; ARIP IMD 50\/25 mg = Long-acting\r Injectable","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ed7cdcf3-6f32-4f32-ba23-dfabb8d75427","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Further,\r the non-inferiority of Abilify Maintena compared to oral aripiprazole 10\u201130 mg\r is supported by the results of the analysis of the Positive and Negative\r Syndrome Scale score (PANSS).<\/span><\/em><\/p>","ID":"f1bc00aa-f238-4c51-8b4e-3cca7a36cd65","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Further,\r the non-inferiority of Abilify Maintena compared to oral aripiprazole 10\u201130 mg\r is supported by the results of the analysis of the Positive and Negative\r Syndrome Scale score (PANSS).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d608d149-34a7-4971-8db7-af8c30e399d0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r avoid\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Table 1       PANSS\r Total Score \u2013 Change From Baseline to Week 38-LOCF:<br\/>\r Randomised Efficacy Sample<sup>a, b<\/sup><\/span><\/b><\/em><\/p>","ID":"ba87aed2-4169-41bd-9156-d6dc53768a88","Styles":"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Table 1       PANSS\r Total Score \u2013 Change From Baseline to Week 38-LOCF:\r Randomised Efficacy Samplea, b","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"4b65adf9-7895-4354-bed8-9e9eaaf3976f","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.2%;margin-left:5.5pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr style=\"height:28.25pt\"> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"top\" width=\"100%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">PANSS Total Score \u2013 Change\r   From Baseline to Week 38-LOCF:<\/span><\/b><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Randomised Efficacy Sample<sup>a,\r   b<\/sup><\/span><\/b><\/em><\/p> <\/td> <\/tr> <tr style=\"height:38.85pt\"> <td style=\"width:24.94%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:38.85pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:19.48%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:38.85pt\" valign=\"top\" width=\"19%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify Maintena<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> 400 mg\/300 mg<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">(n = 263)<\/span><\/em><\/p> <\/td> <td style=\"width:24.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:38.85pt\" valign=\"top\" width=\"24%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Oral aripiprazole<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">10\u201130 mg\/day<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">(n = 266)<\/span><\/em><\/p> <\/td> <td style=\"width:30.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:38.85pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole Long-Acting\r   Injectable<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">50 mg\/25 mg<\/span><\/em><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">(n = 131)<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:16.55pt\"> <td style=\"width:24.94%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Mean baseline (SD)<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:19.48%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"19%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">57.9 (12.94)<\/span><\/em><\/p> <\/td> <td style=\"width:24.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"24%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">56.6 (12.65)<\/span><\/em><\/p> <\/td> <td style=\"width:30.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">56.1 (12.59)<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:16.55pt\"> <td style=\"width:24.94%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">Mean change (SD)<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:19.48%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"19%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">1.8 (10.49)<\/span><\/em><\/p> <\/td> <td style=\"width:24.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"24%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.7 (11.60)<\/span><\/em><\/p> <\/td> <td style=\"width:30.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.55pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3.2 (14.45)<\/span><\/em><\/p> <\/td> <\/tr> <tr style=\"height:12.7pt\"> <td style=\"width:24.94%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.7pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:\r   normal\">P-value<\/span><\/b><\/em><\/p> <\/td> <td style=\"width:19.48%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.7pt\" valign=\"top\" width=\"19%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">NA<\/span><\/em><\/p> <\/td> <td style=\"width:24.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.7pt\" valign=\"top\" width=\"24%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.0272<\/span><\/em><\/p> <\/td> <td style=\"width:30.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.7pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">0.0002<\/span><\/em><\/p> <\/td> <\/tr> <\/table>","ID":"f6892925-824d-4a25-bd86-2f5d5b233b4c","Styles":"width:99.2%;margin-left:5.5pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"   PANSS Total Score \u2013 Change\r   From Baseline to Week 38-LOCF: Randomised Efficacy Samplea,\r   b        Abilify Maintena   400 mg\/300 mg (n = 263)   Oral aripiprazole  10\u201130 mg\/day (n = 266)   Aripiprazole Long-Acting\r   Injectable 50 mg\/25 mg (n = 131)     Mean baseline (SD)   57.9 (12.94)   56.6 (12.65)   56.1 (12.59)     Mean change (SD)   \u22121.8 (10.49)   0.7 (11.60)   3.2 (14.45)     P-value   NA   0.0272   0.0002   ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><em><span lang=\"EN-GB\" style=\"font-size:8.0pt;color:black;font-style:normal\">a:    Negative\r change in score indicates improvement.<\/span><\/em><\/p>","ID":"f7685aa7-b1dc-4ee7-bfb0-06cf7895c2c0","Styles":"margin-left:14.2pt;text-indent:-14.2pt","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"a:    Negative\r change in score indicates improvement.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><em><span lang=\"EN-GB\" style=\"font-size:8.0pt;color:black;font-style:normal\">b:   Only\r patients having both baseline and at least one post baseline were included.\r P-values were derived from comparison for change from baseline within analysis\r of covariance model with treatment as term and baseline as covariate.<\/span><\/em><\/p>","ID":"7f75f2bd-4d07-49f7-badc-68297a03fe3b","Styles":"margin-left:14.2pt;text-indent:-14.2pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"b:   Only\r patients having both baseline and at least one post baseline were included.\r P-values were derived from comparison for change from baseline within analysis\r of covariance model with treatment as term and baseline as covariate.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6e327c78-59a5-4b56-b1dd-e1f4e81d0392","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r second trial was a 52\u2011week, randomised, withdrawal, double\u2011blind,\r trial conducted in US adult patients with a current diagnosis of schizophrenia.\r This trial consisted of a screening phase and 4 treatment phases:\r Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and\r Double-blind Placebo-controlled. Patients fulfilling the oral stabilisation\r requirement in the Oral Stabilisation Phase were assigned to receive, in a\r single-blind fashion, Abilify Maintena and began an Abilify Maintena\r Stabilisation Phase for a minimum of 12 weeks and a maximum of\r 36 weeks. Patients eligible for the Double-blind, Placebo-controlled Phase\r were randomly assigned in a 2:1 ratio to double\u2011blind treatment with Abilify\r Maintena or placebo, respectively.<\/span><\/em><\/p>","ID":"cb72e349-b50a-4d34-85b9-f80d61a48668","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r second trial was a 52\u2011week, randomised, withdrawal, double\u2011blind,\r trial conducted in US adult patients with a current diagnosis of schizophrenia.\r This trial consisted of a screening phase and 4 treatment phases:\r Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and\r Double-blind Placebo-controlled. Patients fulfilling the oral stabilisation\r requirement in the Oral Stabilisation Phase were assigned to receive, in a\r single-blind fashion, Abilify Maintena and began an Abilify Maintena\r Stabilisation Phase for a minimum of 12 weeks and a maximum of\r 36 weeks. Patients eligible for the Double-blind, Placebo-controlled Phase\r were randomly assigned in a 2:1 ratio to double\u2011blind treatment with Abilify\r Maintena or placebo, respectively.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"58383f6e-03cd-4766-8555-66287870bab2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r final efficacy analysis included 403 randomised patients and 80 exacerbations\r of psychotic symptoms\/impending relapse events. In the placebo group 39.6 %\r of the patients had progressed to impending relapse, whilst in the Abilify\r Maintena group impending relapse occurred in 10 % of the patients; thus\r patients in the placebo group had a 5.03\u2011fold greater risk of\r experiencing impending relapse.<\/span><\/em><\/p>","ID":"cc828006-0a9b-476f-8227-3010aaba3a08","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r final efficacy analysis included 403 randomised patients and 80 exacerbations\r of psychotic symptoms\/impending relapse events. In the placebo group 39.6 %\r of the patients had progressed to impending relapse, whilst in the Abilify\r Maintena group impending relapse occurred in 10 % of the patients; thus\r patients in the placebo group had a 5.03\u2011fold greater risk of\r experiencing impending relapse.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d5987a1d-ef2b-4999-bcf5-ea305df66ed7","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Prolactin<\/span><\/em><\/p>","ID":"43787d07-1a5b-494c-9b9c-77bf081c57c6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Prolactin","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r the Double-blind, Active-controlled Phase of the 38\u2011week trial, from\r baseline to last visit there was a mean decrease in prolactin levels in Abilify\r Maintena (\u22120.33 ng\/ml) compared with a mean increase in oral\r aripiprazole tablets 10\u201130 mg (0.79 ng\/ml; p &lt; 0.01).\r The incidence of Abilify Maintena patients with prolactin levels &gt; 1\r time the upper limit of normal range (ULN) at any assessment was 5.4 %\r compared with 3.5 % of the patients on oral aripiprazole tablets 10\u201130 mg.<\/span><\/em><\/p>","ID":"c282f876-2950-4133-ad43-ea1873685dbf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r the Double-blind, Active-controlled Phase of the 38\u2011week trial, from\r baseline to last visit there was a mean decrease in prolactin levels in Abilify\r Maintena (\u22120.33 ng\/ml) compared with a mean increase in oral\r aripiprazole tablets 10\u201130 mg (0.79 ng\/ml; p < 0.01).\r The incidence of Abilify Maintena patients with prolactin levels > 1\r time the upper limit of normal range (ULN) at any assessment was 5.4 %\r compared with 3.5 % of the patients on oral aripiprazole tablets 10\u201130 mg.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Male\r patients generally had a higher incidence than female patients in each\r treatment group.<\/span><\/em><\/p>","ID":"db624f2e-886f-4142-a1c0-7601c258bf33","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Male\r patients generally had a higher incidence than female patients in each\r treatment group.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cdc5c7f3-d153-4653-a4f6-af8d2fea015f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r the Double-blind Placebo-controlled Phase of the 52\u2011week trial, from\r baseline to last visit there was a mean decrease in prolactin levels in Abilify\r Maintena (\u22120.38 ng\/ml) compared with a mean increase in placebo\r (1.67 ng\/ml). The incidences of Abilify Maintena patients with prolactin\r levels &gt; 1 time the upper limit of normal range (ULN) was\r 1.9 % compared to 7.1 % for placebo patients.<\/span><\/em><\/p>","ID":"46b6ff4b-218d-43d4-971b-5ecd18d465be","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r the Double-blind Placebo-controlled Phase of the 52\u2011week trial, from\r baseline to last visit there was a mean decrease in prolactin levels in Abilify\r Maintena (\u22120.38 ng\/ml) compared with a mean increase in placebo\r (1.67 ng\/ml). The incidences of Abilify Maintena patients with prolactin\r levels > 1 time the upper limit of normal range (ULN) was\r 1.9 % compared to 7.1 % for placebo patients.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c7e0ba8f-16a4-4f1f-83b5-a01fa27ac88a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Acute treatment of schizophrenia in\r adults<\/span><\/i><\/p>","ID":"e222cd3d-adbe-491d-8f3e-2f35624e7fc1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Acute treatment of schizophrenia in\r adults","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of Abilify Maintena in acutely\r relapsed adult patients with schizophrenia was established in a short-term\r (12-week), randomised, double\u2011blind, placebo-controlled trial\r (n = 339).<\/span><\/p>","ID":"ab52a45f-69e9-4cf8-907f-0bd095c661cd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The efficacy of Abilify Maintena in acutely\r relapsed adult patients with schizophrenia was established in a short-term\r (12-week), randomised, double\u2011blind, placebo-controlled trial\r (n = 339).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint (change in PANSS total\r score from baseline to week 10) showed superiority of Abilify Maintena\r (n = 167) over placebo (n = 172).<\/span><\/p>","ID":"d51eed4a-a637-4260-91e2-37dbacd29a1c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The primary endpoint (change in PANSS total\r score from baseline to week 10) showed superiority of Abilify Maintena\r (n = 167) over placebo (n = 172).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Similar to the PANSS Total Score, both the\r PANSS positive and negative subscale scores also showed an improvement\r (decrease) from baseline over time.<\/span><\/p>","ID":"b3e59490-e23f-4765-a589-a9ac3538acaa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Similar to the PANSS Total Score, both the\r PANSS positive and negative subscale scores also showed an improvement\r (decrease) from baseline over time.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9061cabe-2125-4252-924d-56daad164712","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Table 2       PANSS Total\r Score \u2013 Change From Baseline to week 10: Randomised Efficacy Sample<\/span><\/b><\/p>","ID":"f1b2a568-bf49-4118-a7d7-2e82995ffeb3","Styles":"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Table 2       PANSS Total\r Score \u2013 Change From Baseline to week 10: Randomised Efficacy Sample","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r avoid\"><\/p>","ID":"a76d9a7a-dd35-4b94-b660-fe7d121437f0","Styles":"margin-left:56.7pt;text-indent:-56.7pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr> <td colspan=\"3\" style=\"width:458.95pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"612\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">PANSS Total Score \u2013 Change\r   From Baseline to Week 10:<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\" style=\"color:black\">Randomised Efficacy Sample <sup>a<\/sup><\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><sup><\/sup><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">400 mg\/300 mg<\/span><\/b><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"177\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"color:black\">Placebo<\/span><\/b><\/p> <p class=\"MsoNormal\"><b><sup><\/sup><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">Mean baseline (SD)<\/span><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><span lang=\"EN-GB\">102.4 (11.4)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">n = 162<\/span><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"177\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><span lang=\"EN-GB\">103.4 (11.1)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><span lang=\"EN-GB\">n = 167<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">LS Mean change\r   (SE)<\/span><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">26.8\r   (1.6)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">n = 99<\/span><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"177\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">11.7\r   (1.6)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:5.65pt;text-align:center\"><span lang=\"EN-GB\">n = 81<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:black\">P-value<\/span><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"177\"> <p class=\"MsoNormal\"><b><sup><\/sup><\/b><\/p> <\/td> <\/tr> <tr style=\"height:3.2pt\"> <td style=\"width:191.4pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:3.2pt\" valign=\"top\" width=\"255\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Treatment difference<sup>b<\/sup>\r   (95 % CI)<\/span><\/b><\/p> <\/td> <td style=\"width:134.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:3.2pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">15.1\r   (<\/span><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">19.4, <\/span><em><span style=\"color:black;font-style:normal\">\u2212<\/span><\/em><span lang=\"EN-GB\">10.8)<\/span><\/p> <\/td> <td style=\"width:132.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:3.2pt\" valign=\"top\" width=\"177\"> <p class=\"MsoNormal\"><b><sup><\/sup><\/b><\/p> <\/td> <\/tr> <\/table>","ID":"fb2f0520-26c4-4f55-bddc-b9b16790ef09","Styles":"margin-left:5.4pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"   PANSS Total Score \u2013 Change\r   From Baseline to Week 10: Randomised Efficacy Sample a        Abilify Maintena 400 mg\/300 mg   Placebo      Mean baseline (SD)   102.4 (11.4) n = 162   103.4 (11.1) n = 167     LS Mean change\r   (SE)   \u221226.8\r   (1.6) n = 99   \u221211.7\r   (1.6) n = 81     P-value   < 0.0001        Treatment differenceb\r   (95 % CI)   \u221215.1\r   (\u221219.4, \u221210.8)      ","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">a        <\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">Data were analysed using a mixed model repeated\r measures (MMRM) approach. The analysis included only subjects who were randomly\r assigned to treatment, given at least one injection, had baseline and at least\r one post-baseline efficacy assessment.<\/span><\/p>","ID":"5b1b69b5-22e9-4b08-897f-5a68f8148714","Styles":"margin-left:14.2pt;text-indent:-14.2pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"a        Data were analysed using a mixed model repeated\r measures (MMRM) approach. The analysis included only subjects who were randomly\r assigned to treatment, given at least one injection, had baseline and at least\r one post-baseline efficacy assessment.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">b        <\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:8.0pt\">Difference (Abilify Maintena minus placebo) in least\r squares mean change from baseline.<\/span><\/p>","ID":"07f0c585-d6d8-41ce-870f-7a62c45f22f7","Styles":"margin-left:14.2pt;text-indent:-14.2pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"b        Difference (Abilify Maintena minus placebo) in least\r squares mean change from baseline.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ab412c86-936f-4466-af1f-06baefb76dea","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abilify Maintena also showed statistically\r significant improvement in symptoms represented by CGIS score change from\r baseline to week 10.<\/span><\/p>","ID":"c519fb2f-62b5-4e93-b272-77930ed97920","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Abilify Maintena also showed statistically\r significant improvement in symptoms represented by CGIS score change from\r baseline to week 10.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9f213e47-5a29-4283-98d8-64223c3c5770","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Personal and social functioning were\r evaluated using the Personal and Social Performance (PSP) scale. The PSP is a\r validated clinician-rated scale that measures personal and social functioning\r in four domains: socially useful activities (e.g. work and study), personal and\r social relationships, self-care, and disturbing and aggressive behaviours.\r There was a statistically significant treatment difference in favour of Abilify\r Maintena 400 mg\/300 mg compared to placebo at week 10 (+7.1,\r p &lt; 0.0001, 95 % CI: 4.1, 10.1 using an ANCOVA model (LOCF)).<\/span><\/p>","ID":"4d9f982f-b912-4664-b2e4-d03e665375af","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Personal and social functioning were\r evaluated using the Personal and Social Performance (PSP) scale. The PSP is a\r validated clinician-rated scale that measures personal and social functioning\r in four domains: socially useful activities (e.g. work and study), personal and\r social relationships, self-care, and disturbing and aggressive behaviours.\r There was a statistically significant treatment difference in favour of Abilify\r Maintena 400 mg\/300 mg compared to placebo at week 10 (+7.1,\r p < 0.0001, 95 % CI: 4.1, 10.1 using an ANCOVA model (LOCF)).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"49e2b6af-8ad0-4906-8893-6c7a75f6dc9f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The safety profile was\r consistent with that known to Abilify Maintena. Nevertheless, there were\r differences from what has been observed with maintenance use in the treatment\r of schizophrenia. In <\/span><span lang=\"EN-GB\">a short-term (12-week),\r randomised, double\u2011blind, placebo-controlled trial with <span style=\"color:black\">Abilify Maintena 400<\/span> <span style=\"color:black\">mg\/300<\/span> <span style=\"color:black\">mg treated subjects the symptoms which had at least twice\r the incidence of placebo were increased weight and akathisia. The incidence of\r weight gain of \u2265 7 % from baseline to last visit (week<\/span> <span style=\"color:black\">12) was 21.5 % for Abilify Maintena compared with the\r placebo group 8.5 %. Akathisia was the most frequently observed EPS\r symptom (Abilify Maintena 11.4<\/span> <span style=\"color:black\">% and\r placebo group 3.5 %).<\/span><\/span><\/p>","ID":"b3863817-5cac-4fed-a974-487e320df073","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The safety profile was\r consistent with that known to Abilify Maintena. Nevertheless, there were\r differences from what has been observed with maintenance use in the treatment\r of schizophrenia. In a short-term (12-week),\r randomised, double\u2011blind, placebo-controlled trial with Abilify Maintena 400 mg\/300 mg treated subjects the symptoms which had at least twice\r the incidence of placebo were increased weight and akathisia. The incidence of\r weight gain of \u2265 7 % from baseline to last visit (week 12) was 21.5 % for Abilify Maintena compared with the\r placebo group 8.5 %. Akathisia was the most frequently observed EPS\r symptom (Abilify Maintena 11.4 % and\r placebo group 3.5 %).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cd1b4c41-bfad-4d14-aa1b-515611c87d61","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Paediatric\r population<\/span><\/em><\/p>","ID":"42554a8e-e509-48c0-8688-4324b857f6ea","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Paediatric\r population","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r European Medicines Agency has waived the obligation to submit the results of\r studies with Abilify Maintena in all subsets of the paediatric population in\r schizophrenia (see section 4.2).<\/span><\/em><\/p>","ID":"e8248bd4-7d55-4930-adb2-a723b6c1f119","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The\r European Medicines Agency has waived the obligation to submit the results of\r studies with Abilify Maintena in all subsets of the paediatric population in\r schizophrenia (see section 4.2).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p>","ID":"d213483a-4f21-4258-a36f-ade21823699c","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.2     Pharmacokinetic\r properties<\/span><\/b><\/em><\/p>","ID":"39ac61ee-6ab9-468b-937c-791ce2502654","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"5.2     Pharmacokinetic\r properties","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ff4f7c10-1012-4e8d-8e99-eabbdfbd3085","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Absorption<\/span><\/u><\/em><\/p>","ID":"d99604df-f721-4df2-b0d6-78f3127088c0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Absorption","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"7a283d26-662c-41f7-a33d-429310fe1d34","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r absorption into the systemic circulation is slow and prolonged following Abilify\r Maintena administration due to low solubility of aripiprazole particles.<\/span><\/em><span lang=\"EN-GB\">The <span style=\"color:black\">average absorption half-life of <em><span style=\"font-style:normal\">Abilify Maintena<\/span><\/em> is 28 days.<\/span>Absorption of aripiprazole from\r the IM depot formulation was complete relative to the IM standard\r (immediate-release) formulation<span style=\"color:black\">. The dose adjusted C<sub>max<\/sub>\r values for the depot formulation were approximately 5% of C<sub>max<\/sub> from IM\r standard formulation.<\/span>Following a single dose administration of Abilify\r Maintena in the deltoid and gluteal muscle, the extent of absorption (AUC) was\r similar for both injection sites, but the rate of absorption (C<sub>max<\/sub>)\r was higher following administration to the deltoid muscle. Following multiple\r intramuscular doses, the plasma concentrations of aripiprazole gradually rise\r to a maximum plasma concentration at a median t<sub>max <\/sub>of 7 days\r for the gluteal muscle and 4 days for the deltoid muscle. Steady state\r concentrations for the typical subject were attained by the fourth dose for\r both sites of administration. <em><span style=\"color:black;font-style:normal\">Less\r than dose-proportional increases in aripiprazole and dehydro-aripiprazole\r concentrations and AUC parameters are observed after monthly Abilify Maintena\r injections of 300 mg to 400 mg.<\/span><\/em><\/span><\/p>","ID":"198ec23b-bafb-4026-8685-7e327b034ea2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole\r absorption into the systemic circulation is slow and prolonged following Abilify\r Maintena administration due to low solubility of aripiprazole particles.The average absorption half-life of Abilify Maintena is 28 days.Absorption of aripiprazole from\r the IM depot formulation was complete relative to the IM standard\r (immediate-release) formulation. The dose adjusted Cmax\r values for the depot formulation were approximately 5% of Cmax from IM\r standard formulation.Following a single dose administration of Abilify\r Maintena in the deltoid and gluteal muscle, the extent of absorption (AUC) was\r similar for both injection sites, but the rate of absorption (Cmax)\r was higher following administration to the deltoid muscle. Following multiple\r intramuscular doses, the plasma concentrations of aripiprazole gradually rise\r to a maximum plasma concentration at a median tmax of 7 days\r for the gluteal muscle and 4 days for the deltoid muscle. Steady state\r concentrations for the typical subject were attained by the fourth dose for\r both sites of administration. Less\r than dose-proportional increases in aripiprazole and dehydro-aripiprazole\r concentrations and AUC parameters are observed after monthly Abilify Maintena\r injections of 300 mg to 400 mg.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"85964f6c-387a-46d3-954c-4e608095c687","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Distribution<\/span><\/u><\/em><\/p>","ID":"21f88dcc-e1f7-48be-9415-934b1f49d72b","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Distribution","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"84286e0b-4472-4387-b85c-6fc2a2cbc581","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Based\r on results from trials with oral administration of aripiprazole, aripiprazole\r is widely distributed throughout the body with an apparent volume of\r distribution of 4.9 l\/kg, indicating extensive extravascular distribution.\r At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are\r greater than 99 % bound to serum proteins, binding primarily to albumin.<\/span><\/em><\/p>","ID":"7337247c-2c3b-4ec7-ade1-c80f7b919864","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Based\r on results from trials with oral administration of aripiprazole, aripiprazole\r is widely distributed throughout the body with an apparent volume of\r distribution of 4.9 l\/kg, indicating extensive extravascular distribution.\r At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are\r greater than 99 % bound to serum proteins, binding primarily to albumin.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bf4bf6d9-bf99-404d-b2bb-319ed1f6d193","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Biotransformation<\/span><\/u><\/em><\/p>","ID":"77b67cf0-f892-4b02-9881-e3ff92ecf056","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Biotransformation","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"691213ad-9977-4f51-acbd-4ba16b154e61","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Aripiprazole\r is extensively metabolised by the liver primarily by three biotransformation pathways:\r dehydrogenation, hydroxylation, and N-dealkylation. Based on <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black\">in vitro<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> studies, CYP3A4 and CYP2D6 enzymes are\r responsible for dehydrogenation and hydroxylation of aripiprazole, and\r N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal\r product moiety in systemic circulation. After multiple dose administration of Abilify\r Maintena, dehydro-aripiprazole, the active metabolite, represents about 29.1\u201132.5 %\r of aripiprazole AUC in plasma.<\/span><\/em><\/p>","ID":"1e99fee0-29c1-47c4-b180-2eb09ecc0829","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Aripiprazole\r is extensively metabolised by the liver primarily by three biotransformation pathways:\r dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are\r responsible for dehydrogenation and hydroxylation of aripiprazole, and\r N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal\r product moiety in systemic circulation. After multiple dose administration of Abilify\r Maintena, dehydro-aripiprazole, the active metabolite, represents about 29.1\u201132.5 %\r of aripiprazole AUC in plasma.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"4dee5fc4-40bc-42e1-adf1-e6bb35caf0d9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Elimination<\/span><\/u><\/em><\/p>","ID":"d3833f07-ef57-4d1b-bb02-683dd5d6623d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Elimination","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"919146c6-2c5e-426e-ad62-c1c33b76f172","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r administration of multiple dose of 400 mg or 300 mg of Abilify\r Maintena, the mean aripiprazole terminal elimination half-life is respectively\r 46.5 and 29.9 days <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">presumably\r due to absorption rate-limited kinetics.<em><span style=\"font-style:normal\"> Following\r a single oral dose of [<sup>14<\/sup>C]-labelled aripiprazole, approximately 27 %\r of the administered radioactivity was recovered in the urine and approximately 60 %\r in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the\r urine and approximately 18 % was recovered unchanged in the faeces.<\/span><\/em><\/span><\/p>","ID":"3ead0781-1790-4726-9de0-3e9f05297429","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"After\r administration of multiple dose of 400 mg or 300 mg of Abilify\r Maintena, the mean aripiprazole terminal elimination half-life is respectively\r 46.5 and 29.9 days presumably\r due to absorption rate-limited kinetics. Following\r a single oral dose of [14C]-labelled aripiprazole, approximately 27 %\r of the administered radioactivity was recovered in the urine and approximately 60 %\r in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the\r urine and approximately 18 % was recovered unchanged in the faeces.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"30a20694-c4d3-47fe-8889-5e2f6f6281e0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Pharmacokinetics\r in special patient groups<\/span><\/u><\/em><\/p>","ID":"5c4860a6-8c53-4680-b7b4-541abb81f50e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Pharmacokinetics\r in special patient groups","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a73124b3-b541-4bde-9077-bd4ed29041d1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">CYP2D6 poor\r metabolisers<\/span><\/em><\/p>","ID":"fb237c4a-330f-497d-a845-bb7100bfd725","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"CYP2D6 poor\r metabolisers","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Based\r on population pharmacokinetic evaluation of Abilify Maintena, the total body\r clearance of aripiprazole was 3.71 L\/h in extensive metabolisers of CYP2D6\r and approximately 1.88 L\/h (approximately 50 % lower) in\r poor metabolisers of CYP2D6 (for dose recommendation, see section 4.2).<\/span><\/em><\/p>","ID":"301079cd-5588-4ced-b0dc-2c5fcebb39b2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Based\r on population pharmacokinetic evaluation of Abilify Maintena, the total body\r clearance of aripiprazole was 3.71 L\/h in extensive metabolisers of CYP2D6\r and approximately 1.88 L\/h (approximately 50 % lower) in\r poor metabolisers of CYP2D6 (for dose recommendation, see section 4.2).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1fc1d66a-0a11-4ec3-923e-2f839c31f163","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Elderly<\/span><\/em><\/p>","ID":"9d00af18-5860-4d5f-a1be-2cb93f712579","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Elderly","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r oral administration of aripiprazole, there are no differences in the\r pharmacokinetics of aripiprazole between healthy elderly and younger adult\r subjects. Similarly, there was no detectable effect of age in a population\r pharmacokinetic analysis of Abilify Maintena in schizophrenia patients.<\/span><\/em><\/p>","ID":"9667f7fc-8a66-4d6d-8f9e-0b8c5ccbf6a2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"After\r oral administration of aripiprazole, there are no differences in the\r pharmacokinetics of aripiprazole between healthy elderly and younger adult\r subjects. Similarly, there was no detectable effect of age in a population\r pharmacokinetic analysis of Abilify Maintena in schizophrenia patients.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"d157c690-c8e5-48fd-b006-66e2112b63e9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Gender<\/span><\/em><\/p>","ID":"3deec594-5210-4916-91b7-12159a66f1ff","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Gender","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">After\r oral administration of aripiprazole, there are no differences in the\r pharmacokinetics of aripiprazole between healthy male and female subjects.\r Similarly, there was no clinically relevant effect of gender in a population\r pharmacokinetic analysis of Abilify Maintena in clinical trials in patients\r with schizophrenia.<\/span><\/em><\/p>","ID":"f2a27729-6b07-4cd0-a7eb-a66771e90904","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"After\r oral administration of aripiprazole, there are no differences in the\r pharmacokinetics of aripiprazole between healthy male and female subjects.\r Similarly, there was no clinically relevant effect of gender in a population\r pharmacokinetic analysis of Abilify Maintena in clinical trials in patients\r with schizophrenia.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a4037cfc-a446-4372-9fa7-ad534a1faeb9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Smoking<\/span><\/em><\/p>","ID":"38847bd6-d704-465e-802f-7f19ab4c0139","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Smoking","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Population\r pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of\r clinically relevant effects from smoking on the pharmacokinetics of\r aripiprazole.<\/span><\/em><\/p>","ID":"e442d40c-e996-4d57-98a9-5ddac59dd616","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Population\r pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of\r clinically relevant effects from smoking on the pharmacokinetics of\r aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"70f7b8e1-cb97-4bde-8867-c34e0f8988ee","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Race<\/span><\/em><\/p>","ID":"9670aec9-edd7-4933-81f4-c0dca8cf98e3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Race","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Population\r pharmacokinetic evaluation showed no evidence of race-related differences on\r the pharmacokinetics of aripiprazole.<\/span><\/em><\/p>","ID":"220d7496-aa09-4af8-aed4-e9d755026342","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Population\r pharmacokinetic evaluation showed no evidence of race-related differences on\r the pharmacokinetics of aripiprazole.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7ebf6743-5976-4c59-901f-9032b81eeb8b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Renal impairment<\/span><\/em><\/p>","ID":"10120271-0517-4b5a-a891-4046c2e473c6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Renal impairment","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r a single-dose study with oral administration of aripiprazole, the\r pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were\r found to be similar in patients with severe renal disease compared to that in young\r healthy subjects.<\/span><\/em><\/p>","ID":"78ecac57-7116-4c75-b77c-4dc7b3795dce","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r a single-dose study with oral administration of aripiprazole, the\r pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were\r found to be similar in patients with severe renal disease compared to that in young\r healthy subjects.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a8d562c0-df16-45f3-a088-e4dedbe866b1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Hepatic impairment<\/span><\/em><\/p>","ID":"26540edc-30a8-41e3-91a5-de5aae3bc012","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Hepatic impairment","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">A\r single-dose study with oral administration of aripiprazole to subjects with\r varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not\r reveal a significant effect of hepatic impairment on the pharmacokinetics of\r aripiprazole and dehydro-aripiprazole, but the study included only\r 3 patients with Class C liver cirrhosis, which is insufficient to draw\r conclusions on their metabolic capacity.<\/span><\/em><\/p>","ID":"e44d554b-a7a2-4a03-888b-c063bd8db426","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A\r single-dose study with oral administration of aripiprazole to subjects with\r varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not\r reveal a significant effect of hepatic impairment on the pharmacokinetics of\r aripiprazole and dehydro-aripiprazole, but the study included only\r 3 patients with Class C liver cirrhosis, which is insufficient to draw\r conclusions on their metabolic capacity.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ab475a60-e243-4848-b8ad-8475fc201484","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">5.3     Preclinical safety\r data<\/span><\/b><\/em><\/p>","ID":"afc09553-6b7c-4c45-9ea8-86763d84e9d0","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"5.3     Preclinical safety\r data","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"55b2da76-7d80-4e2f-9aca-c3dd77cd0efc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r toxicological profile for aripiprazole administered to experimental animals by\r intramuscular injection is generally similar to that seen following oral\r administration at comparable plasma levels. With intramuscular injection,\r however <\/span><\/em><span lang=\"EN-GB\" style=\"color:black\">an inflammatory\r response was seen at the injection site, and consisted of granulomatous\r inflammation, foci (deposited drug), cellular infiltrates, oedema (swelling)\r and, in monkeys, fibrosis. <em><span style=\"font-style:normal\">These effects\r gradually resolved with discontinuation of dosing.<\/span><\/em><\/span><\/p>","ID":"f682b502-9452-444e-8a8e-3354a1cf5898","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The\r toxicological profile for aripiprazole administered to experimental animals by\r intramuscular injection is generally similar to that seen following oral\r administration at comparable plasma levels. With intramuscular injection,\r however an inflammatory\r response was seen at the injection site, and consisted of granulomatous\r inflammation, foci (deposited drug), cellular infiltrates, oedema (swelling)\r and, in monkeys, fibrosis. These effects\r gradually resolved with discontinuation of dosing.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"54f15afb-f65c-4928-aa08-fe010bc54e56","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Non-clinical\r safety data for orally administered aripiprazole reveal no special hazard for\r humans based on conventional studies of safety pharmacology, repeated dose\r toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and\r development.<\/span><\/em><\/p>","ID":"4e656f96-11bd-4d69-99a7-851b76013800","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Non-clinical\r safety data for orally administered aripiprazole reveal no special hazard for\r humans based on conventional studies of safety pharmacology, repeated dose\r toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and\r development.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c9d224ac-fd62-42ae-9acb-dfd27fcb4bf1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Oral\r aripiprazole<\/span><\/u><\/em><\/p>","ID":"e23f0216-8628-47dd-ac0b-38375c561165","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Oral\r aripiprazole","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"6a2ae18f-5317-4c0e-b658-ae02fe31c63d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">For\r oral aripiprazole, toxicologically significant effects were observed only at\r doses or exposures that were sufficiently in excess of the maximum human dose\r or exposure, indicating that these effects were limited or of no relevance to\r clinical use. These included: dose-dependent adrenocortical toxicity in rats\r after 104 weeks of oral administration at approximately 3 to\r 10 times the mean steady-state AUC at the maximum recommended human dose\r and increased adrenocortical carcinomas and combined adrenocortical\r adenomas\/carcinomas in female rats at approximately 10 times the mean\r steady-state AUC at the maximum recommended human dose. The highest\r non-tumorigenic exposure in female rats was approximately 7 times the\r human exposure at the recommended dose.<\/span><\/em><\/p>","ID":"36997aa7-c0d9-434a-b51e-dce5f95a674e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For\r oral aripiprazole, toxicologically significant effects were observed only at\r doses or exposures that were sufficiently in excess of the maximum human dose\r or exposure, indicating that these effects were limited or of no relevance to\r clinical use. These included: dose-dependent adrenocortical toxicity in rats\r after 104 weeks of oral administration at approximately 3 to\r 10 times the mean steady-state AUC at the maximum recommended human dose\r and increased adrenocortical carcinomas and combined adrenocortical\r adenomas\/carcinomas in female rats at approximately 10 times the mean\r steady-state AUC at the maximum recommended human dose. The highest\r non-tumorigenic exposure in female rats was approximately 7 times the\r human exposure at the recommended dose.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f6490102-e18e-40ab-98a6-599f077f90bf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">An\r additional finding was cholelithiasis as a consequence of precipitation of\r sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of\r monkeys after repeated oral dosing at 25 to 125 mg\/kg\/day or\r approximately16 to 81 times the maximum recommended human dose based on\r mg\/m<sup>2<\/sup>.<\/span><\/em><\/p>","ID":"3557cb05-fb11-40e8-a763-99369f3f88aa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"An\r additional finding was cholelithiasis as a consequence of precipitation of\r sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of\r monkeys after repeated oral dosing at 25 to 125 mg\/kg\/day or\r approximately16 to 81 times the maximum recommended human dose based on\r mg\/m2.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b7565698-d9c6-458c-88f4-3f98c843f967","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">However,\r the concentrations of the sulphate conjugates of hydroxy-aripiprazole in human\r bile at the highest dose proposed, 30 mg per day, were no more than\r 6 % of the bile concentrations found in the monkeys in the 39\u2011week\r study and are well below (6 %) their limits of <\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black\">in vitro<\/span><\/em><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"> solubility.<\/span><\/em><\/p>","ID":"3ef02921-e8cb-4394-bb02-5d2ee02cfd92","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"However,\r the concentrations of the sulphate conjugates of hydroxy-aripiprazole in human\r bile at the highest dose proposed, 30 mg per day, were no more than\r 6 % of the bile concentrations found in the monkeys in the 39\u2011week\r study and are well below (6 %) their limits of in vitro solubility.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2953580e-404f-4f07-be71-7248b9672189","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">In\r repeated dose studies in juvenile rats and dogs, the toxicity profile of\r aripiprazole was comparable to that observed in adult animals, and there was no\r evidence of neurotoxicity or adverse events on development.<\/span><\/em><\/p>","ID":"21b067f4-0298-4bcb-b9ef-79b34dd07236","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In\r repeated dose studies in juvenile rats and dogs, the toxicity profile of\r aripiprazole was comparable to that observed in adult animals, and there was no\r evidence of neurotoxicity or adverse events on development.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"99232e97-7e0e-40e7-a621-74d8308fb4f4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Based\r on results of a full range of standard genotoxicity tests, aripiprazole was\r considered non-genotoxic. Aripiprazole did not impair fertility in reproductive\r toxicity studies.<\/span><\/em><\/p>","ID":"ff6f1df3-2744-467d-a9dc-1ec91f7b9454","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Based\r on results of a full range of standard genotoxicity tests, aripiprazole was\r considered non-genotoxic. Aripiprazole did not impair fertility in reproductive\r toxicity studies.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ce308e3a-aad6-411b-b5e2-f1ff521b5638","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Developmental\r toxicity, including dose-dependent delayed foetal ossification and possible\r teratogenic effects, were observed in rats at doses resulting in\r sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in\r exposures approximately 3 and 11 times the mean steady-state AUC at\r the maximum recommended clinical dose. Maternal toxicity occurred at doses\r similar to those eliciting developmental toxicity.<\/span><\/em><\/p>","ID":"105f6a70-1235-415f-81ea-f989b5173957","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Developmental\r toxicity, including dose-dependent delayed foetal ossification and possible\r teratogenic effects, were observed in rats at doses resulting in\r sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in\r exposures approximately 3 and 11 times the mean steady-state AUC at\r the maximum recommended clinical dose. Maternal toxicity occurred at doses\r similar to those eliciting developmental toxicity.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c826fdc8-c25f-46a2-8587-dbed34e51c57","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"952ae6d2-f73f-4f3c-879c-bf11fc0cb1c3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.       PHARMACEUTICAL\r PARTICULARS<\/span><\/b><\/em><\/p>","ID":"9f9feeb8-12ec-4f4e-a628-c7c498de1718","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"6.       PHARMACEUTICAL\r PARTICULARS","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6a8fe3b3-58c4-4167-9b5f-6675b370a2c0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.1     List of excipients<\/span><\/b><\/em><\/p>","ID":"8f9632da-6d13-4b16-99c0-1fb4b2ca1ff5","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"6.1     List of excipients","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"65a9521a-f40a-4080-9214-7026ed450752","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Powder<\/span><\/u><\/em><\/p>","ID":"de7d0ae4-8fc1-4a3f-80ce-4e2417536454","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Powder","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\"><\/span><\/u><\/em><\/p>","ID":"f9d37854-0c20-41b9-ada8-8a0e1b1db76d","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Carmellose\r sodium<\/span><\/em><\/p>","ID":"1e1f00ec-a05d-4d36-b08f-8438b5fac2ac","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Carmellose\r sodium","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Mannitol<\/span><\/em><\/p>","ID":"d2a5a2db-b8e5-4aff-a1ea-14436724ca9a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Mannitol","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Sodium\r dihydrogen phosphate monohydrate<\/span><\/em><\/p>","ID":"1d13886b-7053-4095-a73f-1c60c1d8e0c2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Sodium\r dihydrogen phosphate monohydrate","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Sodium\r hydroxide<\/span><\/em><\/p>","ID":"727c91cd-fb64-459c-93fd-894c837417ec","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Sodium\r hydroxide","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ff9a8304-6a3d-4ff9-a578-9c5ac1a6a3c0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Solvent<\/span><\/u><\/em><\/p>","ID":"f30b439e-ba6d-4ac2-ac51-73bee7264316","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Solvent","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"717cf3d2-0c05-465e-a8e0-0ddfeace9b38","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Water\r for injections<\/span><\/em><\/p>","ID":"637003b1-b1af-4081-adc8-783ecf2140c5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Water\r for injections","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"76228d89-e6c3-46fb-b899-880c5daca9d6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.2     Incompatibilities<\/span><\/b><\/em><\/p>","ID":"bf6e5ffe-9bdb-4253-84bc-2a154d5b3f83","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"6.2     Incompatibilities","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ec6041f8-e852-4a4c-a83a-a08074218dd9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Not\r applicable<\/span><\/em><\/p>","ID":"3f8c923b-d546-48c9-99da-18f60d367f41","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Not\r applicable","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7d46e1b3-3498-40b0-83e3-cb143cba3765","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.3     Shelf life<\/span><\/b><\/em><\/p>","ID":"2971d567-81ae-428a-85e2-34494651daad","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"6.3     Shelf life","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c562368e-f662-4aaa-aae6-1869900889b4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">3 years<\/span><\/em><\/p>","ID":"26e1340e-9611-43df-abba-6db1f6518dc8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"3 years","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3e97c4fd-810c-4321-9841-01e35c44a970","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r powder and solvent for prolonged-release suspension for injection<\/span><\/em><\/p>","ID":"2bad7bec-a611-486e-ac3d-648b210b166c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify Maintena\r powder and solvent for prolonged-release suspension for injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r suspension should be injected immediately after reconstitution but can be stored\r below 25 \u00b0C for up to 4 hours in the vial.<\/span><\/em><\/p>","ID":"2f64f3d4-e453-4e47-8a9e-aa9b9538cea2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The\r suspension should be injected immediately after reconstitution but can be stored\r below 25 \u00b0C for up to 4 hours in the vial.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e6278eae-9103-4210-b276-d74f975143d3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r powder and solvent for prolonged-release suspension for injection in pre\u2011filled syringe<\/span><\/em><\/p>","ID":"2a3f048b-4b5e-486f-9b43-105dcf9984af","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify Maintena\r powder and solvent for prolonged-release suspension for injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r suspension should be injected immediately after reconstitution but can be\r stored below 25 \u00b0C for up to 2 hours in the syringe.<\/span><\/em><\/p>","ID":"190b3532-1ccb-4a9d-9e94-0df7226803d2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The\r suspension should be injected immediately after reconstitution but can be\r stored below 25 \u00b0C for up to 2 hours in the syringe.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"fbcc6433-d5ff-4f15-9d54-bac359bb9d83","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">After reconstitution<\/span><\/i><\/p>","ID":"a9f4c51f-78b2-4316-a239-91d571adc1ca","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"After reconstitution","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"64dc14c9-07e4-4e6b-8447-4fe3267bb5f6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"a3ca108f-c958-4516-bfea-50332420d4b6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"302bcef6-0c09-4358-98ff-0775480247d5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"caf09c8f-4d5b-4f69-997e-d50d5e8986d5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chemical and physical in-use stability has\r been demonstrated for 4 hours at 25 \u00b0C. From a microbiological point\r of view, unless the method of opening\/ reconstitution precludes the risk of\r microbial contamination, the product should be used immediately. If not used\r immediately, in-use storage times and conditions are the responsibility of\r user. Do not store the reconstituted suspension in the syringe.<\/span><\/p>","ID":"4b6f8066-fd9c-4d0f-8b3d-f2b2a526fa67","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Chemical and physical in-use stability has\r been demonstrated for 4 hours at 25 \u00b0C. From a microbiological point\r of view, unless the method of opening\/ reconstitution precludes the risk of\r microbial contamination, the product should be used immediately. If not used\r immediately, in-use storage times and conditions are the responsibility of\r user. Do not store the reconstituted suspension in the syringe.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"936119b0-3dec-4a3c-b077-32a0d0dc7c9b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"29c758c4-57d9-478c-bf26-023c37f5722b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"1af268cf-ba1b-4496-9980-f132e4e214ae","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ab8cc47d-a2ec-4716-9dd1-b019198b336e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If the injection is not\r performed immediately after reconstitution, the syringe can be kept below 25 \u00b0C\r for up to 2 hours.<\/span><\/p>","ID":"c6fc84bd-d9aa-4cf6-93bb-bab8c92c421d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"If the injection is not\r performed immediately after reconstitution, the syringe can be kept below 25 \u00b0C\r for up to 2 hours.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ad375f26-ef52-45a6-ae39-bc7ceda9fba9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.4     Special precautions\r for storage<\/span><\/b><\/em><\/p>","ID":"5c283e53-5b63-40bb-80a9-59d24b01cf04","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"6.4     Special precautions\r for storage","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"67ac78c1-2731-492b-a0e3-f5912dacaaa3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Do\r not freeze.<\/span><\/em><\/p>","ID":"e8b256df-2374-4527-ac6d-c53bcc1e90d8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Do\r not freeze.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0f5b0d3d-2d24-4f32-ae1b-9a49a5c9477b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"59259c50-2699-4fe1-b36e-cdd89c251120","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"ec1927ea-45b8-4c19-9e8f-58e4afa54875","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f284aef6-e102-49ce-81d9-53e4e818f055","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the syringe in the outer carton in\r order to protect from light.<\/span><\/p>","ID":"0a697765-ca51-416e-9edb-bcd6d2168ffc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Keep the syringe in the outer carton in\r order to protect from light.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c1d58da6-21c2-4a08-92c7-e9552a3310b6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after reconstitution\r of the medicinal product, see section 6.3.<\/span><\/p>","ID":"3b0111c8-2e09-4d39-a15f-6b5dbfee42bf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For storage conditions after reconstitution\r of the medicinal product, see section 6.3.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1e8079a9-1fd3-4ea6-9086-c5b2052d2a80","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.5     Nature and contents of\r container<\/span><\/b><\/em><\/p>","ID":"5df26a0c-846a-435c-a47f-867e8a5891e8","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"6.5     Nature and contents of\r container","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cd1c5139-f605-4524-badf-f24bbe94d208","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for injection<\/span><\/u><\/em><\/p>","ID":"435354bb-27f0-47cb-9f49-36087693babb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"0ccc83bb-4ec3-457d-8d94-f488c9834e97","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f4fe5e0c-7bd2-4f2a-b38f-07e0ca134696","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Vial<\/span><\/em><\/p>","ID":"7efc7074-bd7e-4643-b581-37edb1a134bc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Vial","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Type\u2011I\r glass vial stoppered with a laminated rubber stopper and sealed with a flip-off\r aluminium cap.<\/span><\/em><\/p>","ID":"093e684c-0671-453e-b84e-31aa2e5f028b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Type\u2011I\r glass vial stoppered with a laminated rubber stopper and sealed with a flip-off\r aluminium cap.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"48b8b016-c1fe-4dff-b873-2b105cd55443","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Solvent<\/span><\/em><\/p>","ID":"3ad19a57-b84f-4318-847f-af3fae0a986d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Solvent","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">2 ml\r Type\u20111 glass vial stoppered with a laminated rubber stopper and sealed\r with a flip-off aluminium cap.<\/span><\/em><\/p>","ID":"e1ea53f7-2728-429b-bf42-6ce338df3303","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"2 ml\r Type\u20111 glass vial stoppered with a laminated rubber stopper and sealed\r with a flip-off aluminium cap.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e4d3f5cb-f308-453c-a8fc-13749c1016c0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Single pack<\/span><\/em><\/p>","ID":"29a32b25-dffb-468b-8e87-105bcea4c503","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Single pack","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r single pack containing one vial of powder, 2 ml vial of solvent, one\r 3 ml luer lock syringe with pre-attached 38 mm (1.5 inch)\r 21 gauge, hypodermic safety needle with needle protection device, one\r 3 ml disposable syringe with luer lock tip, one vial adapter and three\r hypodermic safety needles: one 25 mm (1 inch) 23 gauge, one\r 38 mm (1.5 inch) 22 gauge and one 51 mm (2 inch)\r 21 gauge.<\/span><\/em><\/p>","ID":"0d468469-9f3b-4d5a-b49d-dcf41947e78d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Each\r single pack containing one vial of powder, 2 ml vial of solvent, one\r 3 ml luer lock syringe with pre-attached 38 mm (1.5 inch)\r 21 gauge, hypodermic safety needle with needle protection device, one\r 3 ml disposable syringe with luer lock tip, one vial adapter and three\r hypodermic safety needles: one 25 mm (1 inch) 23 gauge, one\r 38 mm (1.5 inch) 22 gauge and one 51 mm (2 inch)\r 21 gauge.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"fe757de3-71dd-4957-903d-42409b09aa40","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Multipack<\/span><\/em><\/p>","ID":"55c6db41-0677-4244-a1ab-ba3165e3e61c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Multipack","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Bundle\r pack of 3 single packs.<\/span><\/em><\/p>","ID":"a84104d7-1c25-47ca-83f7-92a050e1bd42","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Bundle\r pack of 3 single packs.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7ac1bc02-ea09-4cff-a8c6-b444548a4df4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/u><\/p>","ID":"58bee156-8a7f-4f23-aa67-ffec2bfd5642","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","Text":"Abilify Maintena\r 300 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe<\/span><\/u><\/p>","ID":"c4e5c0ef-f399-46df-8be1-3e3aaf51e51d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","Text":"Abilify Maintena\r 400 mg powder and solvent for prolonged-release suspension for injection\r in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0b992ed5-6d75-48af-85fc-d467f9a3d533","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Clear glass\r pre-filled syringe (type-I glass) with grey chlorobutyl stoppers (front-,\r middle- and end stopper), polypropylene front assembly, polypropylene finger\r grip, plunger rod, and silicone over-cap. The front chamber between front\r stopper and middle stopper contains the powder and the rear chamber between\r middle stopper and end stopper the solvent.<\/span><\/p>","ID":"7e071710-b4aa-4c2f-b1f7-8e333ad873d9","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Clear glass\r pre-filled syringe (type-I glass) with grey chlorobutyl stoppers (front-,\r middle- and end stopper), polypropylene front assembly, polypropylene finger\r grip, plunger rod, and silicone over-cap. The front chamber between front\r stopper and middle stopper contains the powder and the rear chamber between\r middle stopper and end stopper the solvent.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"30ce1f57-7e3a-4d97-b274-106dab934e6f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Single pack<\/span><\/em><\/p>","ID":"6372802c-1427-474e-856b-053e46af978b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Single pack","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Each\r single pack containing one pre\u2011filled syringe, and three hypodermic\r safety needles: one 25 mm (1 inch) 23 gauge, one 38 mm\r (1.5 inch) 22 gauge and one 51 mm (2 inch) 21 gauge.<\/span><\/em><\/p>","ID":"4ef8d2c0-3b6d-48c3-a5d1-9b58ef0c66ae","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Each\r single pack containing one pre\u2011filled syringe, and three hypodermic\r safety needles: one 25 mm (1 inch) 23 gauge, one 38 mm\r (1.5 inch) 22 gauge and one 51 mm (2 inch) 21 gauge.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f4c84216-3750-4898-8d51-a88f10a16f42","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Multipack<\/span><\/em><\/p>","ID":"7f2ec07e-8474-40a9-b020-e9607a30afa6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Multipack","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Bundle\r pack of 3 single packs.<\/span><\/em><\/p>","ID":"b4d70f46-41ae-4e9a-8b92-932110d31d0b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Bundle\r pack of 3 single packs.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"00400303-4dfe-4c31-ac60-68b5fc463055","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Not\r all pack sizes may be marketed.<\/span><\/em><\/p>","ID":"3da9dd09-6240-4de2-b3b2-66f5f9b6333e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Not\r all pack sizes may be marketed.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6d1c5359-5c06-4f64-8c7a-b5704fcbc277","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">6.6     Special precautions\r for disposal and other handling<\/span><\/b><\/em><\/p>","ID":"aae3ce4d-16ad-4550-b2a3-d0a52a0b7488","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","Text":"6.6     Special precautions\r for disposal and other handling","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5113ed01-351b-45ae-b70e-24ace0a74588","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"0670a76b-a9c8-461c-b531-7c25aa62a950","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"9d93ac03-a97b-42e7-af6e-95214c2eb051","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e4f917fc-854b-4abc-8518-8c0bdc50ce09","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.<\/span><\/p>","ID":"cf6142f1-0534-4fbe-8c38-7be0ab14c2b3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Shake the vial vigorously for at least\r 30 seconds until the suspension appears uniform.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.<\/span><\/p>","ID":"98d56d3d-cc24-4354-b8ca-4612a2a24663","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"If the injection is not performed\r immediately after reconstitution shake it vigorously for at least\r 60 seconds to re\u2011suspend prior to injection.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"79387f4d-0823-4612-8e42-dd6a59bc124e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify Maintena 300 mg powder and\r solvent for prolonged-release suspension for injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"d690da49-fc13-4aa2-863c-ece6cd3a73fb","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify Maintena 300 mg powder and\r solvent for prolonged-release suspension for injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify Maintena 400 mg powder and\r solvent for prolonged-release suspension for injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"6bc4fba5-46de-4d81-ad4b-7c3cc4774811","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify Maintena 400 mg powder and\r solvent for prolonged-release suspension for injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"7c34d796-ac5b-490e-8f7a-5bdf7d67f40c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Vertically shake the\r syringe vigorously for 20 seconds until medicine is uniformly milky-white\r and use immediately. If the injection is not performed immediately after\r reconstitution, the syringe can be kept below 25 \u00b0C for up to 2 hours.\r Shake the syringe vigorously for at least 20 seconds to re\u2011suspend\r prior to injection if the syringe has been left for more than 15 minutes.<\/span><\/p>","ID":"93b9781c-be3d-4b38-a5c6-57c44201ad98","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Vertically shake the\r syringe vigorously for 20 seconds until medicine is uniformly milky-white\r and use immediately. If the injection is not performed immediately after\r reconstitution, the syringe can be kept below 25 \u00b0C for up to 2 hours.\r Shake the syringe vigorously for at least 20 seconds to re\u2011suspend\r prior to injection if the syringe has been left for more than 15 minutes.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0068a6af-d8b7-4377-81ea-3b1152bd76c2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Gluteal muscle\r administration<\/span><\/em><\/p>","ID":"07b61843-1f8a-4b96-909b-347e9d036977","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Gluteal muscle\r administration","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The recommended needle for gluteal\r administration is a 38 mm (1.5 inch), 22 gauge hypodermic safety\r needle; for obese patients (Body mass index &gt; 28 kg\/m<sup>2<\/sup>),\r a 51 mm (2 inch), 21 gauge hypodermic safety needle should be\r used. <\/span><\/em><span lang=\"EN-GB\">Gluteal injections should be alternated\r between the two gluteal muscles.<\/span><\/p>","ID":"dbb2e823-53c8-4e23-ad16-0f01da0ca99a","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The recommended needle for gluteal\r administration is a 38 mm (1.5 inch), 22 gauge hypodermic safety\r needle; for obese patients (Body mass index > 28 kg\/m2),\r a 51 mm (2 inch), 21 gauge hypodermic safety needle should be\r used. Gluteal injections should be alternated\r between the two gluteal muscles.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cce3ade0-7b7f-47b3-86a0-af096e0bb3bd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black\">Deltoid muscle\r administration<\/span><\/em><\/p>","ID":"e7d2d4ba-5569-429d-9476-36d7a8708594","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Deltoid muscle\r administration","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"font-style:normal\">The recommended\r needle for deltoid administration is a 25 mm (1 inch), 23 gauge\r hypodermic safety needle; for obese patients, a 38 mm (1.5 inch),\r 22 gauge hypodermic safety needle should be used.<\/span><\/em><\/p>","ID":"a8a41f9c-d0bd-4508-89f7-61a1ee74dbca","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The recommended\r needle for deltoid administration is a 25 mm (1 inch), 23 gauge\r hypodermic safety needle; for obese patients, a 38 mm (1.5 inch),\r 22 gauge hypodermic safety needle should be used.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Deltoid\r injections should be alternated between the two deltoid muscles.<\/span><\/p>","ID":"6a88e162-da2d-4da1-965f-ea50da630f47","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Deltoid\r injections should be alternated between the two deltoid muscles.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f0c9074d-ebb5-45b1-86c5-3fac65f143f5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">The\r powder and solvent vials and the pre\u2011filled syringe are for\r single-use only.<\/span><\/em><\/p>","ID":"e618d434-cf73-4ed8-b192-532b97d95df4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"The\r powder and solvent vials and the pre\u2011filled syringe are for\r single-use only.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"27ea20cb-4de1-4cc8-bcaf-303682e31fd4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.<\/span><\/p>","ID":"c1390ae5-e117-4dc1-8bfa-4a6bc33af29c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Discard vial, adapter,\r syringe, needles, unused suspension and water for injections appropriately.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"df3c4514-81dd-4581-b15f-3f37396a8272","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/em><\/p>","ID":"5606f4e1-207a-42b0-ad6a-ba1c25401e5c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"8b362c11-8b8f-40eb-b089-c04e165f7e71","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Full instructions for\r use and handling of Abilify Maintena are provided in the package leaflet\r (information intended for healthcare professionals).<\/span><\/p>","ID":"aba340c6-274d-4338-9b08-00637981acd9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Full instructions for\r use and handling of Abilify Maintena are provided in the package leaflet\r (information intended for healthcare professionals).","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"218bbb28-f0b2-498c-afe2-77281eee9953","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9977b203-2f13-475d-9bab-beafd50e80fa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/em><\/p>","ID":"4db6a405-7698-4565-a802-100d97d9ae4d","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"7.       MARKETING\r AUTHORISATION HOLDER","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b253195f-8abe-464d-8dd9-10428437ce53","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Otsuka Pharmaceutical Netherlands B.V.<\/span><\/p>","ID":"89b82f80-caf9-4e1b-99c3-c2f32ea0e206","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Otsuka Pharmaceutical Netherlands B.V.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Herikerbergweg 292<\/span><\/p>","ID":"9331f85f-6244-491f-b25f-9513c7e5d99d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Herikerbergweg 292","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">1101 CT, Amsterdam<\/span><\/p>","ID":"14da9509-df1c-4a3c-b639-8ac8f17e43e4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"1101 CT, Amsterdam","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Netherlands<\/span><\/p>","ID":"2e170d1c-7957-4f14-88a3-48840c7c8236","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Netherlands","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"143d7a7e-a907-4dd0-90e9-b646e6c0bc18","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"dcbdb36b-3092-43cb-9b4d-e2c8ac9899e1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">8.       MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/em><\/p>","ID":"027e788f-0530-4b50-acf7-caac6f82e971","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"8.       MARKETING\r AUTHORISATION NUMBER(S)","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"4dba6ba3-1386-4973-8d10-129ece1dbcba","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"09617c43-8a57-4f59-bccb-1171a47e6362","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"42f66b94-c24a-463d-a725-ce077bb8bab5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/001<\/span><\/p>","ID":"946d14eb-87bf-4627-ad78-f758f14866ad","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/13\/882\/001","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/003<\/span><\/p>","ID":"10c1bef5-c374-48d6-afa2-b10340201dec","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/13\/882\/003","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3161e39d-2c6d-43a1-961c-84e19576409e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection<\/span><\/u><\/em><\/p>","ID":"b03ec1da-f00f-4b18-9e7f-e4f282952a57","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0cad2a85-a7d2-4399-a1a1-ce36f8f706c9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/002<\/span><\/p>","ID":"ff17edb1-568e-4d9b-b8ce-70e940c549c2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/13\/882\/002","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/004<\/span><\/p>","ID":"398dea5c-02b1-4708-9f4a-4c86ee9bd97f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/13\/882\/004","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e15c7acb-72d0-4441-88bd-b9b362ee4f13","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"9f181174-3d60-4ab6-9b7c-bbcc7b0e8d7c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 300 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e5e2683c-eb4b-4ff2-91fe-66841f3b1558","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/005<\/span><\/p>","ID":"05b94b58-098f-4045-bcb6-f1aeeb27280c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/13\/882\/005","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/007<\/span><\/p>","ID":"0f628c61-94eb-4237-92f2-6087d3126f94","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/13\/882\/007","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9718cf46-370e-40c0-84a3-4b065c5eebcb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><u><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe<\/span><\/u><\/em><\/p>","ID":"5757247a-d17d-41aa-95a2-5a6e7be098c0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Abilify\r Maintena 400 mg powder and solvent for prolonged-release suspension for\r injection in pre\u2011filled syringe","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"599b2ba8-ef62-4018-bb6c-fcad6dd730ac","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/006<\/span><\/p>","ID":"172f34ce-f02c-4aa0-88e4-cd2409c61d74","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/13\/882\/006","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/13\/882\/008<\/span><\/p>","ID":"bfef9398-fbe7-4e6d-80ab-a630ddf8e55c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/13\/882\/008","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"359500c4-4a7b-43f3-a9a9-0a9d6eb8c98a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6e59a0d8-a2a4-43ac-aa9b-1166cf714eac","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">9.       DATE OF FIRST\r AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/em><\/p>","ID":"1ed8c788-2469-44cd-8ef1-431574a8caeb","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"9.       DATE OF FIRST\r AUTHORISATION\/RENEWAL OF THE AUTHORISATION","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cd0f0cfe-3e82-4666-ac6b-f4fa7854e723","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Date\r of first authorisation: 15 November 2013<\/span><\/em><\/p>","ID":"1a6f7af6-4a80-4cb9-8960-6fe30c90c23b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Date\r of first authorisation: 15 November 2013","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><em><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">Date\r of latest renewal: 27 August 2018<\/span><\/em><\/p>","ID":"ca06e64e-f454-4228-8b6e-039bc367eb97","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","Text":"Date\r of latest renewal: 27 August 2018","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"8ea7b475-a053-40c9-89c1-c3e7de0d5c86","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"8ff7555a-f5b7-4eb3-b436-b0c19730a5bc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><em><b><span lang=\"EN-GB\" style=\"color:black;font-style:normal\">10.     DATE OF REVISION OF\r THE TEXT<\/span><\/b><\/em><\/p>","ID":"5d020b8a-7fd0-43f6-97b1-5a3bccd8dec3","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":true,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","Text":"10.     DATE OF REVISION OF\r THE TEXT","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1800d20f-b640-47ad-85f9-fcf98ba287c4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">MM\/YYYY<\/span><\/p>","ID":"1bd414ac-c1ef-4192-b5d6-9a6ebf6cbcb8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"MM\/YYYY","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b31e490d-f6aa-4c3e-bc24-481a84ff0b55","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency <a href=\"http:\/\/www.ema.europa.eu\/\"><u>http:\/\/www.ema.europa.eu<\/u><\/a>.<\/span><\/p>","ID":"2d060b6e-80d1-4d1d-ada5-b92c8d91a8de","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Detailed information on this medicinal\r product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu.","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"280df6b7-2100-4bf3-bb18-28981967c12c","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"8e0a973f-8e00-498e-8624-cc02780a0c28"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"3a88bb09-d1da-4e12-b43e-55f62b6323da","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"280df6b7-2100-4bf3-bb18-28981967c12c"}]